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Abstract
This project focused on a group of active ingredients isolated from herbal medicines, 
most of them flavonoids, as a foundation for the development of new anticancer 
drugs. Interactions between these compounds and genomic DNA, synthetic 
polynucleotides, or higher order DNA isoforms (triple and quadruple helical forms) 
have been studied using a range of physicochemical and biological techniques. The 
studies demonstrated that flavonoids and isoflavonoids bind to the various nucleic 
acid forms with weak or moderate affinities and no significant specificity, apart from 
quercetin that demonstrated a differential binding for G-quadruplex structures.
Rational drug design has been subsequently employed to elucidate the mode of 
binding and novel compounds have been synthesized in order to provide precise 
structure-activity related studies and result in a second generation of 
chemotherapeutic anticancer agents with improved properties. Interaction with DNA 
is thought to involve the planar ring structures. The double bond of the O in C4 in a 
flavone scaffold gives planarity to the molecule, and this allows the molecule to 
intercalate between the bases in the different nucleic acid structures. The comparison 
between flavone, flavanone and isoflavonoid indicates that the position of the B ring 
and the double bond in the C ring are important for the interactions with DNA. 
Introduction of nitrogen in the ring did not improve the binding but tertiary amines 
improved binding 100 fold. Introduction of sulfur produced two binding constants. 
Position 7 in the A ring of the flavones is extremely relevant for the binding to the
1
nucleic acids, but substitutions in the B ring did not improve the binding. 
Methoxylation or acetoxylation in positions 5 and 7 decreased the affinity for DNA. 
Novel compounds were tested for their specificity against different DNA isoforms 
and their anticancer activity in various tumour cell lines.
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1.1 .a: Cancer
The adult human is composed of approximately 1015 cells, many of which are 
required to divide and differentiate in order to repopulate organs and tissues 
(Mauelera et al., 1999). Control of cell growth is due to different pathways working 
in harmony, even though some of them are not well defined. Cells which have the 
capacity for division are called stem cells and this ability is found on germ cells and 
some specific organs that require turnover. Normal human somatic cells can divide 
30-50 times; the event limiting this replication is the erosion of the ends of 
chromosomes, which are normally capped by a repetitive six base pair sequence 
(TTAGGG) named telomere (Kamenetskii et al., 1995).
In germ and certain stem cells, the enzyme telomerase is in charge of maintaining a 
normal telomere length. This enzyme is not expressed in somatic cells; therefore, 
after 30-50 cycles of division, the cell enters quiescence. To keep cells continuously 
active, some pathways must be maintained. These pathways receive and process 
growth-stimulatory signals transmitted by other cells. Cell-to-cell signalling generally 
begins when one cell secretes growth-factors. After this event, the proteins move 
through the extra cellular matrix and bind to the specific receptor on the surface of the 
nearby cell.
When the growth-factor attaches to the receptor, the interaction conveys a 
proliferative signal to proteins in the cytoplasm. These downstream proteins emit 
stimulatory signals to a succession of other proteins. Transcription-factors respond by 
activating a group of genes that help the cell through its growth cycle.
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Normal cells have certain characteristics namely, the ability to:
> reproduce an exact copy of themselves
> terminate reproduction at the appropriate time
> attach to neighbouring cells
> self destruct if they are damaged
> specialise or mature !
Cancer is the result of the accumulation of cells that can move, survive and divide by 
passing the body’s normal control mechanisms, and its incidence increases 
dramatically with age. One of the main characteristics of cancer is its complexity. 
Clinically, cancer appears as a diverse set of illnesses with inappropriate cell growth 
(Hanahan et al., 2000). Certain mutations play critical roles in programming the 
malignant state; some mutations are inherited, while others are caused by exposure to 
radiation or to mutation-inducing chemicals. Mutations can also occur spontaneously 
as a result of mistakes during replication. When cells acquire mutations in specific 
genes that control proliferation, such as proto-oncogenes or tumor suppressor genes, 
these changes are copied with each new generation of cells (Aerssens et a l , 2001).
The key features of a malignant clone are:
> immortality -  the cells do not mature and do not die
^  independence -  the clone does not rely on signals from other cells to survive 
or to divide
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> mobility -  ability to violate boundaries between anatomical compartments and 
to seed remote colonies (metastasis)
> subversion -  malignant tumours inhibit components of the immune system, 
and may influence non-malignant cells to create a favourable milieu for the 
cancer cell
> instability -  a characteristic of virtually all malignancies is that they spin off 
ever more genetically aberrant sub-clones
> angiogenesis induction -  malignant tumours, and possibly some benign 
tumours have the capacity to induce the growth of new blood vessels to 
nourish the developing tumour (Boveri, 1914)
GENETIC ALLY ALT ERED CELL jN  JjT U  C A H C B ?
\
HYPERPLASIA DYSPLASIA
i J .  . .  j m f ,  ■ j/
.■ v- 
BLOODVESSEL
Figure 1: Development of cancer. A genetically altered cell gives rise to an 
accumulation of altered cells that can survive by passing the body’s control 
mechanism forming an in situ cancer that can form metastases in the individual’s 
body if these cells enter the blood vessels and disperse into other organs (Weinberg et 
al.: “When cancer arises”, Scientific American, 62-70, 1996).
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l.l.b : Cell Cycle and Apoptosis
The cell cycle is a sequence of stages during which DNA is copied, the fidelity of that 
copying is checked, the cell repairs any errors (or undergoes apoptosis if they are 
irreparable), and the new DNA must be packaged into chromosomes and distributed 
within the cell such that each daughter cell will receive an appropriate complement. 
All this takes some hours in the normal cell, and in cancer cells the division time is 
frequently faster (up to 5 times).
The cell cycle is composed of 4 stages (Vourc'h et al., 1993), see Figure 2:
> G1 (gap 1): the cell increases its size and prepares to copy its DNA by 
synthesis of proteins and molecules
> S (synthesis): the cell copies the DNA and enables itself to duplicate 
chromosomes
> G2 (gap 2): the cell prepares for mitosis by synthesis of proteins
> M (mitosis): the parent cell divides in half to produce two cells
The majority of cells, when not dividing or preparing to divide, are in GO or rest 
phase. Entry into the cell cycle is controlled by a group of regulatory compounds 
(cyclins) -  these in turn transmit their messages to proteins called cyclin dependent 
kinases (Knudson, 2001).
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Figure 2: Cell cycle stages (Weinberg et al.: “When cancer arises”, Scientific 
American, 62-70, 1996).
The cell cycle programs this elaborate succession of events by using various 
molecules. The two essential components, cyclins and cyclin-dependent kinases, 
associate with one another and initiate each of the stages of the cell cycle.
The last stage in a cell’s life cycle is cell death. There are at least two distinct forms 
of cell death:
> necrosis: here a whole group of neighbouring cells die spilling out their 
contents which excites an inflammatory response
> apoptosis: here an individual cell packages its internal contents, breaks down 
its DNA and then displays markers on its surface promoting phagocytic cells 
to come and clear away the debris (Krontiris et al. , 1995)
There is no inflammatory response to apoptosis which is a vital physiological 
process. This is probably because apoptosis is the mechanism whereby the body 
eliminates cells that have acquired defects in their genome. This is a vital part of the
defences against cancer. There are several apoptosis-based anti-cancer agents 
currently under development. Although most cancer therapies depend to some extent 
on the induction of apoptotic pathways, these therapies are designed specifically to 
trigger apoptotic pathways. In the human genome there are approximately 3 billion 
base pairs which must be accurately replicated each time a cell divides. A proof­
reading and error correction pathway ensures the accuracy of this process; this is so 
accurate that the 3 billion base pairs genome will only change by about 10-20 bases a 
year. A back-up system to ensure the integrity of the genome assesses any errors and 
ensures the success of the dividing cell in correcting these. If the cell fails this 
assessment, the apoptotic pathways are triggered and the cell self destructs. It is only 
if both the DNA repair and the apoptosis pathways are defective or suppressed that a 
cell can become malignant (Hahn et a l , 1999).
1.1. c: Signalling pathways
Genes are carried in the DNA molecules of the chromosomes. A gene specifies a 
sequence of amino acids that must be linked together to make a particular protein. 
The protein then carries out the work of the gene. When a gene is switched on, the 
cell responds by synthesizing the encoded protein. Mutations in a gene can disrupt 
this activity. Cells in a tumour descend from a common cell that at one point initiates 
inappropriate reproduction. Furthermore, the malignant transformation gives rise to 
the accumulation of mutations in specific classes of genes (Bertram et al., 2001).
Four classes of genes play major roles in triggering cancer (Weinberg et al., 1996):
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> proto-oncogenes encourage growth whereas tumour suppressor genes inhibit 
it. When mutated, proto-oncogenes can become carcinogenic oncogenes that 
drive excessive replication. Some oncogenes force cells to overproduce 
growth factors, and others perturb the signal cascade
> oncogenes typically act in a dominant fashion and can contribute to malignant 
transformation. They frequently code for tyrosine kinases (internal 
messengers), which act as intermediaries between the signal received by 
growth factor receptors at the cell surface and the sites within the nucleus 
where genes are switched in response to those growth signals. Usually, the 
normal function of an oncogene falls within one of four gene families:
■ growth factors
■ cell surface receptors
■ transcription factors
■ signal transmission proteins
Growth factors are normally produced by one cell to regulate the behavior of 
another cell; if a cancer cell develops the ability to produce its own growth 
factors it becomes independent of external signals. Under normal 
circumstances there are three types of growth factor regulation:
■ endocrine (is released into the circulation and regulates 
behavior of distant cells)
■ paracrine (acts on a close neighbour of the secreting cell)
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■ autocrine (releases a growth factor which can bind to receptors 
on the same cell) (Bertram et al., 2001)
When a cell, which should be regulated by endocrine or paracrine growth 
factors, acquires the capacity for autocrine growth factor secretion it may 
become capable of autonomous division. In some cases cancer cells will 
secrete paracrine growth factors so that they stimulate each other’s growth.
> tumour suppressor genes contribute to cancer when they are inactivated by 
mutations. Tumour suppressor genes are negative regulators of cell division. 
They are necessary for the effective operation of DNA repair mechanisms. On 
proof reading of DNA, if anything above a minimal threshold of errors is met, 
pathways are initiated which put division on hold while DNA repair is 
attempted. If repair is unsuccessful, the cell initiates apoptosis and sacrifices 
itself to save the other cells. If tumour suppressor genes are absent or 
defective then arrest of the cell division process may fail to occur and the cell 
may generate a clone of faulty daughter cells. One of the most important 
tumour suppressor genes is called p53, which monitors stress (like anoxia, 
insufficiency of nucleotides for DNA synthesis, inappropriate inactivation of 
oncogenes and DNA lesions) and directs the cell towards an appropriate 
response (Levine et al., 1997).
>  DNA repair genes are the fourth class of genes important for tumour 
development. Genomic instability is a virtually invariant feature of cancer 
cells. If it is assumed that loss of stability of the genome is an early event in 
malignant transformation, then the subsequent rate of accumulation of
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mutations will be much higher. As in other cases, the DNA repair genes are 
highly conserved across species, implying that they emerged very early in 
eukaryote evolution and are of great importance to the cell. There are various 
different pathways to DNA repair; which pathway is activated depending on 
the exact nature of the defect in the DNA molecule. In some forms of DNA 
damage the two strands will no longer fit together (DNA mismatch). The 
repair mechanism can identify the original strand because it carries methyl 
tags which identify it while the daughter strand does not acquire these tags for 
some minutes after copying occurs. During this time the repair machinery 
compares the two strands and attempts to correct any errors detected 
(Westwell et al., 2001).
To ensure a satisfactory supply of nutrients necessary for continued growth, and to 
eliminate products of metabolism which would potentially be lethal, cells create a 
new network of vessels and capillaries. This process is called angiogenesis and occurs 
through the invasion of endothelial cells from existing vessels in response to multiple 
extra cellular signals such as vascular endothelial growth-factor and fibroblast 
growth-factor. This process is controlled and balanced by inhibitors of angiogenesis, 
such as thrombospondin (Gao et al., 1995). Tumour cells enhance expression of pro- 
angiogenic factors as well as suppress negative regulators. Oncogenes and tumour 
suppressor genes are involved in both processes. Immortality is an escape from 
senescence and deregulation of cell cycle and proliferation programmes.
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l.l.d : Therapies
There is a range of different therapies (Hurley, 2000) for treating cancer, summarised 
as follows:
> surgery: removal of a localised tumour.
> chemotherapy: treatment of cancer with anticancer drugs. It is often used to 
treat patients with cancer that has metastasized and can be used as an adjuvant 
after surgery.
> radiotherapy: exposure of the tumour cells to radiation from a radioactive 
substance / source.
> angiogenesis inhibitors: these prevent the construction of new blood vessels 
for the transport of oxygen and nutrients that rapidly dividing cancer cells 
require.
> immune and vaccine therapy: treatment to stimulate and restore the immune 
system to fight the cancer cell. It normally employs antibodies and vaccines.
> bone marrow and peripheral blood stem cell transplantation: stimulation using 
growth factors of growth of stem cells in a donor blood, which are isolated 
and transplanted into the bone marrow of the patient, to stimulate the growth 
of healthy new cells.
> gene therapy: technique for correcting defective genes responsible for disease 
development. A normal gene is inserted into an abnormal gene (from cancer 
cells). For delivering the gene, a carrier vector is used (usually a virus).
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> laser and photodynamic therapy: investigational technique that employs a 
photosensitizer (e.g.haematoporphyrin), light sources (lasers), and 
oxygenation of tissues.
Chemotherapy is capable of combating the most widespread of metastases. By 
entering into the bloodstream, the chemical compounds are able to disperse 
throughout the body and attack cancer cells. Chemotherapy is not without its side 
effects, and one of the most problematic aspects of creating an anti-cancer agent is 
identifying a way to kill only cancerous cells. Therefore, a group of agents that work 
via different mechanisms has been developed. Unfortunately, most of the chemicals 
that have been found to be successful anti-cancer agents are extremely toxic and must 
be administered very carefully. The side effects incurred are numerous and include 
fatigue, hair loss, anemia, vomiting, diaorrhea, nausea, and, more seriously for the 
patient, decreased resistance to infection, increased likelihood of hemorrhaging and a 
possible need of blood transfusions and kidney -  liver -  heart failure. Many of these 
effects are temporary and can be eased by the intake of palliative medicines, but 
sometimes many of the side effects debilitate the patient so much that they can no 
longer carry on with the treatment.
1.2. a: Herbal remedies as cancer therapy
Worldwide, for many centuries different diseases have been treated with herbs or 
herbal extracts. These treatments are based on common and empiric knowledge. Over
tlithe course of the 20  century, medicinal knowledge became divided into
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contemporary (or western) and alternative medicine. Contemporary medicine mainly 
refers to the use of synthetic and semi-synthetic drugs and vaccines; alternative 
medicine includes the use of herbal medicines. The action of such herbal remedies is 
due to one or more active ingredients with therapeutic properties. In the constant 
search for new medicines, these active ingredients have been put under scrutiny for 
their therapeutic effect or have formed the basis for the generation of novel 
compounds with improved therapeutic properties.
Plant therapy was the first medical system to be used to diagnose, treat, and prevent 
illnesses (Nestler, 2002). Over the centuries, plants have been used to treat countless 
conditions, such as obesity, diabetes, high cholesterol, male (Becker et a l , 2000) and 
female fertility disorders, Alzheimer's disease, digestive disorders, recurrent cystitis, 
allergies (Armstrong et al, 1999), sinusitis, addictions, pain (Lee et a l , 2001), 
menopausal symptoms, osteoporosis, arthritis, infections, sleep disorders, stress, 
constipation, and more recently as chemo-preventative and antineoplastic agents 
(Wong et a l, 2001; Yuan et a l, 2000).
Plants are considered a vast source of anticancer agents (Craig et a l, 1999) and 
several studies have been conducted since the 1950s to test natural and synthetic 
substances for antiproliferative properties. The compounds extracted from plants 
belong to various classes of molecules, including flavonoids, phytoestrogens, 
polymers, carbohydrates, terpenes. Some of these molecules have proved to be 
powerful agents against various conditions and some of them have formed the basis 
for new therapeutic agents (Baguley et a l, 1981). Of the tested compounds, earlier 
discoveries include the vinca alkaloids from Madagascar periwinkle; etoposide
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(Kimchi-Sarfaty et a l , 2002), teniposide (Zhou et a l, 2002), semi synthetic 
derivatives of epipodophylotoxin (Kosmas et a l, 2002) extracted from Podophyllum. 
More recently, taxanes and camptothecins (Engin et a l, 2002) attracted attention as 
new anticancer agents. Another group of agents is constituted by flavonoids. They are 
a large chemical class in the plant kingdom, with over 5,000 different flavonoids 
described. One flavonoid to receive a significant attention as a potential anti-cancer 
agent is flavopiridol (Aventis) (Structure 1). This semi-synthetic compound (it is an 
N-methylpiperinidyl, chlorophenyl flavone) is based on a compound extracted from 
Rohitukine, and is a potent cyclin-dependent kinase inhibitor capable of producing 
mitotic arrest in either G1 or G2 (Murthi et a l, 2000).
Structure 1: Flavopiridol (www.oup.com/.../chl8/chl8 fig70flavopiridol.it>g , 
20/07/2006)
Various studies show flavonoids as a chemical class offering an important approach 
to cancer therapy, as they target and regulate a wide range of enzymatic pathways and 
signal transduction mechanisms in human cells. Flavonoids also appear to be 
relatively discriminating, acting predominantly on dysfunctional cells (Traganos et 
al, 1992).
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Finally, another class of compounds, isolated from plant extracts, that has found use 
in disease treatment is the terpenoids. Examples from this family are artemisinin and 
artesunate (refer to next section for a full description) which have been used in the 
treatment of malaria.
Furthermore, terpenoids have been shown to increase tumour latency, decrease tumor 
multiplicity, elicit a significant reduction in total cholesterol concentration and act as 
a strong antioxidant. Tumour cells synthesize and accumulate cholesterol faster than 
normal cells; therefore the use of terpenoids in cancer therapy would affect tumour 
growth without producing any change in blood lipid concentrations (Zheng et al., 
1992).
Due to their potential as anticancer agents, in this project we have selected for 
preliminary studies two main families of natural extracts:
> terpenoids: from this group we studied artemisinin, artesunate and cantharidin
> flavonoids: baicalein, baicalin, daidzein, puerarin, quercetin and rutin
1.2.La: Terpenoids
1.2.l.b: Artemisinin and artesunate
Artesunate or artesunic acid is the most widely available and widely used of the 
artemisinin derivatives. These drugs have become an essential component of the 
treatment of multidrug resistant Falciparum malaria. Artesunate (Compound 2) is a
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semi synthetic derivative of artemisinin (Compound 1). For structure see compounds 
1 and 2 .
9
13
o
Compound 1: Artemisinin
CH,
CHoO
OH
CH;
Compound 2: Artesunic acid (artesunate)
These compounds belong to a molecular group named sesquiterpene endoperoxides. 
Artemisinin and its derivatives are difficult to identify by standard 
spectrophotometric methods, because they have no distinct UV/Visible spectra or 
fluorescent properties (Batty et al., 1996; Green et a l, 2000). Artemisinin and 
artesunate (usually as Na-artesunate) have a range of applications in health science, 
even though the mode of action of the compounds is not yet defined. They can be 
used in the recovery of the immune system after a disease (Singh, 2001), because
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they have been found to increase the production of IL-2 (interleukin 2) from mouse 
splenocytes stimulated with ConA after bone marrow transplantation.
As an antimalarial drug, artesunate coordinates to ferriprotoporphyrin monomers in 
erythrocytes blocking the formation of hemozoin, thus allowing a significant 
concentration of heme-antimalarial complex to remain in solution, from where it 
makes a plasmo-diotoxic effect by catalysing the formation of reactive oxygen 
species (Campanale et a l , 2003). The nature of the iron atom environment in the drug 
complexes is of prime importance since the iron is the redox centre of the molecule 
and thus the catalytic point at which oxygen activation will occur. Artesunate and 
artemisinin seem to produce reactive oxygen species like hydroxyl radicals. This 
activity could be responsible for the formation of DNA strand-breaks. A study 
involving depletion of glutathione would indicate the formation of free radicals and 
subsequent DNA strand breaks as a mechanism of action. The glutathione redox cycle 
is a detoxification pathway for the elimination of DNA damage and the alkylation of 
proteins (Ho et al., 1992). The redox cycle catalyses the reduction of H2O2 and other 
hydroperoxides (Ho et al., 1992).
In vertebrates, an iron transport system involves a specific interaction between the 
serum iron binding protein transferrin and a cell surface transferrin receptor. This 
interaction results in the facilitated transport of iron across cell membranes. Due to 
their high rates of division, most cancer cells express a higher cell surface 
concentration of transferrin receptors than normal cells and have high rates of iron 
intake. Therefore, cancer cells would be more susceptible to the cytotoxic effect of
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artemisinin and its derivatives under conditions of high iron availability (Batty et al., 
1996; Efferth et al., 2000).
An experiment using dihydroartemisinin (with an OH group in carbon 10) on a 
normal breast cell line and on a human breast tumour cell line with epithelial cell 
morphologies, using holotransferrin as supplier of iron, revealed a synergistic activity 
between the artemisinin derivative and iron (Reizenstein et al., 1999). In other 
experiments involving holotransferrin combined with artemisinin and using human 
lymphoblastoid cell lines, the drug proved to be less effective as measured by cell 
death. Considering this result, an in vivo experiment was designed to determine the 
selective cytotoxic effect of oral administration of artemisinin and ferrous sulfate on 
the growth of implanted fibrosarcoma in rats. The experiment showed that the 
combination of artemisinin and ferrous sulfate acts together to slow down cancer 
growth. However, neurotoxicity has been reported with certain analogues of 
artemisinin (Moore et al., 1995).
Different mechanisms could be used to explain the results obtained from different cell 
lines. A study performed on ovarian carcinoma cell lines showed no cytotoxicity with' 
artemisinin derivatives containing carbonyl and carboxypropyl groups (probably 
because of a negative charge). However, deoxoartemisinin (with a methylene group 
in the CIO position) showed an antitumour effect in the same cell line, indicating that 
lipophilicity might be closely related to their cytotoxic activity. This explanation, 
however, can not be extended to all cases. In human epidermoid carcinoma, it seems 
that carbonyl oxygen of artemisinin acts as a hydrogen bond donor and thus 
artemisinin is able to form hydrogen bonding with tumour target proteins to improve
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cytotoxicity (Lee et al., 2000). Experiments using leukaemic cells show that 
artesunate induces apoptosis. The appearance of an additional Ao phase at lower 
concentrations is characteristic of cells treated with the drug, even though 
antineoplastic activity has not been proven (Efferth et al., 1996). This correlates with 
the fact that artesunate is active in leukaemia and colon cancer cells in vitro, as well 
as in renal, melanomas and central nervous system tumors. Compared with a regime 
composed of cyclophosphamide, methotrexate and vincristine, artesunate is more 
active for breast cancer treatment (Efferth at al., 2001).
The necessity of iron for enhancing the antitumour activity of artesunate and 
artemisinin, allowed the study of different targets, like transferrin receptors for the 
iron-carrying protein (TF). This enhancing of activity occurs in only a few types of 
human cells like basal epidermal keratinocytes, pancreatic islet cells, and liver 
parenchyma. The receptor is more abundant in tumor cells that are rapidly 
proliferating, in particular drug-resistant cells. Since the ligand-bound TF receptor is 
internalised, tumor cells exposed to TF may have increased cellular Fe2+ 
concentrations. As Fe2+ is necessary for activation of artesunate cytotoxicity, this 
suggests a hypothetical strategy for the use of the compound in drug-resistant cells: 
preload the cells with TF and then expose them to artesunate. A study testing this 
hypothesis in drug-sensitive and drug-resistant (that have double concentration of TF 
receptors) SCLC cells, showed that artesunate induced the gradual formation of DNA 
fragments in the cells (pro-apoptotic) which was confirmed by terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeled (TUNEL, method 
indicating apoptosis) staining (Sadava et al., 2002). The same principle was used in a
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holotransferrin treatment on breast cancer cells (Adams et al., 1996) and in implanted 
fibrosarcomas in rats (Beekman et al., 1997). The results obtained indicate that an 
uptake of ferrous sulfate or ferrous citrate makes cells more susceptible to the 
cytotoxic effect of artemisinin and artemisinin-like compounds, but nephrotoxicity 
was found as a side effect in some of the rats.
(
1.2.Lc: Cantharidin
Cantharidin (Compound 3) has been isolated from the dried body of the Chinese 
blister beetle Mylabris phalerata Pallas. Cantharidin showed the effect of producing 
congestion in the urethral mucosa, and because of this effect has been used in the 
treatment of impotence and as an aphrodisiac. Recent studies showed cantharidin to 
have antitumour activity, increasing the number of leucocytes and being a potent and 
selective protein phosphatase inhibitor (Wang et al. , 2000).
Compound 3: Cantharidin
Cantharidin showed toxic side effects like nephrotoxicity and severe toxicity to 
mucous membrane. Amongst the properties that cantharidin possesses, the most 
important is its ability to act as a protein phosphatase inhibitor (protein phosphatases 
are enzymes that remove phosphate groups in proteins). The result of this activity is 
the regulation of many different cellular processes (glycogen metabolism, calcium
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transport, muscle contraction, gene expression, protein synthesis, intracellular 
transport, photo-transduction, cell cycle progression and apoptosis). In compounds 
possessing the anhydride bridge of cantharidin (or a derivative like norcantharidin), a 
single carboxylic acid group and a basic residue gives rise to a new class of 
compounds with the ability to inhibit PP1 and PP2A (McCluskey, 2001).
1.2.2.a: Flavonoids and isoflavonoids
The most powerful antioxidants are to be found amongst the flavonoids and 18 
flavonoids are now known for having 20 times the potency of vitamin C and 50 times 
the potency of vitamin E. They are essential for processing vitamin C and are needed 
to maintain capillary walls as well as protect against infection (Tucker, 2003). It is 
possible that the inhibition of oxidation of low density lipoprotein supports their 
antioxidant and antibacterial properties. They also inhibit inflammation by decreasing 
the release of inflammatory mediators and stabilizing cell membranes. Many 
flavonoids possess antifungal properties, especially the nonpolar polymethylated 
flavones and the prenylated isoflavone. In mammalian biology, flavonoids have been 
implicated in immunity, inflammation and carcinogenicity. In vitro, they inhibit the 
activity of a number of enzymes including histidine decarboxylase, alleviating 
histamine-induced gastric acid secretions; hyaluronidase, responsible for the breakage 
of glucosaminidic bonds involved in tumour cell invasiveness and hypersensitivity 
phenomena; protein kinase C (serine / threonine phosphorylation) involved in a wide 
range of cellular activities including tumour promotion, mitogenesis, inflammation 
and T lymphocyte functions; and lipoxygenase which metabolises arachidonic acid 
released from membrane phospholipids to vasoactive leukotrienes that are involved in
23
signal transduction and cell division processes related to immune systems and 
activated by hormones, neurotransmitters and growth.
In general they inhibit carcinogenesis by acting as blocking agents via:
> inhibiting metabolic P450 mediated activation of the carcinogen to its reactive 
intermediates
>  inducing the enzyme involved in detoxification of the carcinogen, and / or
> binding to reactive forms of the carcinogen.
They are known to inhibit several biochemical events associated with the 
transformation of non-malignant fibroblasts to sarcoma cells (Ibrahim, 2002). Many 
flavonoids exhibit high radical scavenging activity indicating that a diet rich in these 
flavonoids would reduce cancer promoting actions of these radicals and possibly 
other diseases and conditions caused by oxygen related radicals (Sawa et a l, 1999).
Flavonoids and isoflavonoids, found in higher plants constitute a large class of 
compounds containing a number of phenolic hydroxy groups attached to ring 
structures. Many of them form the flower pigments in most angiosperm families but 
they can be found in all parts of the plant. Flavonoids are multifunctional and can act 
as reducing agents, hydrogen donating antioxidants and singlet oxygen quenchers 
(Rice-Evans et a l, 1996). Amongst the medicinal properties, they are reported to 
have free radical scavenging activity and anticarcinogenic effects, to be anti­
inflammatory, antiviral and antiallergic agents, and to inhibit several steps in the cell 
cascade (Ho et a l, 1992). The primary structure posses 15 carbon atoms and involves 
two benzene rings joined by a linear three carbon chain see Structure 2. The
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formation of the C ring (Structure 3) gives rise to a family of compounds, amongst 
which we can find isoflavonoids, flavones, flavonols, flavanones, anthocyanines, etc.
3'
Structure 2: Flavonoid primary skeleton, can be represented as a C6 - C3 - Ce system
Structure 3: The flavonoid chromane skeleton. The B ring can be positioned at C2 as 
well as C3 giving rise to two families of compounds (flavonoids and isoflavonoids 
respectively)
All flavonoids derive their carbon skeletons from two basic compounds, malonyl- 
CoA (synthesized from acetyl-CoA and carbon dioxide) and coenzyme A ester of a 
hydrocinnamic acid. Both of these precursors are derived from carbohydrates. The 
aromatic ring B and its adjacent 3-carbon side chain are derived from L- 
phenylalanine via the shikimate pathway, whereas ring A is formed by the head-to- 
tail condensation of three acetate units via the polyketide pathway that is proposed for
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the biosynthesis of phloroglucinol and resorcinol derivatives (Charron et al., 2000), 
leading to the formation of a C l5 chalcone intermediate (Martens & Forkmann, 
1998).
1.2.2.b: Baicalein and baicalin
Flavonoids are phenolic compounds isolated from plants, and several have been 
documented to be effective in preventing cancer. Baicalein (Compound 4) and its 
derivative baicalin (Compound 5), two flavones extracted from the root of Scutellaria 
baicalensis, are widely used as health supplements and herbal medicines in Asia. One 
of the supplements is the well known PC-SPES (PC is for prostate cancer and SPES 
is for hope), which is a potent eight - herb formulation sold directly to consumers that 
has promising efficacy in the treatment of prostate cancer (Marks, et al. 2002).
o h  o
Compound 4: Baicalein
Compound 5: Baicalin
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The preventive cancer activity of these flavones may be due to an interaction with 
drug metabolizing enzymes. This interaction has been under study on PAH 
(polycyclic aromatic hydrocarbons that are capable of forming carcinogen-DNA 
adducts), Ah receptors (located in cytosolic compartments) and the AhR nuclear 
translocators. The complex can initiate transcription of genes that contain cis-active 
lipophilic xenobiotic responsive elements in their promoter region. The cytochrome 
P450 family of enzymes (monooxygenases that generally act to protect cells) are the 
downstream responsive genes of AhR transactivation. The enzymes CYP1A1 and 
CYP1B1 are expressed in normal and cancer tissue and transform procarcinogens to 
carcinogens. Their inhibition is beneficial in the prevention of PAh-DNA adducts. 
Baicalein has shown effects on CYP 1A1 and CYP1B1 and shown an 
antiproliferative effect on prostate cancer, hepatoma cells and vascular smooth 
muscle cells. These effects have been measured by EROD (7-ethoxyresorufin O- 
ethylase) assay in breast cancer cells, using 7-12-dimethylbenz[a]anthracene 
(DMBA) as DNA damage inducing agent. The result obtained in this experiment 
allowed the conclusion that baicalein is a competitive inhibitor of EROD and 
decreases the expression of CYP1A1 & CYP1B1 through the interruption of AhR 
transactivation (Chan et a l , 2002).
Interaction with DNA has been supposed on a basis of an almost planar structure, 
which was determined by crystallography (Rossi et al., 2001). The compound exists 
in an almost planar conformation with a C-2-C-T bond distance of 1.476 A . The 
position of the three hydroxyl groups maximizes intramolecular hydrogen bonding, 
and each of the hydroxyl hydrogen atoms is a donor in a three-center hydrogen bond.
27
The carbonyl oxygen, 0-4, is an acceptor in an intramolecular hydrogen bond (with 
OH-5) and is also an acceptor in an intermolecular hydrogen bond with OH-6. The 
planarity of the flavone framework is dependent on structural and/or electronic forces 
that stabilize the negative charge on the exocyclic oxygen atom, 0-4.
Baicalein and baicalin were found to have different activities, showing different 
modes of action. Both compounds exhibit inhibition of DNA polymerase. The 
glycosylation of hydroxyl groups on the flavones resulted in compounds that behaved 
gradually as weaker inhibitors as the number of substituents increased (Spampinato et 
a l , 1994).
The antitumour activity of baicalin has been studied on different prostate cancer cell 
lines. The experiments were performed using growth inhibition assay, fluorescent 
staining of nuclei, cytotoxicity assay and TUNEL labeling, analysis of DNA 
fragmentation and Western blot analysis. As a result, baicalin was demonstrated to be 
cytotoxic to the majority of the studied prostate cancer cell lines. The inhibition effect 
was found in concentrations > 200 pM. The presence of baicalin in the nucleus was 
confirmed by the staining of apoptotic cells. It was found that baicalin given orally is 
not toxic, but intramuscular injection can cause fever and muscle aches (Chan et al., 
2000; Hiipaka et al., 2002) and it shows activity against human hepatoma cells 
(Motoo et a l, 1994).
Structural studies in breast cancer cell lines showed that hydroxyl groups at positions 
in carbons 3’ and 4’ decreased antitumour activity. Apparently, there must be an 
optimal pattern of hydroxylation that is necessary for a flavonoid to have estrogenic 
activity. The flavones with hydroxyl substituents at carbon atoms 4’ and 7’ were
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invariably estrogenic and an additional group at carbon 5’ increased estrogenic 
activity. Despite of having more than 4 hydroxyl groups, a methoxylated substituent 
would abolish the estrogenic activity (So et al, 1997). The antiproliferative effect 
may not be due to the effect of the binding to the estrogenic receptor, according to 
results observed in other types of breast cancer cells that do not express the estrogen 
receptor. In these, the flavones inhibited protein kinase C activity in intact cells (So et 
al., 1996; Ferriola et al., 1989).
Quercetin and rutin (Compounds 6 and 7 respectively) are present in Artemisia 
scoparia (Janbaz et al., 2002). They are found to be potent as chemopreventative 
agents (Gerhause et al., 2003) and are used in a wide range of conditions. They are 
sold as supplements and drugs. Between them, quercetin is the most known and 
different studies have been performed to test their activities.
1.2.2.c: Quercetin and rutin
O H
O H
O H
O H  O
Compound 6: Quercetin
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Compound 7: Rutin
Quercetin is an inhibitor of HIV-1 protease (Xu, 2000) and of the Vpr gene product 
(the Vpr gene encodes a protein which induces arrest of cells in the G2 phase of the 
cell cycle). Quercetin also presents a mechanism of action in haem catabolism 
(Khong et a l , 1990; Kopach et al., 1980). As a flavonoid, quercetin has been tested 
for activity as an antiallergic and anti-inflammatory agent. Studies showed that 
quercetin inhibits IgE (immunoglobulin E) mediated release from mast cells, IgG 
mediated histamine and SRS-A (slow reaction substance of anaphylaxis) from 
chopped lung fragments, as well as effective inhibition of AE5 -  lipoxygenase 
(Welton et a l , 1986). Furthermore, rutin also possess hepatoprotective activity (La 
Casa et a l , 2000).
Anticancer activity has been under study in different in vitro and in vivo assays. 
Experiments showed that quercetin inhibits the growth of several cancer cell lines and 
the antiproliferative activity of the molecule is mediated by a type II estrogen binding 
site.
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An investigation of the effect of quercetin and cisplatin, alone and in combination, on 
ovarian cancer cells showed a synergestic antiproliferative activity (Scambia et al., 
1990).
The same result was found on human promyelocytic leukemia cells as well as in 
murine leukemia cells (Cipak et a l , 2003). Probably one of the modes of action of 
quercetin for its antitumour activity is the influence on mitosis (Gawron, 1995), as 
well as inhibition of mutated p53 (Avila, 1994).
This last result was observed on breast cancer cells where an accumulation of cells at 
the G2 -  M phase was observed. The cytotoxic effect of quercetin would be via an 
intracellular metabolic activation of the compound to o-quinone (Segura-Aguilar et 
a l , 1999).
Quercetin appears to be cell-type specific, displaying a decrease in heat-induced 
synthesis of hsp27 (heat shock protein) and hsp70 in hepato carcinoma cells.
The drug displayed inhibition of HSF (heat shock factor) (1 and 2), DNA-binding 
activity and HSF expression (Hansen et a l, 1997).
Derivatives of quercetin have been under investigation on human myelogenous 
leukemia cells and adriamycin-resistant human myelogenous leukemia cells. As a 
result, a rank order of anticancer promoting activity of flavonoid derivatives has been 
established as: pentaallyl ethers > pentamethyl ethers > pentaethyl ethers > 
pentapropyl ethers > pentabutyl ethers (Ohtani et al, 2002).
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Considering the flavonol structure, quercetin could induce apoptosis by the release of 
cytochrome c to the cytosol, by procaspase-9 processing, and through a caspase-3- 
dependent mechanism (Lin M et a l , 1999).
The activity of quercetin on breast cancer cells has been extensively investigated. 
Inhibition of protein, DNA and RNA synthesis has been observed, as well as an 
increase in the amount of intracellular reduced glutathione content. Alteration on the 
cell morphology of the cells after a 24 h exposure to 25 pM of quercetin has been 
observed.
Quercetin seems to inhibit the activity of DT-diaphorase, NADPH cytochrome c 
reductase and glutathione reductase (Rodgers et a l , 1998). Quercetin appears also to 
inhibit the transcription with RNA polymerase II. This was observed in the 
transcription of a-amanitin-sensitive and resistant transcription in permeable cells 
(Rodgers etal., 1998).
Dietary iron may contribute to colon cancer risk by production of reactive oxygen 
species. To prove this premise, effects of Fe-NTA were measured with H2O2 in a 
Fenton reaction with quercetin (in concentrations of 25-100 pM) in breast 
adenocarcinoma. Inhibition of damage by quercetin reflects the potential of 
antioxidant compounds to influence this risk factor (Nose et a l , 1984; Latunde-Dada 
et a l , 2002).
Quercetin is known to inhibit heat shock protein synthesis of cancer cells and has 
being compared with the mixture of flavonoids named Sunphenon on effects on 
human cholangio-cellular carcinoma cell lines. Quercetin showed an inhibitory effect 
on tolerance to heat shock treatment. This effect may be due to a marked suppression
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of hsp72 and a delay in the reorganization of filamentous actin (F-actin) during the 
recovery period after the heat shock. As hsp90 could preserve F-actin structure during 
stress, quercetin might affect the interaction between hsp90 and F-actin without 
influencing hsp90 expression (Kudo et al., 1999).
Quercetin has been investigated as a potential chemopreventative agent against 
certain carcinogens. Acting alone, quercetin showed no interaction with DNA, but in 
the presence of Cu (II) quercetin induced DNA damage. The most effective doses of 
quercetin are 20 pM, 50 pM and 100 pM. A possible mechanism is shown in Scheme 
1(Yamashita et a l , 1999).
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Scheme 1: The mode of action of quercetin (Yamashita, 1999)
Flow linear dichroism spectra showed evidence that quercetin can intercalate DNA. 
The interaction is probably due to van der Waals interactions between the most
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hydrophobic segment of the flavonol (benzopyran-4-one) and the intercalation site 
(Zhu et a l , 2002), also 3’ and 4’ adjacent hydroxyl groups play an important role in 
the process of intercalation. This allows the chromophore to penetrate the DNA helix 
and to arrange its planar structure more or less parallel to the adjacent planes of the 
nitrogenous bases. However, the affinity is very low compared with that of a typical 
intercalating agent (Yamashita et al., 1999).
Repair effects of rutin and quercetin on purine deoxynucleotide radical cations were 
proposed as a chemopreventative activity of the flavonols. A pulse radiolysis 
technique was used for testing this premise on oxidizing deoxyguanosine 
monophosphate (dGMP). DNA damage can be caused by ionizing radiation, UV 
light, chemical agents and / or reactive oxygen species formed in the normal 
metabolism. The primary and transient forms of DNA damage are DNA base 
radicals, including radical cations and anions, which are the major products of 
ionizing radiation or oxidizing intermediates of chemical carcinogens. These radicals 
may be responsible for inducing strand breaks and form stable base lesions. Quercetin 
and rutin act as potent antioxidants, reacting with the reactive oxygen species (with 
high rate constants) and producing a stable phenoxyl radical. These properties are 
also essential for the fast repair of purine deoxynucleotide radical cations (Solimani et 
a l , 1996; Wang et al., 2001).
The mechanism of action (Zhao et al., 2002; Evgeny et al., 2003) could be explained 
by:
dGMP + • OH —> dGMP-OH* (ki)
Q (or R) + • OH —» Q(R)-PhO- (fe)
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where the reaction probability (P) is:
P=A:/[dGMP]/(&/[dGMP]+&2[Q])=0.966
This calculated result means that 96.6% of *OH produced react with dGMP to form 
dGMP-OH*. The P of dGMP reacting with *OH in repair system containing 0.1 mM 
rutin was calculated to be 97.4%. Therefore, it may be assumed that in the present 
repair system *OH reacts with dGMP predominantly to generate dGMP-OH*. 
Addition of *OH to dGMP produced two types of *OH adducts with respect to their 
redox properties, oxidizing *OH adduct (50%) and reducing *OH adduct (50%). The 
oxidizing dGMP-OH* is formed mainly by the addition of *OH to C4 (dGMP-4-OH*) 
of the purine ring. With unpaired spin density located on O atom, dGMP-4-OH* is 
oxidizing, and hence can react with quercetin and rutin. High stability of the 
complexes Q-PhO* and R-PhO* would prevent phenoxy radicals reacting with other 
biomolecules.
L2.2.d: Daidzein
Daidzein (Compound 8) belongs to a variety of organic molecules named 
isoflavonoids.
Isoflavonoids are divided into seven categories: isoflavone, isoflavane, isoflavanone, 
coumestane, pterocarpane, rotenoid, coumarone and chromone.
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Compound 8: Daidzein.
The majority of isoflavonoids are present in soybeans. Daidzein, amongst them, is 
present in the form of glycoside; esterified with malonic acid (Watanabe et al., 2002). 
Isoflavonoids are thought to be the biologically active components in soy. They play 
a role in the prevention of coronary heart disease and breast and prostate cancer. 
Mechanisms to explain how isoflavonoids mediate beneficial effects have not yet 
been clearly established.
Another characteristic of isoflavonoids is their structural similarity with estrogens. 
They are, thus, named phytoestrogens (plant substances similar to 17-beta-estradiol 
with estrogenic effects (Lei et al., 2002).
The antitumour activity of daidzein has been tested in order to elucidate a mechanism 
of action. It has been found that daidzein is active against human colon tumour cells. 
A study based on cell cycle progression and differentiation of murine and human 
cells, showed that daidzein increased the cell number at S phase and decreased the 
cell number at G1 phase.
Daidzein can inhibit certain malignant phenotype of melanomas via different 
mechanisms, and could be a potential candidate for melanoma cancer therapy (Wang 
G et a l, 2002). Some epidemiological studies suggest a protective effect on the 
development of colon cancer in humans, even though this hypothesis could not be
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proven in ApcMin mice model (Sorensen, 1998). Some dietary studies demonstrated 
that certain phytoestrogens are capable of reductase induction on the ratio of 
NADPH:quinone (NADPH is reduced P-nicotinamide adenine dinucleotide 
phosphate) in colon cells by promoting NADPH iquinone reductase mRNA 
expression. This suggests a novel mechanism by which dietary phytoestrogens may 
be implicated in colorectal cancer chemoprevention (Wang W et al., 1998).
Other targets have also been related to the activity of daidzein. Daidzein presents the 
ability to induce osteoclasts directly or indirectly from their progenitors and might be 
a tool for the study of osteoclast differentiation (Tobe et al., 1997).
1.2.2.e: Puerarin
Puerarin is the major active ingredient isolated from Radix puerriae (Compound 9). 
In China, it has long been used to treat patients with coronary atherosclerosis, because 
it has the effect of dilating coronary arteries. Puerarin decreases the myocardial 
oxygen consumption by a receptor blocking effect (Youwen et al., 1999) and 
improves the microcirculation both in animal and in patients. Puerarin also acts by 
blocking the L-type calcium channels in ventricular myocytes, thus improving 
microcirculation.
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Compound 9: Puerarin
Reactive oxygen species play an important role in the genesis and development of 
many diseases, such as ageing, hypertension, inflammation, shock and 
atherosclerosis. ROS turn LDL into oxidized LDL by oxidative modification. A new 
way to prevent atherosclerosis is the scavenging of free radicals and preventing LDL 
oxidation. To test the puerarin activity, studies were performed using a riboflavin 
system to generate superoxide anions, Fenton reactions to generate hydroxyl radical, 
hydrogen peroxide to induce strand breaks on DNA and UV radiation and Cu(II) 
sulfate to cause the oxidative modification of LDL. The scavenging activity on ROS, 
the inhibitory effects on oxidative erythrocyte hemolysis, and the inhibitory action of 
puerarin on the oxidative modification of LDL were studied. The results showed that 
puerarin is active on reactive oxygen species and inhibits the oxidative effect on 
modifications of LDL; it also decreases the content of malondialdehyde and enhances 
the activity of superoxide dismutase. Puerarin could also inhibit the oxidative 
erythrocyte hemolysis and decrease the production of LPO induced by hydrogen 
peroxide (Guerra et a l , 2000).
It seems that puerarin acts as an enzymatic inhibitor of oxygen radical production, 
mediated by the peroxidase/H202/luminol/enhancer radical reactions, rather than a
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true antioxidant. A protective effect of puerarin against myocardial reperfusion injury 
has been shown, as well as ischemic retinopathy, since oxygen free radicals are the 
major culprits in these physiopathological processes (Overstreet et al., 1996).
The isoflavonoid puerarin has been traditionally used to combat alcohol problems. A 
study using rats chronically exposed to alcohol and withdrawn, showed an anxiety­
like behavior generated by a BZD agonist or a human serotonin receptor agonist in a 
social interaction test. Puerarin increased and induced significantly the level of social 
interactions in the alcohol-withdrawn rats by modifying the GABAergic (y- 
aminobutyrate receptor) and serotonergic systems that underlie alcohol withdrawal 
symptoms (Lin R et al., 1996).
1.3.a: The role o f DNA
The definition of cancer chemotherapy is the use of cytotoxic drugs either to effect a 
cure or to prolong the life of cancer patients, on their own or as an adjuvant to surgery 
or radiation.
The desired effects of an antineoplastic drug are the disruption of the cell cycle in any 
phase and the interference with the ability of malignant cells to synthesise proteins, 
enzymes or cell-support chemicals.
The targets of cancer therapies are the molecules that participate in cell reactions 
leading a cell to a carcinogenic state or molecules vital to the survival of the cancer
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cell. The three most common targets for interrupting a disease process are: enzymes, 
receptors, nucleic acids.
The genetic information stored in the DNA double helix is replicated with a high 
degree of fidelity, transcribed into messenger RNA, maintained by DNA repair, 
rearranged by recombination processes, and translated into amino acid sequences of 
proteins (this is called the “central dogma” of molecular biology (Figure 3)) (Alberts, 
1994).
We can consider that attacking the DNA will produce an effect by interrupting the 
transcription of an undesirable protein and / or the replication of the DNA in the 
dividing cancerous cell.
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Figure 3: The “central dogma” of molecular biology
(http://www.accessexcellence.org, 20/07/2006)
The process starts with the replication of DNA and the transcription of the coded 
information by a transcription process involving synthesis of RNA. The information, 
as messenger-RNA and transcription-RNA crosses the nuclear membrane where is 
translated in the ribosomes into proteins.
Cancer cells divide rapidly and an anticancer agent’s task is to prevent the cell from 
dividing. Each division requires the replication of the cell’s DNA (S phase of the cell 
cycle) and the transcription and translation of genes needed for growth; therefore any 
drug that can attack DNA is a potential inhibitor of cancer cell growth.
1.3.b: Types o f  DNA interactive agents
The interaction between the DNA and a drug can be addressed according to the 
properties that the drug shows towards DNA. Drugs bind to DNA in the following 
ways:
> intercalation: a drug slips between the base pairs thereby unwinding the DNA
> covalent binding: the drug binds covalently to N2, N7, 06, etc groups. The 
preference for guanines can be attributed to the participation of the 2-amino 
group in nucleophilic substitution and addition reactions
> groove binding: the drug binds no-covalently to specific regions of the major 
and/or minor grooves of the DNA, such binding occurs via:
■ hydrogen bonding between the drug and the hydrogen bond 
acceptors / donors of the base in the major and minor groove
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■ close van der Waals1 contacts
■ electrostatic attraction between drug and DNA
These ways of binding to DNA are used to describe and divide the drugs into the 
following different categories (Figure 4):
>  alkylators: the oldest class and most widely used anticancer agents. 
Almost all of these molecules are direct acting or latent prodrug forms of 
nitrogen mustards. The prodrug forms require enzymatic activation or chemical 
breakdown to the active species. Alkylators like quinacrine, bind covalently to 
electron-rich nucleophilic moieties (Stockmana et al., 2002). The most frequent 
site of DNA alkylation is the N-7 position of guanine; however, adducts are also 
formed at the 0-6 and N-l positions of guanine; N-7, N-3, and N-l positions of 
adenine; the N-3 position of cytosine; and the 0-4 position of thymidine (Ren et 
a l , 1999).
> intercalators: the intercalation process involves the insertion of an 
agent, usually a compound containing a planar, aromatic ring between the base 
pairs of the duplex nucleic acid, together with localization of substituents on the 
ring system in opposite grooves of the helix (Ren et al., 1999). In the binding 
process, therefore, one of the side chains needs to pass through the duplex. It 
has been found that intercalation is a necessary, though insufficient, property for 
high in vivo and in vitro anticancer activity.
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> crosslinking agents: these drugs are bi-functional and are able to
covalently bind to DNA and link either the 2 strands of DNA covalently 
together or link two parts of the same DNA chain in an intramolecular way. The 
chemical groups capable of this are present in nitrogen mustards, nitrosoureas, 
hydrazines and platinum compounds.
> code reading agents: These have the ability to bind sequentially and
selectively certain segments of DNA.
> double stranded breaking agents: they are usually known as a specific
category of antibiotics.
Figure 4: DNA interactive agents (Hurley, 2000). This figure clearly shows the mode 
of binding of a crosslinker agent, and intercalator, a double stranded break, a code 
reading agent and a quadruplex interactive agent.
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1.3. c. 1: Duplex DNA strucutures
Cancers mostly originate from alterations in the DNA, leading to the expression of 
unwanted enzymes and proteins. Targeting the DNA is one possible way to stop the 
cancer cells from reproducing themselves. Some types of DNA anticancer agents 
(cisplatin, doxorubicin) are non-selective agents, targeting the whole genome, while 
others are sequence selective agents permitting the interference with an undesired 
gene (amide linked imidazole / pyrrole oligomers) (Hurley, 2000).
Different types of DNA structures can be found in cells. In the most common duplex 
DNA form (Figure 5, B-DNA), the ribose -  phosphate backbone is on the outside, 
due to the mutual repulsion of the negative charges of the phosphates; therefore the 
bases face inwards and pack together. The bases are associated by complimentary 
hydrogen bonding: A:T and G:C. The bonding C:G is stronger than A:T due to the 
formation of 3 hydrogen bonds instead of two as in A:T (Baguley, 1981). The two 
chains are held together ( Figure 6) by hydrogen bonds between these complementary 
bases. The planes of the bases are perpendicular to the fibre axis and they are joined 
in pairs. One of the pair must be a purine and the other a pyrimidine for bonding to 
occur. If it is assumed that the bases only occur in the structure in the most plausible 
tautomeric forms (that is, with the keto rather than the enol configurations) it is found 
that only specific pairs of bases can bond together. These pairs are: adenine (purine) 
with thymine (pyrimidine), and guanine (purine) with cytosine (pyrimidine) (Sun et 
a l , 2003). At lower water contents the bases tilt so that the structure could become 
more compact leading to an unusual form of DNA (Figure 5, A-DNA). Another
44
r'i
unusual form of DNA is the so-called Z-DNA that appears under high salt 
concentrations, low pH and the DNA contains a large amount of G-C sequence.
P  ,  Major Groove
Major Groove
'  Minor Groove*
A -fo rm  R N A  B -fo rm  D N A  Z -fo rm  D N A
Figure 5: DNA duplexes (www.tulane.edu) in 3 possible conformations. Form A 
appears under dehydration, form B is the most common, and Z appears under high 
salt concentrations.
Figure 6: Hydrogen bonding (www.chembio.uoguelph.ca) between adenine - 
thymidine and guanine -  cytosine.
B-DNA is the most stable helical form adopted by random sequence DNA in 
physiological conditions (see Figure 5) and is the one mostly targeted by DNA 
interactive agents.
A-DNA is a conformation that appears under dehydrating conditions. This 
conformation is also stable for RNA because it avoids the steric interference of 2'-0 
and phosphate as well as for DNA-RNA hybrids.
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Z-DNA is formed at high salt concentrations by sequences rich in GC and have 
alternating purine -  pyrimidine pairs (GCGCATGCGC). Its relevance is still 
controversial (Mergny et al., 1992).
L3.C.2: DNA triple structures
Intermolecular triplex DNA only forms under certain conditions and thus its normal 
appearance in cells is still a matter of research. However, the formation of this 
unusual structure is explored as part of the antigene therapy, where triplex forming 
oligonucleotides have been shown to inhibit transcription of a promoter region, 
indicating that they could be used as selective gene repressors in cells (Spitzner et a l , 
1995). Some drugs (NB-506) are known to stabilize these structures allowing a better 
repression of the genes (Ren et al., 2000). The inter-molecular DNA triplex is formed 
when pyrimidine or purine bases occupy the major groove of the DNA double helix, 
forming additional Hoogsteen pairs with purines of the Watson-Crick base pairs 
(Figure 7). Intermolecular triplexes, formed by the addition of a sequence specific 
third strand to the major groove of duplex DNA, are shown to have potential as site- 
directed mutagens, repressors of transcription and inhibitors of replication. Antigene 
therapy is based on the use of triplex forming oligonucleotides to control gene 
transcription and replication (Jenkins, 2000).
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Figure 7 - Triplex base arrangements. The first arrangement is an example of TA.T 
triplet, the second is an example of CG.C+ triplet (which is protonated). The Watson 
-  Crick hydrogen bonds are the ones between the two bases on the right (in both 
examples), and the Hoogsteen hydrogen bonds are located on the left. Reverse 
Hoogsteen bonds (antiparallel fashion) can be found when the third strand consists of 
purine bases (www.imbg.ku.dk)
The triplet AT:T is more stable than CG:C, the latter requiring a non-ground-state 
protonated form of C. There are two types of triplex motifs: parallel motif (YRY) and 
antiparallel motif (RRY). The parallel motif is characterised by a homopyrimidine 
(dT, dC) third strand that binds parallel to the homopurine strand (dA, dG) of the 
duplex (central strand of the triplex). This motif has two types of triplets: a T:AT 
triplet which is formed when a thymine in the third strand Hoogsteen base pairs with 
an adenine in the duplex; and a C+:GC triplet which is formed when a protonated 
cytosine in the third strand Hoogsten base pairs with a guanine in the duplex 
(favoured by low pH) (Lipsett, 1964). The antiparallel motif is characterised by a 
homopurine third strand that binds antiparallel to the homopurine strand of the
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duplex. This motif has three canonical triplets: a G:GC triplet which is formed when 
a guanine in the third strand reverse Hoogsteen base pairs with a guanine in the 
duplex; an A:AT triplet which is formed when an adenine in the third strand reverse 
Hoogsteen base pairs with an adenine in the duplex; and a T:AT triplet which is 
formed when a thymine in the third strand reverse Hoogsten base pairs with an 
adenine in the duplex. The canonical triplets are not isosteric (Rajagopal et a l , 1989).
1.3.C.3: Telomeres
The vast majority of cancers occurring in human adults are carcinomas of epithelial 
origin. These tumours present highly rearranged karyotypes with a high frequency of 
non -  reciprocal translocations. These events are closely linked to cancer 
development by the generation of fused genes, modification of gene copy number or 
de-regulation of the expression of various oncogenes (O’Hagan et al., 2002). 
Epithelial tumours derived from normal cell lineages undergo continual proliferation 
throughout life, even though they present low telomerase activity leading to 
progressive telomere shortening in these cells (Maser et a l , 2002). The frequency of 
chromosomal fusion events seems to be proportional to the frequency of rapid 
telomere length changes. Some chromosomes with less than 200 base pairs telomere 
sequence show a rapid and heterogenous increase in chromosomal instability 
(Mumame et al., 1994).
Telomeres are complex structures comprised of higher order chromatin loop and 
specific binding proteins at each chromosome end. Telomeres can contain repetitive
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sequences such as G4T4G4, generated by telomerase, which are species dependent. 
Their function is to extend the genomic sequence so that the loss of nucleotides from 
the 3’ end is harmless.
Telomere length may be maintained in cancer cells by:
> the ribonucleoprotein telomerase (a specialised reverse trancriptase) (Lingner 
etal., 1997) or
> an alternative lengthening of telomeres (ALT) mechanism. The significance 
of this mechanism in carcinogenesis remains unclear (Stewart, 2002), 10% of 
human tumours present no detectable telomerase activity and some of them 
display an ALT positive mechanism, meaning that ALT + cells could induce 
tumours in vivo without excluding the possibility that some telomerase 
negative tumours might not have any telomere lengthening mechanism
Cytogenetic studies suggest that telomere maintainance via an ALT mechanism or 
telomerase activity is not equivalent in tumorigenesis efficiency (Scheel et a l , 2001). 
Inherited abnormalities of telomere maintenance may contribute to cancer and ageing 
(Reddel et a l , 2003).
In normal human cells, the telomeres contain up to 15 kilobases of tandem repeats of 
the hexanucleotide, TTAGGG, and this amount decreases by an average of 50-150 
base pairs per cycle, this event limits the number of times a cell can divide and acts as 
a tumour suppressor mechanism (Desmaze et al., 2003). The great majority of 
cancers escape from the limitations on proliferation, imposed by normal telomere 
shortening, via activation of a telomere length maintenance mechanism. In most
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cancers, telomere length is maintained by telomerase, but some are telomerase- 
negative and they maintain the length of their telomeres by ALT. The telomeric DNA 
sequence is recognised by specific binding proteins, and they form a putative cap 
structure that protects the chromosome end from degradation or from attempted DNA 
repair. The telomere of normal and telomerase positive cells form a loop structure in 
which the chromosome end is effectively hidden. Uncapping results in the 
recognition of the telomere by the cell as a DNA break, and the probability of 
uncapping increases as the telomere shortens (Blackburn, 2000). Repression of 
telomere maintenance in ALT cell lines results in cell death or senescence, this 
suggests that inhibitors to telomere length maintenance mechanism may be a useful 
form of cancer treatment (Perrem et a l , 1999).
Telomere sequences are composed by four strands that associate through guanine 
quartets, (Figure 8); this structure is called a tetraplex or quadruplex. A central role 
for the whole structure is played by the single stranded 3’G -  rich overhang of around 
150 -  200 bases in length, which can form characteristic G-quadruplex secondary 
structures under physiologic ionic conditions.
DNA quadruplex and G quartets are four stranded structures, (Figure 9). They are 
found naturally as terminating sequences at the ends of eukaryotic chromosomes or 
telomeres (Wang J, 1991).
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Figure 8: Guanine quartets (www.il.mahidol.ac.th/.../quadruplex3.gif, 20/07/2006 )
Quadruplex strands may be arranged parallel or antiparallel; when they are 
antiparallel the guanines are in syn conformation on one strand and in anti on the 
other; see Figures 9 (Cheng, 1999).
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Figure 8: Guanine quartets (www.il.mahidol.ac.th/.../auadruplex3.gif. 20/07/2006 )
Quadruplex strands may be arranged parallel or antiparallel; when they are 
antiparallel the guanines are in syn conformation on one strand and in anti on the 
other; see Figures 9 (Cheng, 1999).
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The intermolecular antiparallel G -  quadruplex model and the intramolecular basket 
G -  quadruplex model are potentially involved as anaphase bridges, telomeric and 
promoter regions. It has been hypothesised that these structures might be important 
for telomere function (Sen, 1988); the 3’ overhang structure could hinder the telomere 
from elongating and inhibit the activity of the enzyme. Compounds like 3,6-bis- 
amidoacridines (Schultes et a l , 2004) stabilise G-quadruplex structures and 
stabilisation of these structures is an attractive target for telomerase (or ALT in some 
cancers) inhibition leading to a new strategy in the search of anticancer agents.
1.3.d.e: DNA -  metal interactions
Trace and ultratrace metal concentrations play a definitive role in many biological 
processes and without their intervention many reactions would not proceed. Metals 
have a natural aptitude for interacting with DNA because of their affinity for basic 
nitrogen and oxygen donors. Cellular regulation also depends on metals, in the form 
of metallonucleases, to catalyse and repair DNA strand breaks. Lewis acidic metal 
ions like Cu2+, Zn2+, Fe3+ are supposed to cleave the phosphodiester bonds as they 
would lower the pK* of coordinated water forming an active hydroxide nucleophile 
(Boemer et al., 2005).
A positively charged metal ion can interact in different ways with the negatively 
charged residues of DNA phosphates and the electron donor atoms of the bases, such
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as N and O. The predominant mode of metal binding takes place at the N7 and O6 of 
guanine, the N7 and N1 of adenine, and the N3 of pyrimidines.
Alkali metal ions prefer to interact with AT rich region of the minor groove. 
Transition metal ions usually bind directly to the bases and indirectly to the 
phosphate groups. Most of them react with the N7 atom of purine or N3 of 
pyrimidine thereby disturbing the double helix. The binding of transition metal ions 
particularly at G-C sites of DNA leads to damage through radical generation from 
oxidation by H2O2 . Figure 10 shows different possibilities of metal -  DNA binding.
Figure 10: Metal ions can bind to one or two sites of the same strand (intrastrand) or 
of the opposite strand (interstrand), or through intercalation in a complex form 
between the bases. The binding of metal ions can lead to single strand break (ssb) or 
to double strand breaks (dsb) (Anastasopoulou, 2003).
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1.4: Aims o f this PhD
The development of drugs that are highly selective and produce minimal toxicity to 
host tissue remains one of the most difficult challenges in cancer therapeutics. Since 
the majority of malignancies are treated with drugs in combination, one approach to 
solve this problem is to develop new therapeutic agents that will potentiate the 
effectiveness of current clinical treatments.
Drug discovery begins with the extraction of molecules from natural products, 
combinatorial libraries or by computer aided drug design; biophysical and biological 
tests are performed in order to identify a lead compound. Progressive modifications 
are performed in the selected scaffold with the aim of improving binding and 
anticancer activity; this is an iterative step, where tests give indications for 
synthesising a next generation of compounds, which are tested again. This leads to 
candidate compounds, to be tested in hospital facilities at clinical trials.
The intentions of this project are:
> to understand the mode of binding of selected compounds of natural origin 
with proven anticancer activity to a selected target
> to generate structure-activity studies that will provide a better insight into 
their mode of binding
> to synthesise compounds with improved affinity, selectivity and anticancer 
activity
To do this we have used a range of different biophysical and biological techniques to 
study drug -  DNA interactions. We subsequently used the results from these studies
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to propose additional structures to investigate and organic synthesis in order to obtain 
the desired molecules. We divided this project in 3 main steps:
> analysis of natural products for activity against a chosen target (Chapters 3); 
from here we selected a scaffold appropriate to use as a foundation for a first 
generation of modified compounds
> organic synthesis in order to modify the scaffold (chapters 2 and 4)
> structure-activity related studies and biological evaluation of the first 
generation of compounds with DNA (chapter 4).
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Chapter 2: Materials and methods
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2.1.a: Buffers
Buffer A: Na2HPC>4 2 mM, NaH2P04  8 mM with ImM EDTA 
(Ethylenediaminetetraacetic acid), pH 7.4.
Buffer B: Na2HP04 20 mM, NaH2P04 80 mM, NaCl 300mM, EDTA O.lmM.
Buffer C: cacodylate 50 mM, MgCh 50mM, EDTA O.lmM, pH 6.5.
Buffer D: Na2HPC>4 6 mM, Na^PCU 2 mM, NaCl 185mM, EDTA O.lmM, pH 7.4.
Buffer PBS: NaCl 150 mM, Na2HP04 8.1 mM, NaH2P04 1.9 mM,
Buffer TE IX: Tris HC11 mM, EDTA 0.1 mM
Buffer TBE IX: Tris borate 89 mM, EDTA 2 mM
Buffer TAE IX: Tris acetate 0.8 mM, 0.02 mM EDTA
Buffer E: hepes (N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)) 10 mM
2.Lb:- Nucleic acids
STDNA (highly polymerized sodium salt; 58.8% A-T and 41.2% G-C (Arrowsmith, 
1999)), was purchased from SIGMA Aldrich (United Kingdom) and used in filtered 
buffer solutions. The molar concentration was determined spectrophotometrically, 
using an extinction coefficient: £260 = 13200 M^cm'1 for STDNA (Arrowsmith, 1999) 
and expressed in base pairs. Poly(dAdT)2, poly(dGdC)2, polydAdT, polydGdC, 
polydT polynucleotides were purchased from Sigma Aldrich (United Kingdom) and 
dissolved in water to generate stock solutions. The molar concentrations were 
determined spectrophotometrically, using the following extinction coefficients: £260 = 
13100 M^cm"1, 16800 M^cm’1, 12000 M^cnT1, 14800 M^cm'1 (in the case of 
polydGdC we used maximum wavelength 253 nm, £253) and £260 = 8500 M^cm'1 
respectively and expressed in base pairs (Arrowsmith, 1999). Triplex DNA 
polydAdTdT was prepared using a ratio of 1:1 poly(dAdT):poly(dT). The molar
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concentration was determined spectrophotometrically, using the following extinction 
coefficient: 8260=17200 M^cm'1 (Arrowsmith, 1999) and expressed in base triplets. 
Triplex purine (G3A4G3:C3T4C3:G3A4G3) was prepared using a ratio of 2:1 
(G3A4G3:C3T4C3). The molar concentrations were determined spectrophotometrically, 
using the following extinction coefficient: £255=11500 for G3A4G3 and 8271=8300 
M^cm'1 for C3T4C3 (Arrowsmith, 1999). For the quadruplex DNA, the human 
telomeric sequence (AG3T2AG3T2AG3T2AG3), was used. The molar concentration 
was determined spectrophotometrically, using the following extinction coefficient: 
£260= 73000 M^cm'1 and expressed in base quadruplex (Arrowsmith, 1999). 
Oligonucleotides were purchased from MWG (United Kingdom) and SIGMA 
Genomics (United States of America).
2.1.C.1: Chemicals
All compounds used in binding studies were dissolved in DMSO in stock 
concentration solutions of 10 mM. Artemisinin, baicalein, baicalin, chrysin, 
flavanone, flavone, hemin, holotransfenin, luteolin, puerarin, quercetin, rutin and 7- 
hydroxyflavone were purchased from Sigma -  Aldrich (United Kingdom). Artesunate 
was donated by Dr Thomas Efferth (Germany). 3',4'-Dihydroxyflavone was 
purchased from Lancaster Chemicals (United Kingdom). Daidzein was purchased 
from Acros Chemicals (United Kingdom). 8,13-Diethyl-6-methylquino[4,3,2- 
&/]acridinium iodide (in the future referred to as acridine derivative) was provided by 
Prof. Malcolm Stevens (University of Nottingham), e506 nm = 11635 M'1 cm'1 
(Missailidis, 2002). FeCL, FeCl3, MgCl2, ZnCl2, CuO and MnCl2 were dissolved in 
DMSO to form stock concentration solutions of 10 mM.
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2.1.C.2: Synthesis
Instruments:
Mass Spectrometry: ESMS VG Quattro from Fisons with a Waters 7.1.7 
autosampler, solvent 10:90 watenmethanol.
JH NMR and 13C NMR: 300 MHz Jeol instrument, chemical shifts and coupling 
contants are given in ppm and J in Hz, solvent used deuterated chloroform (CDCI3). 
IR (infrared): Perkin Elmer: 1710 Infrared Fourier Transform Spectrometer, all the 
samples were measured in methanol as solvent.
Melting point: Electrothermal Digital Melting Point apparatus, all measures were 
uncorrected.
Elemental Analysis: Medac Ltd.
2.1.d.I - Isoflavone (3-Phenyl-4//-chromen-4-one)
Compound 12
We followed the protocol of Singh (Singh et al., 1990): TTA (thallium (III) acetate) 
(1.2 equiv.) was added to a solution of flavanone (0.672g, 3 mmol) in acetonitrile (20 
ml) in the presence of p-toluenesulfonic acid (p-TSA, 0.4 equiv.). The reaction 
mixture was refluxed at 95°C for 24 h and cooled to room temperature; CH2CI2 (50 
ml) was added and the solution kept at 0°C for 15 min; the reaction was followed by 
TLC. The solid obtained was filtered to remove thallium salts and washed with 
CH2CI2 (2 x 25 ml). The combined filtrate was washed with H2O (2 x 50ml), 
followed by saturated aqueous NaHCC>3 (2 x 100 ml) then dried (MgSCU). The
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solvent was evaporated under vacuum and the residue purified by semi-preparative 
HPLC (high performance liquid chromatography) in an hexane:ethyl acetate (9:1) 
eluant. ES-MS m/z (relative intensity): 223(MH+). 'H NMR: 8.29 (dd, J 8.1/8.1, 1H), 
7.99 (s, 1H), 7.66 (t, J 7 .0 ,1H), 7.55-7.34 (m, 7H); 13C NMR (CDCL3): 176.2,156.2, 
153.0, 133.6, 131.8, 128.9, 128.5, 128.2, 126.4, 125.4, 125.2, 124.6, 118.0. Melting 
point: 135-136.5°C, literature reference 134-135°C (Singh et al, 1999). Yield: 0.33g. 
Extinction coefficient: 9266 M'1 at 310nm. 1
2.1.d.2 - Thioflavone (2-Phenyl-4//-chromene-4-thione) (Abdou et a l , 1994)
Compound 14
Lawesson’s reagent was used for this simple substitution of oxygen by sulfur: 
Lawesson’s reagent (0.6 equiv.) was added to flavone (2.23g, 10 mmol) dissolved in 
toluene (100 ml) and the reaction mixture was refluxed overnight. The reaction was 
followed by TLC. The solvent was evaporated and the residue purified by silica 
column chromatography using a hexane:ethyl acetate gradient as eluent followed by 
further purification by preparative TLC using hexane:ethyl acetate (70:30) as eluents 
to give a red solid. ES-MS m/z (relative intensity): 238.01 (M). !H NMR: 8.55 (dd, J 
8.25/8.25, 1H), 7.93 (dd, J 2.01/2.01, 2H), 7.73 (s, 1H), 7.65 (m, 1H), 7.5 (m, 4H), 
7.35 (m, 1H); 13C NMR (CDCLj): 202, 154.2, 151.5, 134.15, 131.8, 131.1, 129.9,
129.2, 128.6, 126.5, 126.2, 120.3, 118.4. IR: 2924.8, 2853, 1743, 1597, 1501, 1460, 
1261, 1121.4, 928.5, 769. IR (cm'1): 2924.8, 2853.1, 1743.3, 1597.4, 1501.8, 1460,
1261.5, 1124.4, 928.5. Elemental analysis found: C 75.2%, H 4.2%, calculated: C
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15.6%, H 4.24%. Yield: 1.65g. Extinction coefficient: 7799 M'1 at 470nm. Melting 
point: 84-85.5°C, literature reference 85-86° (Abdou et al., 1994).
2.1.d.3 - Azaflavone (2-Phenyl-4//-benzo[e][ 1,3]oxazin-4-one) (Kemp et al., 1980)
Compound 15
Benzoyl chloride (1 equiv.) was added to a solution of salicylamide (0.685g, 5 mmol) 
in toluene (30 ml). The reaction mixture was refluxed till no further change by TLC 
was observed. p-TSA was added, the solution refluxed and 1 equiv. of water was 
extracted by azeotropic distillation. The remaining solution was washed with 
saturated aqueous NaHCC>3 (2 x 50 ml), followed by H2O (2 x 25ml), then dried with 
MgSCU. The solvent was evaporated and the residue purified by silica column 
chromatography using a gradient of hexane:ethyl acetate as eluent. ES-MS m/z 
(relative intensity): 241.84 (M+NH^, 263 (M+K+). *H NMR: 8.18 (dd, J 7.5/1.03, 
2H), 7.5 (m, 5H), 7.3 (t, J 7.14, 1H), 6.83 (d, J 7.86, 1). 13C NMR: 167, 163, 155.1, 
134.5,133.9,129,128.6, 128,126.4,118.3,117. Yield: 0.05g.
2.1.d.4 - Flavone (2-Phenyl-4£7-chromen-4-one) (Ares et al., 1993)
Compound 10
KOBu (1 equiv) was added to dry THF (100ml) under a nitrogen atmosphere. The 
mixture was cooled to 0-5 °C, and 2-hydroxyacetophenone (0.408g, 3 mmol) in THF 
(100  ml) was added dropwise, the ice bath was then removed and the mixture allowed 
to warm to room temperature and stirred for 50 min. The reaction mixture was re­
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cooled to 0-5 °C and benzoyl chloride (1 equiv) was added dropwise, the ice bath was 
removed and the mixture stirred at room temperature for 60 min. The mixture was 
again recooled to 5 °C and KOBu (1 equiv) was added, stirred at room temperature 
for 10 min and finally refluxed overnight. The mixture was diluted with water (100 
ml) and acidified to pH 2 with 1M HC1, the diketone was extracted into ethyl acetate 
(3 x 50 ml), washed with saturated sodium hydrogen carbonate (2 x 100 ml), dried 
with MgS(>4, and evaporated. Crystallization with ethanol afforded white needles. 
This crystalline diketone was dissolved in glacial acetic acid (30 ml) containing 
concentrated sulfuric acid (2 ml) and refluxed for 40 min. The acetic acid was 
removed by high vacuum evaporation, and the residue was poured onto crushed ice 
(200 ml) and the resulted solid was filtered. The product was purified by silica 
column using a gradient of hexane:ethyl acetate as eluent to give pure flavone. ES- 
MS m/z (relative intensity): 223.5 (M+H+l). ‘H NMR: 8.29 (dd, J 7.95/1.7, 1H), 7.91 
(dd, J 8.5/1.03, 2H), 7.68 (m, 1H), 7.55 (m, 4H), 7.35 (t, J 7.1/1.1, 1H), 6.76 (s, 1H); 
I3C NMR: 178, 162, 155, 133.8, 131.6, 129, 126.2, 125.5, 125.2, 118, 107.4. Yield: 
15.4% respect to 2-hydroxyacetophenone. Extinction coefficient: 9325.8 M1 at 313nm. 
Melting point: 98.5-100°C, literature reference 99°C (Shivhare et al, 1985).
2.1.d.5 - 3’,4’-Dichloroflavone (3',4'-Dichloro-3-phenyl-4//-chromen-4-one) (Singh, 
1993)
Compound 31
KOBu (1 equiv) was added to dry THF (tetrahydrofuran) (100ml) under nitrogen 
atmosphere. The mixture was cooled to 0-5 °C, and 2-hydroxyacetophenone (0.408g,
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3 mmol) in THF (100 ml) was added dropwise, the ice bath was then removed and the 
mixture allowed to warm to room temperature and stirred for 50 min. The reaction 
mixture was re-cooled to 0-5 °C and 3,4-dichloridebenzoyl chloride (1 equiv) was 
added dropwise, the ice bath removed and the mixture stirred at room temperature for 
60 min. The mixture was again recooled to 5 °C and KOBu (1 equiv) was added, 
stirred at room temperature for 10 min and finally refluxed overnight. The mixture 
was diluted with water (100 ml) and acidified to pH 2 with 1M HC1, the diketone was 
extracted into ethyl acetate (3 x 50 ml), washed with saturated sodium hydrogen 
carbonate (2 x 100 ml), dried with MgS0 4 , and evaporated. Crystallization with 
ethanol afforded white needles. This crystalline diketone was dissolved in glacial 
acetic acid (30 ml) containing concentrated sulfuric acid (2 ml) and refluxed for 40 
min. The acetic acid was removed by high vacuum evaporation, and the residue was 
poured onto crushed ice (200 ml) and the resulted solid was filtered. The product was 
purified by silica column using a gradient of hexane: ethyl acetate as eluent to give the 
pure flavone derivative. ES-MS mlz (relative intensity): 293 (M+H+). !H NMR: 8.1 
(dd, J 8.04/8.04, 1H), 8.03 (d, J 8.16, 1H), 7.8 (dd, J 8.678.6, 1H), 7.7 (t, 1H), 7.65- 
7.55 (m, 2H), 7.4 (t, 1H), 6.78 (s, 1H). 13CNMR: 117.5, 160.46, 155.7, 135.2, 134,
131.2, 131, 127.7, 125.3, 125.2, 125, 123.4, 118, 107.7. Melting Point: 203- 205 °C. 
Yield: 11.5% respect to 2-hydroxyacetophenone. Extinction coefficient: 2439 M'1 at 
320nm.
2.1.d.6 - 2-Acetylphenyl-3’,5,-dinitrobenzoate
no2
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Under argon dry triethylamine (1 equiv) was added dropwise to 2- 
hydroxyacetophenone (0.408g, 3 mmol) in dry diethylether (50 ml) with stirring and 
cooling in ice bath. The reaction mixture was allowed to stir for 15 min and 3,5- 
dinitrobenzoyl chloride (1 equiv) dissolved in dry diethyl ether (50 ml) was added 
dropwise over 30 min. The reaction mixture was allowed to attain room temperature 
and the product was used directly for the next procedure.
2.1.d.7 - 3*,5’-Dimtroflavone (3',5'-Dinitro-2-phenyl-4//-chromen-4-one) (Marder et 
a l ,1997)
NO,
N02
Comound 30
KOBu (1 equiv) was added to dry THF (100 ml) under a nitrogen atmosphere. The 
mixture was cooled to 0-5 °C and 2-acetylphenyl-3',5'-dinitrobenzoate (0.99g, 3 
mmol) in THF (100 ml) was added dropwise. The ice bath was then removed and the 
mixture allowed to warm to room temperature for 50 min and then refluxed 
overnight. Upon cooling, the mixture was diluted with water (100 ml), acidified to pH 
2 with 1M HC1, and the diketone was extracted into ethyl acetate (3 x 50 ml). The 
extraction was washed with saturated sodium hydrogen carbonate (2 x 100 ml), dried 
with MgSC>4, and evaporated. Crystallization with ethanol afforded yellow needles. 
This crystalline diketone was dissolved in glacial acetic acid (30 ml) and concentrated 
sulfuric acid (2 ml) and refluxed for 40 min. The acetic acid was removed by high 
vacuum evaporation, the residue was poured into crushed ice (200  ml) and the 
product was extracted with ethyl acetate. After evaporation of the solvent, the product 
was purified by silica column using a gradient of hexane:ethyl acetate as eluent to
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give the pure flavone. ES-MS m/z (relative intensity): 313.03 (M+H+). *H NMR: 9.8 
(d, J 2.2, 1H), 9.1 (t, J 2.01, 1H), 9.04 (d, J 2.01, 2H), 8.17 (dd, J 7.89/1.47/1.47, 1H), 
7.7 (m, 1H), 7.4 (dd, J 6.9/1.1/1.1, 1H), 7.01 (s, 1H); 13C NMR: 182.3, 162.5, 159,
149.1. 148.3, 137.3, 134, 132.7, 128.9, 127.5, 126.8, 124.9, 120.1, 109.2, 106.8. IR 
(cm’1): 3097.3, 1709.7, 1629.4, 1544, 1343, 1160, 756. Melting Point: 127 -  129.5 
°C. Yield: 0.4g. Extinction coefficient: 2276 M'1 at 403nm.
2.1.d.8 - 2,6-Dihydroxy-3-nitroacetophenone (Cushman et al., 1994)
o 2n
OH O
Nitric acid (density=1.42 mg/ml, 1.2 ml) in glacial acetic acid (2 ml) was slowly 
added to a solution of 2,6-dihydroxyacetophenone (2.4g, 16 mmol) in glacial acetic 
acid (13 ml) with stirring and cooling using an ice-water bath. The reaction mixture 
turned a dark-red colour and was stirred for 40 min at room temperature. The mixture 
was poured onto ice-water (80 ml) to give a solid product that afforded 2 ,6 - 
dihydroxy-3-nitroacetophenone by purification with silica column using a gradient of 
hexane:ethyl acetate as eluent and used directly for the next procedure.
2.1.d.9 - 5-Hydroxy-8-nitroflavone (5-Hydroxy-3',5'-nitro-3-phenyl-4H-chromen-4- 
one) (Cushman e ta l , 1994)
Compound 26
KOBu (1 equivalent) was added to dry THF (100ml) under nitrogen atmosphere. The 
mixture was cooled to 0-5 °C, and 2,6-dihydroxy-3-nitroacetophenone (0.6g, 3mmol) 
in THF (100 ml) was added dropwise. The ice bath was then removed and the mixture
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allowed to warm to room temperature and stirred for 50 min. The mixture was again 
cooled to 0-5 °C and benzoyl chloride (1 equiv) was added dropwise, the ice bath was 
removed and the mixture stirred at room temperature for 60 min. The mixture was 
recooled to 5 °C and KOBu (1 equiv) was added, stirred at room temperature for 10 
min and finally refluxed overnight. The mixture was diluted with water (100 ml) and 
acidified to pH 2 with 1M HC1. The diketone was extracted into ethyl acetate (3 x 50 
ml) and washed with saturated sodium hydrogen carbonate (2 x 100 ml), dried with 
MgS0 4 , and evaporated. Crystallization with ethanol afforded yellow needles. This 
crystalline diketone was dissolved in glacial acetic acid (30 ml) and concentrated 
sulfuric acid (2 ml) and refluxed for 40 min. Acetic acid was removed by high 
vacuum evaporation. The residue was poured onto crushed ice (200 ml) and the solid 
filtered. The product was purified by silica column using a gradient of hexane:ethyl 
acetate as eluent to give pure flavone. ES-MS m/z (relative intensity): 324 
(M+H+2/K). ‘H NMR: 8.3 (d, J 9.3, 1H), 7.8 (d, J 2.1, 2H), 7.5 (m, 3H), 6 .6  (s, 1H),
6.3 (d, J 9 .3 ,1H); 13CNMR: 182,169.1, 164.6, 157, 139, 132.3, 131.9, 130.4, 127.9,
126.5, 121.6, 119.5, 117, 107.8. Yield: 0.37g. Extinction coefficient 3355.3 M'1 at 
410nm.
2.1.d.l0 - 5-Hydroxyflavone (5-Hydroxy-3-phenyl-4//-chromen-4-one) (Ares et a l, 
1993)
Compound 20
KOBu (1 equiv) was added to dry THF) (100ml) under nitrogen atmosphere. The 
mixture was cooled to 0-5 °C, and 2,6-dihydroxyacetophenone (0.456g, 3 mmol) in
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THF (100 ml) was added dropwise, the ice bath was then removed and the mixture 
allowed to warm to room temperature and stirred for 50 min. The reaction mixture 
was re-cooled to 0-5 °C and benzoyl chloride (1 equiv) was added dropwise, the ice 
bath removed and the mixture stirred at room temperature for 60 min. The mixture 
was again recooled to 5 °C and KOBu (1 equiv) was added, stirred at room 
temperature for 10 min and finally refluxed overnight. The mixture was diluted with 
water (100 ml) and acidified to pH 2 with 1M HC1, the diketone was extracted into 
ethyl acetate (3 x 50 ml), washed with saturated sodium hydrogen carbonate (2 x 100 
ml), dried with MgS0 4 , and evaporated. Crystallization with ethanol afforded pale 
yellow needles. This crystalline diketone was dissolved in glacial acetic acid (30 ml) 
containing concentrated sulfuric acid (2 ml) and refluxed for 40 min. The acetic acid 
was removed by high vacuum evaporation, and the residue was poured onto crushed 
ice (200 ml) and the resulted solid was filtered. The product was purified by silica 
column using a gradient of hexane:ethyl acetate as eluent to give pure flavone. ES- 
MS m/z (relative intensity): 238.75 (M+H*). *H NMR: 12.58 (s, 1H, OH), 8.2 (m, 
2H), 7.9 (m, 2H), 7.55 (m, 2H), 6.8 (dd, J 8.25/8.25, 1H), 6.4 (d, J 8.2, 1H), 6.7 (s, 
1H); 13C NMR: 183.4, 163.7, 162.9, 158.9, 137.8, 136.8, 136.2, 135.5, 132.1, 129.1, 
126.4, 111.26, 107.2, 105.8. Melting Point: 148- 150.5 °C. Yield: 0.06g. Extinction 
coefficient: 2396.8 M'1 at 330mn.
2.1.d.ll - 6-Hydroxyflavone (6-Hydroxy-3-phenyl-4//-chromen-4-one) (Aksnes et 
a l ,1996)
HO"
Compound 19
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KOBu (1 equiv) was added to dry THF (100ml) under nitrogen atmosphere. The 
mixture was cooled to 0-5 °C, and 2,5-dihydroxyacetophenone (0.456g, 3 mmol) in 
THF (100 ml) was added dropwise, the ice bath was then removed and the mixture 
allowed to warm to room temperature and stirred for 50 min. The reaction mixture 
was re-cooled to 0-5 °C and benzoyl chloride (1 equiv) was added dropwise, the ice 
bath removed and the mixture stirred at room temperature for 60 min. The mixture 
was again recooled to 5 °C and KOBu (1 equiv) was added, stirred at room 
temperature for 10 min and finally refluxed overnight. The mixture was diluted with 
water (100 ml) and acidified to pH 2 with 1M HC1, the diketone was extracted into 
ethyl acetate (3 x 50 ml), washed with saturated sodium hydrogen carbonate (2 x 100 
ml), dried with MgS0 4 , and evaporated. Crystallization with ethanol afforded yellow 
needles. This crystalline diketone was dissolved in glacial acetic acid (30 ml) 
containing concentrated sulfuric acid (2 ml) and refluxed for 40 min. The acetic acid 
was removed by high vacuum evaporation, and the residue was poured onto crushed 
ice (200 ml) and the resulted solid was filtered. The product was purified by silica 
column using a gradient of hexane:ethyl acetate as eluent to give pure flavone. ES- 
MS m/z (relative intensity): 238.85 (M+H4). *H NMR: 11.6 (s, 1H), 7.8 (m, 2H), 7.4 
(m, 3H), 7.3 (d, J 8.1, 1H), 7.2 (dd, J 7.49/1.5, 1H), 7.1 (d, J 2.5, 1H), 6.7 (s, 1H). 13C 
NMR: 179.4, 163.9, 155.1, 154.7, 150.3, 148.7, 131.4, 128.8, 126.2, 123.7, 119.2,
107.7, 106. MP: 145 -  147 °C. Yield: 0.070g.
68
2.1.d.l2 - 7-Methoxyflavone (7-Methoxy-3-phenyl-47/-chromen-4-one) (Shin et al., 
1999)
Compound 24
Methyl iodide (1 equiv) was added dropwise to 7-hydroxyacetophenone (0.714g, 
3mmol) in dry THF (100ml) with stirring at 50°C in presence of K2CO3 (3 equiv). 
The reaction mixture is allowed to stir till no further change was observed by TLC. 
The product was purified by silica column using a gradient of hexane:ethyl acetate as 
eluent. ES-MS m/z (relative intensity): 253.3 (M+H+). *H NMR: 7.9 (d, J 8.4, 1H), 
7.74 (m, 2H), 7.39 (m, 3H), 6.84 (d, 2.37, 1H), 6.8 (dd, J 8.72/2.3, 1H), 6.6  (s, 1H), 
3.78 (s, 3H). 13C NMR: 177.8, 164, 162.9, 157.9, 131.3, 128.9, 126.9, 126, 117.7,
114.3, 107.4, 100.3, 55.72. Melting Point: 111 -  112.8 °C. Yield: 0.67g. Extinction 
coefficient: 27255 M'1 at 310nm.
2.1.d.l3 - 5-Hydroxy-7-methoxychrysin (5-Hydroxy-7-methoxy-3-phenyl-7/7- 
chromen-4-one) (Shin et al., 1999)
0H 0 Compound 25
Methyl iodide (1 equiv) was added dropwise to chrysin (0.766. 3mmol) in dry THF 
(100 ml) with stirring at 50°C in the presence of K2CO3 (3 equiv). The reaction 
mixture was allowed to stir till no further change was observed by TLC. The product 
was purified by silica column using a gradient of hexane:ethyl acetate as eluent. ES- 
MS m/z (relative intensity): 269 (M+H4). !H NMR: 12.65 (s, 1H, OH), 7.77 (m, 2H), 
7.43 (m, 3H), 6.54 (s, 1H), 6.48 (d, J 2, 1H), 6.25 (d, J 2 ,1H), 3.77 (s, 3H). 13C NMR:
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182.3, 165.5, 163.8, 163.8, 162, 157.6, 131.7, 128.9, 126.1, 125.4, 105.6, 98.1, 92.6,
55.7. Elemental analysis, found: C 72.09%, H 5.17%, calculated: C 71.64%, H 
4.51%. Yield: 0.48g. Extinction coefficient: 5478 M'1 at 340nm.
2.1.d.l4 -  5,7-Dimethoxychrysin (5,7-Dimethoxy-3-phenyl-4H-chromen-4-one) 
(Shin etal., 1999)
Compound 22
Sodium hydride (2 equiv) was added to 5-hydroxy-7-methoxychrysin (0.8 lg, 3mmol) 
in dry THF (100 ml) with stirring at 50°C. Methyl iodide (1 equiv) was added 
dropwise to the reaction mixture, which was allowed to stir till no further change was 
observed by TLC. The product was purified by silica column using a gradient of 
hexane:ethyl acetate as eluent. ES-MS m/z (relative intensity): 283.51 (M+H+). *H 
NMR: 7.77 (m, 2H), 7.4 (m, 3H), 6.58 (s, 1H), 6.48 (d, J 2.2, 1H), 6.28 (d, J 2.2, 
1H), 3.86 (s, 3H), 3.82 (s, 3H). 13CNMR: 177.5, 163.9, 160.8, 160.5, 131.09, 128.8, 
125.8, 108.9, 96, 92.7, 56.3, 55.7. Elemental analysis, found: C 72.13%, H 4.96%, 
calculated: C 72.33%, H 5.00%. Yield: 0.24g. Extinction coefficient: 11494.9 M'1 at 
320nm.
2.1.d.l5 -  5,7-Diacetoxychryysin (5,7-Diacetoxy-3-phenyl-4//-chromen-4-one) 
(Shin etal., 1999)
oac o Compound 23
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Acetic anhydride (2 equiv) was added dropwise to chrysin (0.762 g, lmmol) in dry 
pyridine (50 ml). The reaction mixture was allowed to stir under reflux till no further 
change was observed by TLC. The product was purified by silica column using a 
gradient of hexane:ethyl acetate as eluent ES-MS m/z (relative intensity): 338 
(M+H+). ‘H NMR: 7.78 (m, 2H), 7.45 (m, 3H), 7.3 (d, J 2 .4 ,1H), 6.79 (d, J 2.4, 1H), 
6.59 (s, 1H), 2.35 (s, 3H), 2.29 (s, 3H). I3C NMR: 184.9, 164.5, 163.9, 163, 158.5, 
157, 149, 131.6, 128.7, 125.9, 124.4, 123.6113.5, 109, 108, 57, 39.7. Melting Point: 
196.2 -  197 °C. Yield: 0.68g. Extinction coefficient: 3577.8 M 1 at 315nm.
2.1.d.l6 - 7-(2-(Dimethylamino)ethoxy)-5-hydroxy-3-phenyl-4//-chromen-4-one 
(Briggs et al., 1982)
Compound 27
N,N-Dimethylethanolamine (1 equiv) was added to chrysin (1.52g, 6mmol) in dry 
THF (30 ml) in the presence of triphenylphosphine (1.1 equiv); sonication at 40 kHz 
was carried out till the materials were soluble. DIAD (1.3 equivalent) was added 
dropwise and sonication carried out for 60 min. The solvent was evaporated and the 
product poured into acidic water (100 ml). Dichloromethane (50 ml) was used to 
extract the triphenyl oxide and hydrazine derived product. The aqueous layer was 
neutralized (pH 7), extracted with ethyl acetate (3 x 20 ml), the extract washed with a 
saturated solution of NaHCC>3 (3 x 25 ml), dried with MgSCU and the solvent 
evaporated. The product was purified by silica column using a gradient of 
hexane:ethyl acetate:isopropanolamine as eluent. ES-MS m/z (relative intensity): 
325.48 (M+H+ 4). 'H NMR: 12.5 (s, 1H), 7.8 (d, J 2 .2 ,2H), 7.4 (m, 3H), 6 .6  (s, 1H),
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6.4 (d, J 2.2, 1H), 6.3 (d, J 2.2, 1H), 4.07 (t, J 5.6,2H), 2.7 (t, J 5.7, 2H), 2.3 (s, 6H). 
13C NMR: 182.4, 164.7, 164, 162, 158, 132, 131.3,129, 126.3, 106, 98.6, 93.2, 66.7, 
58, 45.9. Melting Point: 126 - 126.8 °C. Yield: 0.55g. Extinction coefficient: 10229 
M 1 at 309nm.
2.1.d.l7 - 7-(3-(Dimethylamino)propoxy)-5-hydroxy-3-phenyl-4//-chromen-4-one
Compound 28
N,N-Dimethylpropanolamine (1 equiv) was added to chrysin (1.52g, 6mmol) in dry 
THF (30 ml) in the presence of triphenylphosphine (1.1 equiv); sonication at 40 kHz 
was carried out till the materials were soluble. DIAD (1.3 equivalent) was added 
dropwise and sonication carried out for 60 min. The solvent was evaporated and the 
product poured into acidic water (100 ml). Dichloromethane (50 ml) was used to 
extract the triphenyl oxide and hydrazine derived product. The aqueous layer was 
neutralized (pH 7), extracted with ethyl acetate (3 x 20 ml), the extract washed with a 
saturated solution of NaHCC>3 (3 x 25 ml), dried with MgSC>4 and the solvent 
evaporated. The product was purified by silica column using a gradient of 
hexane:ethyl acetate:isopropanolamine as eluent. HRMS m/z (relative intensity): 
found 340.1543, calculated 340.1544. ‘H NMR: 7.8 (dd, J 1.65/ 2.2, 2H), 7.4 (m, 
3H), 6.6  (s, 1H), 6.4 (d, J 2.2, 1H), 6.3 (d, J 2 .2 ,1H), 4.07 (t, J 5.6, 2H), 2.7 (t, J 5.7, 
2H), 2.3 (s, 6H), 1.03 (q, J 6 .6 , 2H). I3C NMR: 187, 169.7, 168.4, 162.4, 136.5,
133.7, 130.8, 128.7, 126.4, 118.4, 110.2, 103.3, 97.63, 71.53, 60.7, 37.2, 31.9. Yield: 
0.52g. Extinction coefficient: 2476 M'1 at 370ntn.
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2.1.d.l8 - 7-(2-(mMorphoImoethoxy)-5-hydroxy-3-phenyl-4//-chromen-4-one
Compound 29
2-Moipholinoethanol (1 equiv) was added to chrysin (1.52g, 6mmol) in dry THF (30 
ml) in the presence of triphenylphosphine (1.1 equiv); sonication at 40 kHz was 
carried out till the materials were soluble. DIAD (1.3 equivalent) was added dropwise 
and sonication carried out for 60 min. The solvent was evaporated and the product 
poured into acidic water (100 ml). Dichloromethane (50 ml) was used to extract the 
triphenyl oxide and hydrazine derived product. The aqueous layer was neutralized 
(pH 7), extracted with ethyl acetate (3 x 20 ml), the extract washed with a saturated 
solution of NaHCC>3 (3 x 25 ml), dried with MgSC>4 and the solvent evaporated. The 
product was purified by silica column using a gradient of hexane:ethyl 
acetate:isopropanolamine as eluent. HRMS m/z (relative intensity): found 368.1492 
calculated calc 368.1494. ‘H NMR: 7.8 (dd, J 1.65/2.2,2H), 7.4 (m, 3H), 6.6 (s, 1H),
6.4 (d, J 2 .2 ,1H), 6.3 (d, J 2 .2 ,1H), 4.09 (t, J 5.6,2H), 3.64 (t, 4H), 2.7 (t, J 5.7, 2H),
2.5 (t, 4.74, 4H). 13C NMR: 182, 164.3, 163.6, 161.6, 157.3, 131.7, 131.5, 130.7,
128.7, 128.3, 128.1, 125.9, 105.4, 98.3, 92.8, 66.4, 53.6, 53.3, 39.9. Yield: 0.50g. 
Extinction coefficient: 5495 M'1 at 314nm.
2.l.e: Tumour cell lines
Clonal populations of the MCF7 cell line and the CCRFCEM cell line were used for 
cell viability, flow cytometry and Comet assay experiments; they were donated by the
University of Nottingham. They were cultured in an initial concentration of 5 x 106 
cells per well and used 24 hours later. These cells were routinely grown in RPMI 
(Roswell Park Memorial Institute) - glutamax (SIGMA Aldrich, United Kingdom) 
supplemented with 5%, respectively of heat-inactivated foetal calf serum (GIBCO, 
United Kingdom) at 37°C, and 6% CO2 in air. The cells were subcultured twice a 
week.
2.2.a.l: Methods
Drug - DNA ligand associations can be achieved via a combination of electrostatic 
forces, hydrogen-bonding, hydrophobic interactions, van der Waals forces, etc. Other 
factors, like neighbour exclusion and cooperativity, also play a role. The result of 
these interactions is the formation of a nucleic acid -  drug complex.
The interactions of salmon testes DNA, polynucleotides, DNA triple helix and DNA 
quadruplex structures with a range of compounds were studied using a range of 
physicochemical techniques such as spectrophotometric analysis, thermal 
denaturation and competition dialysis. These techniques allow us to study the strength 
of binding, mode of action and stability. Biological techniques, such us nucleic acid 
damage assay and footprinting, make it possible to identify the sequence specificity 
of the drugs towards nucleic acids structures. Some nucleic acid intercalators have 
been shown (Liu, 1989) to alter topoisomerase activity. Therefore topoisomerase I / II 
inhibition assays were performed to elucidate any activities of our compounds as 
verified by DNA unwinding. CYP1A1 belongs to the Cytochrome P450 family, and 
is involved in detoxification -  metabolic pathways. An analytical assay has thus been
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performed in order to find possible metabolites resulting from the metabolism of 
some of our compounds by CYP1 Al.
Cell work on breast cancer (MCF7) and leukemia (CCRFCEM) cell lines was 
performed for certain compounds in order to evaluate biological activity.
2.2.a.2 -  Spectroscopic methods for the study o f DNA-drug
interactions
There are several available methods for the study of the intercalation process, 
allowing the determination of the nature and affinity of the binding. Intercalation is 
an equilibrium binding process. To determine the association constant for this 
process, the concentration of free and bound drug in the DNA-drug mixture must be 
determined. This can be done by a number of techniques including 
spectrophotometric methods and equilibrium dialysis. Intercalation also causes 
changes in the physical properties of the molecules. These changes include the 
stabilization of the DNA double helix against thermal denaturation and the unwinding 
of the double helix, which can be monitored through changes in the absorbance of the 
DNA during melting.
2.2. a. 3 - Temperature denaturation studies
When the temperature of a solution containing helical nucleic acid is raised 
sufficiently, strand separation occurs, through a process called melting. The 
temperature that marks the midpoint of the melting process is termed the melting 
temperature (Tm), it is defined as the point where 50% of the DNA is in duplex form 
and 50% of the DNA is denaturated into single strands. Single strand DNA absorbs
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more UV light than double strands and as the bases unwind an hyperchormic shift can 
be observed in the absorbance at 260 nm during the melting assay.
The equilibrium for this is:
Helical nucleic acid ^ ^  Single stranded nucleic acid
For triple helix, two Tm values can be found; the equilibria are as follow:
Triple n. ----- ► Helical n. a. + single stranded n.a. <----- ► Single stranded n. a.
Association of ligands to nucleic acids can have dramatic effects on the helix -  coil 
transition, leading to an increase or decrease in the melting temperature. The bonding 
between AT bases is the first to break (as these bases are connected through two 
hydrogen bonds), followed by the CG pairs (as they have three); the ionic strength of 
the buffer also plays an important role, as salts can shield repulsion of negatively 
charged phosphate groups. The melting curve is sigmoid, which is an indication of a 
cooperative process; this increase in absorbance is because of the reduction in 
electronic interactions through base stacking and the final absorbance therefore 
approaches that of the nucleic acid bases taken as monomers. The inflection point in 
the curve is the Tm.
To determine the drug -  NA (nucleic acid) complex stability, the drugs were 
evaluated for their ability to stabilise or destabilise STDNA and polynucleotides 
against thermal denaturation. A positive result in this experiment indicates a 
stabilization of the nucleic acid through the drug interaction, while a negative result 
indicates that the drug destabilises the DNA structure.
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Optical thermal denaturation experiments were performed in stoppered quartz 
cuvettes using a UVIKON spectrophotometer fitted with a temperature control unit 
and a programmable heated cell holder capable of maintaining the temperature to 
within ±0.1 °C over a temperature range of 25 to 98°C in a 1 cm pathlength, 3 ml 
quartz cell. DNA-drug solutions were prepared by addition of the ligand compound 
to give a final drug concentration of 2 x 10'6 M and a final DNA concentration of
10'5M in the appropriate buffer. A fixed DNA:drug molar ratio of 5:1 was used. 
Heating was applied at l°C/min until the denaturation process was completed, the 
optical absorbance at 260 nm was recorded throughout the process. The data were 
plotted using the software program Origin (Microcal, USA) giving a sigmoid curve, 
the first derivative was used to identify the maximum which is the Tm (melting 
temperature; Tcompiex ). In each case the drug -  DNA complex was compared with 
DNA alone and ATm were obtained, where AT=Tb0UndDNA -  TfreeDNA-
2.2. a. 4 -  UV titrations
When light -  either visible or ultraviolet -  is absorbed by valence (outer) electrons 
these electrons are promoted from their normal (ground) states to higher energy 
(excited) states (Sheffield, 2004). Absorption of ultraviolet and visible radiation by 
organic molecules is restricted to certain functional groups (chromophores) that 
contain valence electrons of low excitation energy. The spectrum of a molecule 
containing these chromophores is complex because the superposition of rotational 
and vibrational transitions on the electronic transitions gives a combination of 
overlapping lines appearing as a continuous absorption band. Most absorption 
spectroscopy of organic compounds is based on transitions of n or n electrons to the
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7i* excited state (200 - 700 nm). These transitions need an unsaturated group in the 
molecule to provide the n electrons fhttn://www.cem.msu.edu. 20/07/2006).
The majority of flavones and flavonols exhibit two major bands in the UV/Vis region. 
Band I is in the 320-385 nm range representing B-ring absorption, and band II is in 
the 250-285 nm range representing the A-ring absorption. An increase in the number 
of hydroxyl groups induces a red shift, for instance baicalein (with hydroxyl groups 
in the 5-, 6- and 7-positions) has a maximum at 359 nm whereas quercetin (3-, 5-, 7-, 
3’-, 4’-positions) has a maximum of absorbance at 375 nm. The absence of a 3-OH 
group in flavones (which distinguish flavones from flavonols) means that band I is 
always at a shorter wavelength by about 20-30 nm. O-Methylation and glycosylation 
produce hypsochromic shifts (Markham, 1989).
2.2.a.5: Data fitting and experimentation
Measurement of NA-drug interactions using spectroscopic methods is based on the 
fact that electronic absorption spectrum of the unbound drug is altered upon binding 
to the nucleic acid. The optical changes, due to the binding process, can be 
quantitatively measured by performing a titration and a binding curve can be plotted 
(Connors, 1987). It is relevant to consider the drug’s absorption spectrum; as it would 
need to be in the UV/Visible region, but outside the range of 200 -  300 nm, where the 
nucleic acid absorbs, so any changes in the spectrum are attributed solely to changes 
in the drug spectrum (McGhee, 1974).
For most spectra, the sample solution obeys Beer’s law, which states that the light 
absorbed is proportional to the number of absorbing molecules (concentration of
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absorbing molecules); this is true for dilute solutions. A second law, Lambert’s law, 
says that the fraction of radiation absorbed is independent of the intensity of the 
radiation. The Beer -  Lambert law is expressed as:
A = ecl = \ogiolo/1
where A is the absorbance, e is the extinction coefficient, 1 is the cell path length (in 
this project it will be considered as 1cm) and c is the concentration of the analyte, Io is 
the intensity of the incident radiation and I is the intensity of the transmitted 
radiation. The absorbance of the free drug and NA must be linearly dependent upon 
concentration, and the extinction coefficient must be invariant. The flavonoid 
compounds and the NA obey the Beer - Lambert law in the range between 10'6 -  10'3 
M. Considering this fact, any changes observed during the titration can be related to 
the drug-DNA binding process.
The data obtained by this assay have been fitted in the following equation 
(Missailidis et a l 2002, Arrowsmith, 1999), using automated fitting in the Origin 
program:
(Absf -  jl + KnD + KAbso- yj(l + KnD + KAbso)2 -  AKKnDAbso j
Absc=--------------------------------------------------------------------------------------- \-AbsonD
2KnD
where:
Absc is the absorbance calculated (by the above equation); Absf is the final 
absorbance of the drug after titration (parameter 1, PI); Abs0 is the initial absorbance 
of the drug before titration (parameter 2, P2); K is the binding constant which
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indicates the strength of binding (parameter 3, P3); D is the drug concentration in the 
solution (parameter 4, P4); n is the number of drugs per base pair when fully bound 
(parameter 5, P5; see Figure 11 for an explanation)
n=1 n=2 n=3
\s\ \^\
L ^ J  i / k S J
Figure 11: DNA binding sites. The drug is represented by the green ball, and the 
binding site (n) is the number of base pairs per drug when fully bound, base on the 
nearest neighbour model. For n=l, the drug intercalates on each base pair, that 
situation would make the DNA to extend 100%, a very unstable situation.
Absorption spectra of the compounds were obtained using a UVIKON UV/Visible 
spectrophotometer. The Beer-Lambert law was obeyed within the concentration 
ranges used for both drug and DNA solutions. The extinction coefficients of the 
compounds were determined using the following procedure: measurement of 
intensity of absorbed light for solutions with various concentrations of the test drug; a 
plot of A vs c was constructed and the line-of-best-fit through the experimental points 
was obtained. The slope of the line passing through the origin (this intercept is zero) 
was taken as the molar absorptivity. To study the changes in the UV-visible 
absorption spectra of the drugs upon interaction with NA, the following general 
method was used for a fixed volume (1 ml for each compound in appropriate buffer) 
of an aqueous drug solution (unless stated differently, the concentration were made 
up to give an absorbance between 0.5 -  1, this resulted in values of 50 pM for 
duplexes and 25 pM for triplexes and tetraplexes). The concentration of the nucleic
acids was increased by sequentially adding 2 pi of a 0.02M nucleic acid stock 
solution. The concentration of the drug in the cuvette consequently varies and the 
absorbance was therefore corrected using a standard formula: Abscorr = Abs0ng x 
(1000 + V) / 1000; where V is the volume of nucleic acid added. The UV spectrum of 
the free drug was initially measured and its UV absorbance was included in the 
calculations of association binding constants as the initial titration point. The final 
titration point was the absorbance recorded as the completely bound ligand; 
experimentally, this point was obtained by adding volumes of nucleic acid till there 
was no further observed change in the absorbance or any increase in the absorbance 
was solely due to the nucleic acids’ absorbance.
2.2.a.4 - Fluorescence titrations
Absorption of UV radiation by a molecule excites it from a vibrational level in the 
electronic ground state to one of the many vibrational levels in the electronic excited 
state; this excited state is usually the first excited singlet state. A molecule in a high 
vibrational level of the excited state will fall to the lowest vibrational level of this 
state by losing energy to other molecules through collision. Fluorescence occurs 
when the molecule returns to the electronic ground state, from the excited singlet 
state, by emission of a photon, see Figure 12.
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Figure 12: Electronic states during different fluorescence processes. The blue line 1 
is the absorption process and the blue line 2 is the fluorescence process.
(Modification o fkerouac.pharm.ukv.edu/ASRG/HPLC/fluorescence.html. 
20/07/2006).
To study the changes in the fluorescence emission spectra of the drugs upon 
interaction with NA, the following general method was used for a fixed volume (3 ml 
for each compound in appropriate buffer) of an aqueous drug solution in a 3 ml quartz 
cuvette with 1 cm path length ; the excitation and emission slit widths were set at 5 
nm; the excitation and emission values were set by scanning of the free drug and 
emission wavelengths were chosen where there was no overlap with emission from 
STDNA or the buffer A. The concentrations of the nucleic acids were increased by 
adding 6 pi of a stock solution. The concentration of the drug in the cuvette varies 
and the emission was corrected using: Abscorr = Absorjg x (3000 + V) / 3000; where V 
is the volume of nucleic acid added. Fluorescence intensity values were monitored at 
the emission maximum of the free drug, the change in the emission maximum was 
followed during the titration and the values were recorded in a FluoromaxP (Jobin 
Yvon, Japan) equipment. The fluorescence emission of the free drug was initially 
measured and was included in the calculations of association binding constants as the 
initial titration point. The final titration point was the emission recorded as the 
completely bound ligand; experimentally, this point was obtained by adding volumes
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of nucleic acid till no further change in the emission was observed. Data were plotted 
to obtain binding constants as explained in 2.2.C.2.3
2.2.a.5: Competition dialysis
The competition dialysis is based on the thermodynamic principle of equilibrium 
dialysis. In the competition dialysis experiment, a volume of NA is dialysed against a 
solution containing the drug under study. After equilibrium is reached (usually in 24 
hours), the amount of drug bound to NA is measured by UV absorbance.
The amount of analyte bound is directly proportional to the association constant for 
ligand binding to a particular structure. In 200 ml of buffer D containing 1 pM of the 
test drug, a disposable dialyser membrane (DispoDialyzer® cat: 135506, cut off of 
1000 MW) was placed with 0.5 ml of 75 pM concentration of nucleic acids. The 
beaker was covered with Parafilm and wrapped in foil, and its contents were allowed 
to equilibrate with continuous stirring at 4 °C overnight. At the end of the 
equilibration period, nucleic acid samples were carefully removed to microcentrifuge 
tubes, and were made to a final concentration of 1 % (w/v) SDS (sodium dodecyl 
sulfate) by the addition of appropriate volumes of a 10 % stock solution of SDS up to 
1 ml. The total concentration of each test sample (Ct) was determined 
spectrophotometrically, the free ligand concentration (Cf) was determined 
spectrophotometrically using an aliquot of the dialysate solution. The amount of 
bound drug (Cb) was determined by difference, Cb = Ct - Cf
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2.2.b: Determination o f pKa in an automatic titrator
Many of the interactions between drugs and receptors are dependent on the ionization 
state of the functional groups involved in the interactions, the protonation state of an 
amino group will change the type of hydrogen bonding interactions it can be involved 
in, as well as allow for it to be involved in ionic or ion dipole interactions. The 
protonation state will also affect the solubility and availability.
Determination of the pKa values of the drugs was realized according the method 
developed by Seijeant, 1984. The measures were performed in an ETS822 end-point 
titration system (Radiometer, Copenhagen). The titrations started at approximately 
pH=2, with a concentration of each drug at 0.001 M and were performed using 
aliquots of 0.1 ml from a stock solution of 0.01M NaOH. After reaching the pKa, the 
titrations were continued till a basic pH was reached and no further change was 
observed. pKa values were calculated by plotting pH vs [NaOH] in Origin 6.0, the 
inflection point being the pKa value.
2.2.c: Nucleic acid damage
Oxidative DNA damage appears to play an important role in carcinogenesis, 
commonly as a result of mutations. This damage can become apparent as alterations 
in base pairs, adduct formation, strand breaks, and cross linkages. The most common 
is the DNA single strand break. In an agarose gel, circular and open NA runs with 
different speed. Open nucleic acid runs faster than nicked nucleic acid, and they can 
be seen as separate bands. Different band lengths in a same gel will allow us to 
identify interactions between the nucleic acids and the compounds.
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The samples were incubated for 30 min at 37°C. Standard solutions of STDNA, 
polydAdT, poly(dAdT)2, polydGdC, poly(dGdC)2 and polydAdTdT at 10'5M in 
buffer A and in buffer B for triple helix, were mixed with the various drugs (2 x 10' 
6M). The gel was 1% agarose, stained with ethidium bromide (2pg/ml) in buffer 
TAE, visualized under UV light and photographed. Gel electrophoresis was 
performed at room temperature at 75 volts in an electrophoretic tank (model Passed 
MPSU-125/200 submarine gel unit). The gel was photographed using Polaroid 
Black& White film #667.
2.2.d- Linear Taqpolymerase stop PCR and Footprinting assays
Footprinting analysis provides a means of identifying the sites of equilibrium binding 
drugs on DNA. The most frequently used probe in footprinting studies is the 
endonuclease DNase I. The enzyme not only reports the sites of ligand binding but, 
since it is sensitive to local changes in DNA structure, it has also been used to 
determine the sites of ligand-induced structural changes in DNA. These are reflected 
in enhancements in the DNase I cleavage rate, appearing as sites on the DNA lattice 
bind ligand. The rate of cleavage by DNase I at a phosphodiester linkage of DNA, is 
governed by rate expression. In the drug-DNA footprinting experiment, the drug may 
influence the cleavage rate by blocking the enzyme from cleaving at certain sites, 
altering DNA structure away from the sites of binding, or causing redistribution of 
the enzyme to regions where no drug binding is occurring. The redistribution of 
enzyme should lead to increases in the rate of cleavage associated with all sites not 
involved in binding. If the total amount of cleavage on the fragment remains constant 
as drug loading occurs, the amount of enzyme on the fragment is also constant. Thus,
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drug binding shifts enzyme to unblocked sites, increasing DNAse I concentration at 
these sites. This mechanism predicts that all unblocked sites will exhibit the same 
fractional enhancement, the magnitude of which is related to the fraction of the total 
number of enzyme cleavage sites which are blocked by drug (Ward et al., 1988).
The DNAsel footprinting protocol is based on the principle that DNAsel digests the 
DNA that is not bound to the drug. The result is gaps on the sequence of the DNA. A 
basic protocol is: incubation with the drugs, incubation with the DNAsel and loading 
of samples into a denaturating polyacrylamide gel for reading. In Figure 13 a 
footprinting scheme is shown.
Autoradiogram
X  '
DNA fragment
DNAsel
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Figure 13: Dnase I footprinting representation. The drug is incubated with the DNA 
and the complex is digested with DNAsel that after radiography shows a gap in the 
bases when run in a polyacrylamide gel; this gap is called a footprint and represents 
the drug -  DNA binding site (Musciatti, 1995).
86
DNA polymerase assay also determines the specificity of binding of drugs for DNA 
sequences. In this procedure the drug is incubated with the DNA and then the DNA is 
extracted from an agarose gel in order to remove any unwanted drug and buffer. A 
PCR (polymerase chain reaction) cycle is performed on the sample using a DNA 
polymerase (ex: Sequenase); after the sample is load in a denaturating polyacrylamide 
gel, the result is similar to the one obtained by footprinting as it is shown in Figure 
13. Topo 2.1 plasmid (390 pg) was linearised with EcoRl restriction enzyme (10 
Units) in lOx reaction buffer SH (50pl) and water (450pl), 1 hour at 37°C. The 
sample was precipitated with NaOAc (3M) and ethanol 95%. Linearised DNA (0.5 
pg) was incubated with 50 and 100 pM of each drug for 30 minutes at 37°C, in buffer 
A. The DNA was extracted from a 1% agarose gel using the gel extraction Qiagen 
Kit. Linear amplification was performed in a premix total volume of 17 pi containing 
0.5 pg of DNA, primer M13 Forward -21 (5'-TGTAAAACGACGGCCAGT-3') 
(lpl), primer M13 Reverse (5'-CAGGAAACAGCTATGACC-3') (lpl), 3.5x 
sequencing PCR buffer (7.2pl) and Sequenase (lpl); 4 pi of this premix was divided 
in 4 and added in a 0.2 ml eppendorf containing each one 2 pi of dATP -  dCTP -  
dGTP -  dTTP. The amplification procedure was carried out for 30 cycles, each 
consisting of 30 sec denaturation at 94°C, 15 sec annealing at 48°C and 1 minute 
chain elongation at 72°C. The samples were taken up in formamide dye (5 pi), 
denaturated at 95°C (4 min) and removed onto ice. The DNA fragments were 
separated on 0.4 mm, 41 cm, 6% polyacrylamide gels with buffer TBE at 50°C, 
3000V for approx. 10 hours. Results were observed on LI COR 4200 sequencing 
series. The sequence specificity of covalent DNA modification by the drugs has been 
determined using footprinting assays. Oligonucleotides were purchased from SIGMA
Genomics (United States) on a scale of 0.2 pM. Duplex DNA fragments were 
prepared by PCR reaction. Linear amplification was performed in a total volume of 
100 pi containing 0.5 pg of DNA (5- 
GGGAGACAAGAATAAACGCTCAAGCAGTTGATCCTTTGGATACCCTG GG
CCTGTTGTGAGCCTCCTGTCGAA-3'), primer M13 Forward -21 (5'-
GGGAGACAAGAATAAACGCTCAA-3') (lpl), primer M13 Reverse (5'- 
GCCTGTTGTGAGCCTCCTGTCGAA-3') (lpl), lOx PCR buffer (lOpl), 0.4 mM 
dNTP mix, 0.6 pi MgCk and 2U Taq polymerase. The amplification procedure was 
carried out for 35 cycles, each consisting of 1 minute denaturation at 94° C, 1 minute 
annealing at 48°C and 1 minute chain elongation at 72°C, with a final step of 10 
minutes at 72°C. The DNA was extracted by ethanol precipitation and incubated with 
100 pM of each drug for 60 minutes at 37°C, in lOmM phosphate buffer. DNAse I 
digestion was performed for 5 minutes at 37°C using 2 pi DNAse I diluted solution to 
achieve O.Olunits/ml. The solution was stopped with DNAse I stop solution (3 pi) 
and the DNA was heated to 95°C for 10 minutes and frozen immediately in liquid 
nitrogen. The samples were stored at -20°C.
Ladder: permanganate oxidizes the C5-C6 double bond in thymines and renders the 
DNA backbone sensitive to cleavage by piperidine. The 40 mM KMnC>4 solution is 
prepared in 0.01 M phosphate buffer and stored on ice. KMnC>4 stop solution consists 
of 20 mM Tris pH 7.4, 20 mM NaCl, 40 mM EDTA, 1% SDS, 0.4M B-MeOH and 
stored at room temperature so the SDS doesn't precipitate. DNA (0.5 pg) was mixed 
with 10 pi of ice cold 40 mM KMnC>4 and incubated for 2 minutes. The reaction was 
finished by adding 20 pi of stop reaction. The DNA is extracted by ethanol
88
precipitation. The DNA was subsequently resuspended in 10 pi of 10% piperidine 
and incubated at 95°C for 30 minutes. The digested DNA was extracted by ethanol 
precipitation and resuspended in 2 pi of 0.05% bromophenol blue [w/v]; 20 mM 
EDTA in formamide) and 8 pi of distilled water.
Gel electrophoresis: the smallest glass plate was treated with 4 pi of PlusOne Bind 
Silane (Amersham Pharmacia Biotech, Sweden), in 1 ml of acidic ethanol (0.5% 
glacial acetic acid in 95% ethanol) to covalently attach the gel onto the glass plate, 
and let to dry for 5 min and remove the excess using a paper tissue moistened with 
95% ethanol. The larger glass plate was treated with 1 ml of a 2% solution of 
PlusOne Repel-Silane ES (Amersham Pharmacia Biotech, Sweeden) to assure gel 
release and let to dry for 5 min. A solution was prepared for 8% polyacrylamide 
sequencing gel; 7 M urea; 15 ml of RapidGel, 4 ml of formamide, 7.5 ml of 5X TBE 
with 525 pi of freshly prepared 10% ammonium persulfate and 112.5 pi of TEMED; 
and distilled ultra pure water added to make 50 ml of solution. The gel solution was 
applied to the assembled gel plates (0.4 mm thickness) and allowed 120 min for the 
gel to polymerize. The sequencing gel run at 80 W (42 mA; 1500 V) for 20 min or 
until the gel temperature reaches 55°C in 1 X TBE) 2 pi of 0.05% bromophenol blue 
[w/v]; 20 mM EDTA in formamide was added to the 10 pi reaction. The samples 
were denaturated for 10 min at 94°C in the thermocycler and placed on ice. Samples 
(5 pi) were loaded onto and run at 50 W for 80-100 min at 50-55°C.
Silver staining: the gel apparatus was disassembled carefully, separating the glass 
plates. The glass plate with the bound gel was placed onto a plastic tray. 1 L fixing 
solution (10% ethanol, 1% acetic acid) was applied and shaken gently for 10 min.
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The gel was washed with distilled H2O for 1 min. The oxidised gel was pretreated 
with 1 L of 1.5% nitric acid for 3 min, shaking gently. The gel was rinsed with 1000 
ml distilled H2O for 1 min. The gel was impregnated with 1 L of 0.2% AgNC>3 
solution for 20 min, shaking gently. The gel was rinsed with 1 L distilled H2O for 30 
s, twice. The gel was developed by applying 1 L of developing solution (30 g/1 
Na2CC>3; 0.54 ml 37% formaldehyde) and gently shaken until the solution is dark. 
The developing solution was subsequently removed. The developing reaction was 
stopped by adding 1 L of 5% acetic acid for 5 min. The gel was air dried overnight 
and scanned.
2.2. e : Topoisomerase I  and II inhibition -  DNA unwinding
DNA topoisomerases are a class of enzymes involved in the regulation of DNA 
supercoiling. Type I topoisomerases change the degree of supercoiling of DNA by 
causing single-strand breaks and re-ligation (see Figure 14). Type II topoisomerases 
cause double-strand breaks (see Figure 15). The different roles of DNA 
topoisomerase I and II may indicate an opposing pair of roles in the regulation of 
DNA supercoiling. Both activities are crucial during DNA transcription and 
replication, when the DNA helix must be unwound to allow proper function of large 
enzymatic machinery, and topoisomerases have been shown to maintain both 
activities. Inhibition of any of them would interrupt the processes of transcription and 
replication. Compounds like camptothecin and ureas are known inhibitors of these 
enzymes (Esteves-Souza, 2005)
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Figure 14: DNA binds to topoisomerase I and the double strand is nicked allowing 
resealing passing under the other way. Dissociation of topoisomarese I gives rise to a 
different supercoil DNA (http://bioweb.wku.edu/courses/biol220Q0/14Topoisomerase
/default.htmk 19/07/2006)
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Figure 15: Topoisomerase II interconverts topological isomers of DNA by breaking 
and resealing phosphodiester bonds (http://bioweb.wku.edu/courses/biol 
22000/14Topoisomerase/default.htmk 9/07/2006)
The topo I and II inhibition assays were carried out according to the manufacturer’s 
protocol of the topo I and topo II assay kit (TopoGen Inc., USA).
The kits used for these experiments were:
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TopoGEN Topo I Drug Screening Kit (representative for 100 assay kit size: 
supercoiled plasmid substrate DNA, 25 pg; relaxed and nicked plasmid DNA 
markers; 10X Topoisomerase I assay/cleavage buffer, 300 pi; sodium dodecyl sulfate 
(SDS) termination buffer (10%); 10X gel loading dye). Purified human 
topoisomerase was purchased from TopoGen and used according to the protocol 
provided by TopoGen. The control inhibitor was camptothecin, purchased by SIGMA 
Aldrich (United Kingdon), in a final concentration of 100 pM. Proteinase K was 
purchased by SIGMA Aldrich (United Kingdom).
TopoGEN Topo II Drug Screening Kit (representative for 100 assays: supercoiled 
DNA [pRYG DNA] 25 pg; markers are linear pRYG DNA and open circular DNA; 
10X Topoisomerase II relaxation assay buffer; 10X Topoisomerase II cleavage 
buffer; sodium dodecyl sulfate (10%); 10X Gel loading buffer (bromophenol blue, 
glycerol); control inhibitor, etoposide. Purified human topoisomerase II was 
purchased from TopoGen (USA) and used according to the protocol provided in the 
kit. Proteinase K was purchased by SIGMA Aldrich (United Kingdom). For 
toposiomerase II, cleavage as well as relaxation experiments were performed. kDNA 
/ topol and pRYG DNA / topo II were incubated at 37°C for 60 minutes with 
different concentrations of the drugs: 50 pM, 75 pM and 100 pM.
The reactions were stopped by adding 2 pi of SDS 10% and were followed by 
digestion with proteinase K, with an incubation time of 15 min at 37°C. The samples 
were run on a 1% agarose gel in TAE buffer, visualized under UV light and 
photographed. Gel electrophoresis was performed at room temperature at 75 volts in 
an electrophoretic tank (model Passed MPSU-125/200 submarine gel unit). For topol
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drug screening assay, the gel was stained after running in a solution of EtBr 5 jug/ml 
and destained in distilled water prior to be photographed using Polaroid 
Black%&White film #667.
For topo II drug screening assay, the agarose and buffer gel were containing EtBr 
(ethidium bromide) 5 pg/ml during running.
2.2./.1: Evaluation o f compounds in tumour models
The preclinical screening of potential anticancer drugs in tumour models involves in 
vitro and in vivo systems. This screening is based on the assumption that a correlation 
exists between the activity of a compound against human cancer cell lines and its 
therapeutic effect in human cancer.
2.2.f.2: Flow cytometry
The term "flow cytometry" derives from the measurement (meter) of single cells 
(cyto) as they flow past a series of detectors. The concept is that cells flow one at a 
time through a specific region where biophysical properties of each cell can be 
measured at rates of over 1000/sec. These biophysical properties are then correlated 
with biological and biochemical properties of interest. The cells are stained with 
fluorescent dyes which bind specifically to cellular constituents and the dyes are 
excited by the laser beam, emitting light at a longer wavelength. This emitted light is 
picked up by detectors, and these analogue signals are converted to digital so that
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they may be stored, for later display and analysis (Jaroszeski, 1997). Light scatter is 
utilized to identify the cell population of interest, while the measurement of 
fluorescence intensity provides specific information about individual cells. The 
measurement of the DNA content of cells was one of the first major applications of 
flow cytometry, the DNA content of the cell can provide information about the cell 
cycle, apoptosis, etc and consequently the effect of drugs on the cell cycle. This 
technique also provides percentages of cells on each cycle stage. The percentage of 
cells in the S-phase gives an indication of the proliferative activity of that cell 
population, as in this stage the cell synthesizes DNA. Another major stage is preGl, 
during which the cells prepares for RNA and protein synthesis and grows in size.
The ability of four structurally related flavonoids (baicalein, baicalin, daidzein and 
quercetin) to affect chemotherapy-induced apoptosis and cell cycle arrest of breast 
cancer MCF7 and leukemia cancer CCRFCEM cell lines was studied. The antitumour 
ability of flavonoids has been extensively documented, but the effect on cell cycle 
distribution is still unclear. Flow cytometry has been performed in order to elucidate 
the effect of our compounds to the cell cycle stages and induction of apoptosis.
MCF7 breast cancer and CCRFCEM leukemia cell lines were grown in 6 well-plates 
in an initial concentration of 3 x 105 cells/ml in the appropriate medium for 24 hours 
at 37°C and 6% CO2 in air. A period of 24 hours of incubation with 100 pM of the 
test compounds and similar concentration of DMSO, followed the initial step. MCF7 
cells were trypsinised, and both cell lines were collected in FACS tubes. After a 
centrifugation period of 8 minutes at 1200 rpm and decantation of supernatant, the 
cells were kept at 4°C overnight in a Fluorochrome solution (0.1 % Triton X I00,
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0.1% Na-citrate, 50 fxg/ml Propidium Iodide, 0.1 mg/ml RNAseA), this solution is 
used as a dye for the DNA content in cells (the propidium iodide intercalates into the 
major groove of the DNA and produces a highly fluorescent adduct that can be 
excited at 488 nm with a broad emission around 600 nm) the samples were read in a 
Beckam Coulter Epics XL equipment employing a EXP032 (Applied Cytometry 
Systems) software.
2.2.f.3: MTS cell proliferation assay
Viability assays measure the percentage of a cell suspension that is viable. This is 
generally accomplished by a dye exclusion stain, where cells with an intact 
membrane are able to exclude the dye while cells without an intact membrane take up 
the coloring agent. The MTT/S cell proliferation assay is a colorimetric assay system 
which measures the reduction of a tetrazolium component into an insoluble formazan 
product by the mitochondria of viable cells. After incubation of the cells with the 
reagent, a detergent solution is added to lyse the cells and solubilize the colored 
crystals. The samples are read using an ELISA plate reader at a wavelength of 570 
nm. The amount of color produced is directly proportional to the number of viable 
cells. The system is a quantitative test, and because there is a linear relationship 
between cell activity and absorbance, the growth or death rate of cells can be 
measured. The Cell Titer 96® AQue0us Non Radioactive Cell Proliferation Assay 
(Promega, United Kingdom) is a colorimetric method for determining the number of 
viable cells in proliferation. The tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)- 
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2//-tetrazolium, inner salts) was
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dissolved in buffer PBS and electron coupling reagent (phenazine methosulfate) was 
added according to the protocol supplied. MCF7 breast cancer and CCRFCEM 
leukemia cell lines were grown in 96 well-plates in an initial concentration of lx l0 4 
cells/ml -  0.2 ml in the appropriate medium for 24 hours at 37°C and 6% CO2 in air. 
A period of 24, 48 and 72 hours of incubation with 0, 1,5, 10, 50, 100, 500 and 1000 
pM of the test compounds followed the first step. According to the protocol 40 pi of 
MTS -  PMS solution was added and incubated at 37°C and 6% CO2 in air for 2 hours 
prior to reading. Readings were recorded at 490 nm in a plate reader (model Anthos 
Labtec 2001), employing a Deltasoft3 (Biometallics Inc) software.
2.2.f. 4: COMET ASSAY -  Alkaline electrophoresis
Analysis of Oxidative DNA damage using the Comet assay: Oxidative DNA damage 
was measured in both cell lines using the Trevigen Comet assay. The assay is a 
sensitive technique for detection of DNA damage.
The samples are treated for 24 hours with the test drugs and for positive control, H2O2 
is used. When the samples are loaded in an agarose gel and electrophoresis is carried 
out, the DNA (negatively charged) will run towards the positive pole. The cells will 
remain in their position. If the DNA has been damaged, a smear band (like comet) 
will be observed coming out of the cell representing the various DNA fragments. In a 
negative result, the cell remains intact.
An explanation of the comet assay is shown in Figure 16.
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Figure 16: Comet Assay. In presence of a DNA damage agent (like hydrogen 
peroxide) the nucleus experience a retardation when the cell is run in an agarose gel, 
giving rise to a shape of a comet tail.
Protocol was based on the Trevigen Comet Assay manufacturer’s specifications 
provided in the respective kit. Briefly, both cell lines were grown overnight in an 
initial concentration of 3xl05 cells/ml in the appropriate medium for 24 hours at 37°C 
and 6% CO2 in air. A period of 24 hours of incubation with 100 pM of the test 
compounds followed the initial step. Treatment with H2O2 was used as positive 
control. Cells were suspended in LM Agarose, lOpl of sample per 70pl low melting 
Agarose (Trevigen) and pipetted (75 pi) onto each sample well of Trevigen Comet 
Slides. Subsequently, all slides were refrigerated at 4°C for 1 hour to allow adherence 
of the agarose to the slide, then immersed in lysis solution (Trevigen). Following 
lysis, all slides were placed in alkali buffer (0.3 M NaOH, 200mM EDTA, pH>13) 
for 40 minutes at 4°C to unwind the DNA. Next, the slides were electrophoresed at 
25V, 300mA for 30 minutes. After electrophoresis, slides were neutralized in 0.4M 
Tris-HCl buffer (pH 7.4), deionized water / ethanol and allowed to dry overnight.
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Slides were then stained with SYBR green in buffer TE pH 7.4. Samples were viewed 
on a fluorescent microscope with FITC filters (excitation 494 nm, emission 521 nm).
2.2.g: CYP1A1: Analytical assay for metabolites products
The cytochrome (CYP) P450 family of enzymes is responsible for the metabolism of 
the majority of drugs and xenobiotics, consisting in subfamilies of CYP1A, 2C, 2D 
and 3A. P450s most commonly catalyse monohydroxylation, but other reactions can 
be catalysed as well. CYP1A1 is an extrahepatic enzyme responsible for bioactivating 
several classes of food or environmental procarcinogens (polycyclic aromatic 
hydrocarbons (PAHs)) like cigarette smoking products and other products of 
combustion. The CYP1A enzymes are substrate inducible; and this induction occurs 
at the level of transcription and is mediated by the cytosolic aryl hydrocarbon 
receptor. Ligand binding to the receptor induces conformational changes (named 
transformation) which allow the AhR to translocate to the nucleus and dimerize with 
the AhR nuclear translocator protein. The complex AhR-ARNT functions as a 
transcriptional activator by binding to consensus sequences present in the 5’ flanking 
DNA of numerous genes (Williams, 2001). Decreased activation of carcinogens due 
to modulation of the CYP1A enzymes has been proposed as a possible chemo- 
preventive mechanism. Flavonoids are present in the daily diet, therefore we studied 
the possible number of hydroxylations for compounds 3, 4, 6 and 8 after incubation 
with CYP 1A1, as this enzyme is the one responsible for the majority of flavonoid 
metabolism in the human body. Solutions of substrates were prepared in DMSO at a 
concentration of 10 mM. Microsomal fractions of CYP1A1 were incubated in the
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presence of a NADPH-generating system at 37°C for 60 min in test tubes. The 
incubation mixture consisted of 0.2 g/L microsomal protein, 0.1 M potassium 
phosphate buffer (pH = 7.4), 0.066 mol/L glucose 6-phosphate, 0.026 M NADP+, 
0.065 M MgCL26H2 0 , 40 IU/ml glucose 6-phosphate dehydrogenOOase and 
concentrations of 0, 25, 50 and 100 pM of test compounds in final volume of 0.5 ml. 
The metabolic reaction was initiated by the addition of microsomal protein. After 
incubation for 60 min, the reactions were stopped by cooling on ice and the mixtures 
were vortexed for 1 min, centrifuged at 12,000 g for 10 min and the reaction 
supernatants were transferred to a clean tube and freeze dried. Samples required to be 
derivatised with BFTSA (N-methyl-N-(trimethylsilyl)-trifluoroacetamide) to enable 
analysis by GC-MS; as carbohydrates cannot withstand derivatisation, baicalin 
underwent acid hydrolysis prior to treatment with BFTSA.
Acid hydrolysis: H2SO4 (0.5 M) (1 ml) was added to each sample of baicalin. The 
solutions were incubated at 37 °C for 1 h. Double distilled water (1.0 ml) was added 
and the solutions were acidified by addition of concentrated HC1 (20 ml) and 
extracted twice with diethyl ether (2.0 ml). Diethyl ether was removed under a 
reduced pressure. Derivatisation: dried samples were derivatized by addition of 
BSTFA (100 ml) at 80°C for 12 hours.
Gas chromatography coupled with mass spectrometry (GC-MS): Analyses were 
performed using a HP 5973 mass spectrometer coupled to a HP 6890 gas 
chromatograph. Separation of the analytes was achieved using an HP 5MS capillary 
column, (30 m x 0.25 mm I.D., 0.25 mm film thickness). Helium was used as carrier 
gas with a linear velocity of 0.9 ml/s. The oven temperature program was: initial
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temperature 100°C, 100-270°C at 4°C/min, 270°C for 20 min. The GC injector 
temperature was 250°C; the transfer line temperature was held at 280°C. The mass 
spectrometer parameters for El mode were: ion source temperature: 230°C; electron 
energy: 70 eV; filament current: 34.6 mA; electron multiplier voltage: 1200 V.
2.2.h: Hemin sesquiterpenes interactions
The mechanism of action of artemisinin is still unclear, but most likely involves the 
formation of free radical intermediates, originating from the direct interaction of the 
endoperoxide group with the heme iron (Messori, 2003). Artemisinin becomes 
cytotoxic in the presence of ferrous iron. Since iron influx is high in cancer cells, 
artemisinin and its analogs selectively kill cancer cells under conditions that increase 
intracellular iron concentrations.
Solutions of 1 ml of hemin 18x1 O'6 M in buffer E were titrated with 0.01 M stock 
solutions of STDNA, artesunate and artemisinin in different ratios; with and without 
stock solutions of FeCh 0.01M. Absorption spectrums of the complexes were 
obtained with a UVIKON UV/Visible spectrophotometer. Data were plotted to 
analyse interactions.
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Chapter 3: Preliminary results
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3.1: Screening o f natural compounds
As explained in Chapter 1, a group of compounds isolated from herbal extracts was 
selected for biophysical and biological testing in order to establish if there is an 
interaction between these compounds and DNA.
3.2: Drug -  DNA interactions
3.2. a: Melting temperature
A stabilising DNA agent would increase the melting point of a DNA motif, a process 
that would interfere with the replication of DNA and would not allow the cell to 
synthesise DNA and replicate, eventually leading the cell to apoptosis. On the other 
hand a destabilising agent would shift the melting point to lower temperatures 
promoting the DNA structure to open. For STDNA and polynucleotides polydAdT 
and poly(dAdT)2, one transition from double helix to single stranded is present. In the 
case of triple helix polydAdTpolydT, two transitions are observed, from triple to 
double helix, and from double to single strands.
The experiments were conducted at pH 7.4 (physiological conditions) and pH 6.5 for 
purine triplex motif (environment required to facilitate the triple structure formation) 
and in the appropriate buffer according to the nucleic acid used; buffer A for 
duplexes, buffer B for polydAdTdT, buffer C for purine triplex motif and buffer D for 
quadruplex DNA (see section 2.2.a.l); all structures were monitored by melting 
denaturation to assess formation (refer to Figures 17 a , 17 b and Appendix). Melting
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points have been calculated as the maxima of the first derivative (or differential) of 
the sigmoide curve observed when measuring the UV spectra of DNA at various 
temperatures and fitting the data in Origin 6.0 (Figure 17). The results are shown in 
Table 1.
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Figure 17a: Representation of STDNA alone melting curve and the first differential 
indicating the maxima in the curve (pink) is the inflexion point in the melting curve 
(blue).
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Figure 17b: Representation of G-quadruplex alone melting curve and the first 
derivative (1st differential) indicating the maxima in the curve (pink) is the inflexion 
point in the melting curve (blue). The first inflexion point is the transition of the TTA 
bases belonging to the loop of the tetraplex and the second point is the transition of 
the G-tetrads in the tetraplex.
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Melting points for polydGdC and poly(dGdC)2  could not be calculated as the strength 
of the GC bonds is so high that denaturating points can not be measured in the range 
of 25 - 98°C. For STDNA quercetin and rutin showed a slight destabilising effect. In 
the case of polydAdT, none of the drugs showed any activity. For polydAdT-dAdT 
the drugs proved to be non-effective (Figure 18). Quercetin (Figure 19) and baicalein 
showed to stabilised the triplex helix polydAdTdT in the first transition, by 3.2°C for 
baicalein and 7.3°C for quercetin. However, the drugs provoked a slight 
destabilisation of the second transition (Figure 19 and Table 1). An acridine 
derivative was used as the positive control for melting stabilisation of STDNA 
(AT=12°C).
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Figure 18: The results of the temperature denaturation studies for polydAdT-dAdT -  
artesunate show how artesunate (pink) does not affect the double helix melting profile
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Figure 19: The results for the temperature denaturation studies for polydAdTdT -  
quercetin show clearly that quercetin stabilises the first transition from triplex to 
double strand.
G-quadruplex oligonucleotides presented two transitions, the opening of the TTA 
loop, with a first melting point at 35.9°C and the opening of the G-bases forming the 
tetraplex strucutre with a second melting at 69.1°C. Artesunate, artemisinin, 
cantharidin and rutin do not have an effect on the stability of any DNA structure. 
Baicalein made the first melting point of the G-quadruplex disappear but did not 
affect the second, which indicates that baicalein binds preferentially to the TTA 
sequence. Baicalin and daidzein destabilised the G-quadruplex and caused its 
denaturation at a lower temperature. Puerarin did not affect the first transition of the 
G-quadruplex but stabilised the second one, implying a preference for the G-bases 
forming the quadruplex strucutre. Quercetin did not affect considerably the melting 
points of the G-quadruplex but it affected the denaturation pattern, producing the 
appearance of a third melting point (refer to Appendix).
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3.2.b.l: Association binding constants
Artesunate, artemisinin and cantharidin have no UV/visible spectrum and fluorescence 
emission; thus this experiment was performed only for the remaining compounds. 
Extinction coefficients were determined for those peak maxima that lay outside the range of 
the absorbance of nucleic acids.
Compound Wavelength (nm) Extinction coefficient (M" 
*)
Baicalein 359 14898
Baicalin 315 15556
Daidzein 310 15639
Puerarin 340 14572
Quercetin 375 11806
Rutin 365 16956
Table 2: Extinction coefficients for baicalein, baicalin, daidzein, puerarin, quercetin and 
rutin in buffer A.
The appropriate concentration of drug for binding interactions was obtained after titrations 
were performed using different drug concentrations, based on a range of absorbance/drug 
concentrations. The best results were obtained for values of 0.5 of absorbance giving a 
general concentration of 5x1 O'5 M.
To examine the DNA binding properties, we performed UV/Vis and fluorescence titrations 
(see section 2.2.a.2. to 2.2.a.4). In practice, a solution containing the test compound is 
placed into a quartz cuvette, an initial spectra is recorded (Abso), nucleic acid aliquots are 
added and stirred into the test solution and a spectra is recorded after each addition; aliquots 
are added till no further change in the aborbance. The results are initially plotted into Excel 
(Figure 20, 22). Absorption measurements at the absorption maxima wavelength vs. DNA
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concentration were fitted into the binding equation (see section 2.2.a.3) to result in a 
binding curve points and a best fitted curve coresponding to a binding constant value (full 
line) (Figure 21).
A bathochromic shift was found in all cases, except for baicalein which exhibited a 
hypochromic shift. Isosbestic points are an indication of a two-state situation, one involving 
the drug unbound and the other the drug-DNA complex (drug bound); poorly defined 
isosbestic points may indicate an interaction involving more than two states (multiple 
binding motifs). For our preliminary set of compounds we observed the following 
isosbestic points: baicalein (312, 413 nm), daidzein (297, 365 nm), quercetin (302, 464 nm) 
and rutin (311, 420 nm).
baicalein STDNA
0.9 T
0.7
0.2
362 382 402302 322 342 422
nm
Figure 20: The results of the titration of baicalein with STDNA is shown and the arrows 
indicate two defined isosbestic points; a clear indication of the formation of a sinlge drug
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-  DNA complex.
Data: baicalein - polydAdT 
Model: missailidis
0 .4 6 - ChiA2 = 9.8976E-6 
RA2 = 0.9874
±0.00479
±0.00167
0.35708 
0.45464 
13823.62303 ±2688.07637
±0
±0
0 .4 4 - P2
P3
P4
P5
0.00005
'(0 0.42 -X!
-Q 0 .4 0 -
JD
0 .3 8 -
0.36
0.00040.0001 0.0002 0.00030.0000
poly[dAdT]
Figure 21: The results of fitting the data into the binding association equation is shown
for baicalein -  STDNA complex. Please refer to see section 2.2 in Methods for an 
explanation of the parameters and the formula used.
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quercetin polydAdTdT
Figure 22: The results of the titration of quercetin with polydAdT-dT show two clear 
isosbestic points indicating a single binding of the drug to DNA triplex.
3.2.b.2: Duplex binding
The compounds do not have a strong binding affinity to any sequence A-T / G-C, with 
association constants in the range of 104 M"1. These results are in agreement with the 
melting temperature studies, where the AT of compounds for STDNA was not found to be 
> 1°C. The duplex binding data are presented in Table 3 for duplex binding constants and 
Figures 20a and 20b for fitting curves. All figures are shown in the Appendix section.
An acridine derivative was used as positive control for binding to STDNA (K lx l0 6 M '1) 
(Missailidis, 2002).
Other techniques besides UV/Vis titrations were employed in order to assess the binding 
association constants, like ethidium bromide displacement and quenching but they did not
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provide conclusive results. Another technique that would provide information is 
fluorescence (see section 2.2.a.4), this technique requires the compound to have 
fluorescence properties. For the fluorescence titrations with STDNA, the following 
excitation and emission wavelengths were used respectively: baicalein, daidzein and 
puerarin were excited at 450 nm and emitted at 530 nm, baicalin and rutin were excited at 
450 nm and emission was recorded at 531 nm, quercetin was excited at 450 nm and the 
emission recorded at 532 nm.
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Baicalein and quercetin presented similar values in magnitude for the different duplex 
forms in the order of 104M'1, with quercetin showing a slight preference for polydAdT. 
Baicalin, daidzein, puerarin and rutin presented low values for association constants, in the 
order of 103M'1, only rutin and puerarin presenting slightly higher values. With the results 
obtained from the duplex binding experiments we decided to investigate further the activity 
of the compounds on other DNA structures. Alternative DNA structures offer significant 
differences in terms of shapes and rigidity, compared to double stranded DNA. Specific 
recognition of higher order DNA, such as triplexes and quadruplexes by small ligands has 
been demonstrated in a number of studies (Ren, 1999).
3.2.b.3: Competition dialysis
To evaluate the selectivity of the drugs for different DNA structures, we performed a 
competition dialysis experiment using eight nucleic acid structures against a common drug 
solution. It is possible to correlate the amount of the bound dye to a given structure with the 
affinity of the dye for that sample (Ren, 2000), this means that the more drug found to be 
bound to the nucleic acid the more this drug will prefer that structure over the others. Each 
solution compound was placed in a beaker with the eight different nucleic acid structures 
(each structure was placed into a membrane in where the drug can cross the membrane 
freely but the nucleic acid will remain inside) and left to reach equilibrium for 24 h at 4°C. 
After this period of time the bound drug (the amount of drug inside the dialysis membrane) 
was measured by UV/Vis absorbance.
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Amongst the group of compounds, baicalein and quercetin proved to have the strongest 
activity when related to the amount of bound drug. Baicalein bound to all the structures in 
the same proportion while baicalin showed a slight preference for polydAdT and 
polydAdTdT. Daidzein and puerarin showed strongest selectivity for G-triplex, possibly 
due to the isoflavone skeleton penetrating easily the base pairs by having the B ring in 
position C-3. From these results we can pressume that hydroxyl groups in the A and B ring 
help to improve the binding; and sugar substitutions as in the case of baicalin and rutin, 
decrease the binding activity. In the case of the isoflavonoids, the B ring situated in C-2, 
decreases the binding activity. See Figures 23 a, b, c, d, e, f  for results.
b a ic a le in
polydGdC~dGdC r-T.r, . . ?^ . r;^ r.7,.V i.- r r i
polydGdC
polydAdT-dAdT
polydAdT
polydAdT-dT
Gquadruplex
STDNA
C 0.2 0.4 0.6 0 bound[u
Figure 23 a: Competition dialysis for baicalein showed preference for STDNA, this 
indicates a lack of selectivity of this compound for any precise sequence.
b a ic a lin
p o ly d G d C
p o ly d A d T
p o ly d A d T - d T
______________ 0-09 0.1 0.105 b o u n J ^ q
Figure 23 b: Competition dialysis for baicalin showed preference for polydAdTdT and 
polydAdT.
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polydGdC-dGdC 
polydGdC 
polydAdT-d AdT 
polydAdT 
polydAdT-dT 
Gquadruplex 
Gtrlplex 
STDNA
0.15  boundfiiM ]
Figure 23 c: Competition dialysis for daidzein showed preference for purine triplex and 
polydAdTdT. It might be triple structures can accommodate a plain isoflavonoid scaffold 
with the B ring facing outwards.
polydGdC-dGdC
polydGdC
polydAdT-dAdT
polydAdT
polydAdT-dT
Gquadruplex
Gtriplex
STDNA
° '15 b o u n tftA l]
Figure 23 d: Competition dialysis for puerarin showed preference for triplex purine. 
Puerarin has a similar structure that daidzein, indicating that isoflavonoids can interact 
better with G-triplex structures.
q u erce tin
polydGdC-dGdC
polydGdC
polydAdT-dAdT
polydAdT
polydAdT-dT
Gquadruplex
Gtrlplex
STDNA . . ........ ,
C 0.5 1 boundpj H]
Figure 23 e: Competition dialysis for quercetin showed a high preference for G- 
quadruplex, this coincides with the binding constant this compound has exhibited for this 
structure.
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Figure 23 f: Competition dialysis for rutin showed preference for triplex purine, G- 
quadruplex and polydGdC-polydGdC. This compound seems to prefer GC sequences at 
any structure, as rutin is similar to quercetin except for rutinoside segment in OH-3 we can 
presume this sugar substituent plays a relevant role in binding to different DNA isoform.
3.2. b. 4: Triplex binding
Baicalein and quercetin showed higher affinity for both purine and pyrimidine triplexes 
therefore we selected these two compounds for binding studies to triplex and quadruplex 
DNA. Temperature denaturation studies confirm the hypothesis that these two flavonoids 
stabilize the triplex DNA structures. In the case of polydAdT, no significant increase on AT 
was observed, but when we performed the experiment with polydAdTdT, we found an 
increase of 3.2°C for baicalein and 7.3°C for quercetin (Table 2; see also Table 4 for 
binding constants). Baicalein presented similar values for both structures, which are similar 
to the one of quercetin for polydAdTdT; but quercetin exhibited very low binding for the 
GAG triplex.
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Table 4: The results of the binding constants for triplexes structures show baicalein and 
quercetin to have similar values
Compound dAdTdT
(UV)
GAG triplex 
(UV)
K (M'1) n R1 K (M'1) n R2
Baicalein 22704.5 4 0.98 23361.8 3 0.94
Quercetin 27058.1 3 0.99 2446.1 1.4 0.98
3.2.b.5: G-quadruplex binding
G-quadruplexes are a family of high order DNA structures formed in the presence of 
cations and consist of four strands of guanines stabilized in quartets. The 3’ terminal region 
of the G-rich strand of human telomeres is single stranded and may adopt a G-quadruplex 
conformation. This structure has been shown to inhibit telomerase elongation activity in 
vitro. Telomerase is expressed in germinal, but not somatic cells, as well as almost 80% of 
all cancers. Therefore, stabilization of G-quadruplex could interfere with telomerase 
elongation and replication of cancer cells. Competition dialysis suggests that some of the 
flavonoids interact with tetraplexes. To confirm this observation we performed UV-visible 
titrations for baicalein and quercetin. The chosen oligonucleotide mimics the repeats of 
human telomeric motif, and is supposed to adopt an intramolecular quadruplex structure 
(Sen, 1988). Titrations were performed using quercetin that showed moderate activity in the 
magnitude of near 105M_1 for the G quadruplex which is in agreement with quercetin’s 
stabilising effect to the melting denaturation pattern of the tetraplex strucutre. Baicalein
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presented a lower binding activity with a K of 19012.3 M"1, similar to the values obtain for 
the triplex structures. See Table 5 for binding constants.
Table 5: The results of the binding constants for G quadruplex show quercetin to be the 
more active compound.
Compound Quadruplex
(UV)
K /M '1 n R2
Baicalein 19012.3 2 0.98
Quercetin 85417.6 2 0.96
3,2.b.6: DNA-drug-metal interactions
In nucleic acids there are two classes of binding sites available for metal interaction: the 
heterocyclic bases and the negatively charged phosphate groups. As metals are positively 
charged we would expect them to interact with the phosphate groups. However, metal ions 
have been shown to interact also directly with the DNA base or through hydrogen bonding 
via water moleclules (Anastopoulou, 2003). Quercetin has shown to interact with copper 
and produce DNA damage (Yamashita et al., 1999). We decided to investigate if the 
carbonyl bond and hydroxyl group in the ortho position really produces this effect, or at 
least increase the binding activity. Four compounds from our original group have been 
investigated for their binding to STDNA (see section 2.2.a.2 and 2.2.a.3) in the presence of 
metal ions. Baicalein, baicalin, quercetin and rutin all have at least one OH group in the 
ortho position respectively to the carbonyl in C4 (for structures please refer to 
Introduction). Six cations (as oxides) were investigated as these are commonly found in the 
cell environment: Fe2+: as part of haems (Grandorri et al., 2000); Fe3+: as part of the
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94-transferrin family (Lambert et al., 2005); Cu : already described in drug -  DNA
94 - •interactions (Asadi et al., 2005); Mg : as the second most abundant intracellular cation 
modulating many processes (Mooren et al., 2005); Mn2+: active role in mitogen activated 
protein (MAP) kinase dependent pathways (Touyz et al., 2003); Zn 2+: as part of the zinc 
finger DNA binding proteins (Sepp et a l , 2005). Monovalent cations like Na+ and K+ do 
not bind directly to the DNA, the bind by the inner water sphere and they are also less 
reactive than divalent cations (Anastopoulou, 2003); for this reason we decided to study 
only divalent and trivalent cations. Spectrophotometry was the methodology of choice and 
we performed UV-Vis titrations as described before. We approached these experiments in 
two main ratios: metal -  drug, ratio 1:1 and then titrated with STDNA and metal -  drug, 
ratio 2:1 (when two unsubstituted hydroxyls are in ortho position) and then titrated with 
STDNA, in this way we saturated all the possible hydroxyl groups in the ortho positions of 
the drugs.
Results are presented in Table 6. For quercetin the binding was not improved overall 
compared with the binding to the STDNA alone, but it is possible that the hydroxyl in 
position 3 interacts with the carbonyl and the hydroxyl in position 5 forms a complex with 
the metal cation. In the case of rutin, the binding was increased dramatically for interactions 
with Fe2+ / Fe3+ / Zn2+ in ratios 1:1, probably due to the interaction of the metals in position 
7; it is also possible the rutinoside sugar in position 3 would allow the carbonyl to interact 
alone with the hydroxyl in position 5 and form a complex with the cation. The binding of 
baicalein to DNA was decreased in all situations, which shows that hydroxyls in ortho 
position of the A ring clearly form complexes with the metal that does not allow the 
molecule to intercalate the double helix; only with Fe2+ in ratio 2:1 did the binding constant
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for STDNA remained unchanged. Baicalin maintained in the same value for STDNA 
binding constant in presence or not of any metal cation.
Table 6: The results of the titrations of the metal -  drug -  DNA complexes. The ratios of 
drug: metal are indicated under the name of the drug, the binding association constants are 
expressed in M'1, the n value appears between brackets.
Cation Baicalein Baicalein Baicalin Quercetin Quercetin Rutin Rutin
1:1, K
/M*1
1:2, K
/M*1
1:1, K
/M*1
1:1, K/M* 
i
1:2, K/M*1 1:1, K/M*1 1:2, K/M*1
Cu2+ 2395 (2.2) 1388 (2.3) 1674 (2) 12132 (2) 16222.6 6.6) 1202.7 (2.7) No interaction 
observed
Fe2+ 1117(2.7) 15385
(2.3)
2027 (2) 12899 (2) 14447.8(8.4) 130794 (2.6) 1049.2 (2)
Fe3+ 1258 (2) 1164 (2.1) 2794 (2) 9504 (2.7) 10868 (7.7) 75787 (3.2) 1154(2.1)
Mg2" 1139(2.5) 1334 (2.2) 1523(2.6) 10959 (2) 7413 (4.8) 1121 (2.5) 1119.3 (2.4)
Mn2+ 1210 (2.5) 1235 (2.3) 1086(1.9) 7885(3.3) 11307 (6.9) 10129(2) 1091.9(2.3)
Zn2+ 1625 (2.1) 1170(2.2) 1884(2.1) 10739(2.1) 10101.3 3.3) 46157 (2.5) 927(2.1)
3.2.c: Nucleic acid damage assay
Nucleic acid damage was examined by gel electrophoresis. This experiment would allow us 
to see if there is any interaction between the different nucleic acid structures and all the 
compounds, including artesunate, artemisinin and cantharidin that could not be tested by 
UV/Vis spectroscopy. Samples of complexes formed between the different nucleic acid 
isoforms and the test drugs were incubated for 30 minutes at 37°C (see section 2.2.c).
For artesunate and artemisinin, we used Fe2+/Fe3+ redox couple (ratio 1:1:1, 
metal:metal:DNA) to allow a possible mechanism of stand break as was postulated by Dr
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Efferth (recommendation by personal communication). Unfortunately, the redox couple 
damages the nucleic acid by itself and no further improvement was found when the drugs 
were added. We tested all the compounds with all the nucleic acid isoforms and no 
remarkable interaction was found for the different nucleic acid structures. In Figure 24 an 
example can be seen for the case of polydAdTpolydT.
polydAdT
holotransferrin 
+ferrosanol
Figure 24: The results of the nucleic acid damage of the drugs on polydAdTdT are shown 
in this figure with no apparent positive results. 1- NA; 2- NA+artesunate; 3- 
NA+artesunate+ Fe2+/Fe3+; 4- NA+artemisinin;5- NA+artemisinin+ Fe2+/Fe3+; 6-
NA+baicalein7-NA+baicalin; 8 -NA+cantharidin; 9 -NA+daidzein; 10- NA+puerarin, 11- 
NA+quercetin; 12- NA+rutin; 13- holotransferrin+ferrosanol
3.2.d: Linear Taq Polymerase stop PCR and Footprinting assays
The study using the Taq stop PCR (see section 2.2.f) polymerase assay did not produce 
positive results. Different PCR conditions and different treatments for purification were 
performed in order to get appropriate result. Two conclusions can be drawn, either the 
drugs are taq DNA polymerase inhibitors in the concentrations tested, or the strength of 
binding between the drugs and the plasmidic DNA is not strong enough to remain bound 
during the consecutive purification steps.
Footprinting (section 2.2.f) provides the identification of the binding sites between the 
drugs and the DNA. We used Dnase I footprinting to allocate the interaction between the
'w
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drugs and the bases. Dnase I digests the DNA that is not protected by bound drug, through 
cleaving of the phosphodiester bonds. The bound sites will appear as holes in the 
photographed gel. We used KMn0 4  and piperidine cleavage for the ladder as they cleave 
thymidine bases. As positive control we used acridine, that shows preference for (dAdT)2  
and dGdC. Our oligo was designed to have dGdC and dTdA sequences. Unfortunately 
radioactive footprinting could not be performed, which would provide a clear gel; and 
silver staining was used to replace this technique. As shown in Figure 25, the quality of the 
gel is really poor, and no precise results were obtained.
ladder
Control (-)
daidzein
puerarin
baicalein  
baicalin
quercetin
rutin
chrysin  
x a n th o n e  
acrid ine
Figure 25: The results of the footprinting assay showed silver staining is not an appropriate 
technique to use in this experiment. Two more compounds were added in this experiment, 
xanthone and chrysin, which will be explained in Chapter 4.
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3.23.e: Topoisomerase I  & II inhibition assay
We tested all the compounds for inhibition of both enzymes. The samples were tested at 
different concentrations of the test drug (50, 75 and 100 pM) for both enzymes. As in the 
case of the nulceic acid damage, the samples were run in agarose gels and they were 
visualised as bands under UV light with ethidium bromide staining. Different lengths in the 
bands are an indication of inhibition processes. Negative controls were taken as samples 
with the same volume of DMSO used in order to demonstrate the solvent has no effect by 
itself on inhibiting the enzymes. For the topo I inhibition assay camptothecin was used as 
positive control and etoposide was used for topo II. For topo II positive result, we should 
find 3 bands in the gel (open circular DNA, linear DNA and form I DNA) and the medium 
band should be in the same length as the linearised DNA. In the topo II inhibition test, we 
tested cleavage (if then drug affects the cleavage relegation cycle) and relaxation activities 
(section 2.2.g, Figures 14 and 15).
The results showed the drugs are not topo I inhibitors. Artesunate, artemisinin and baicalein 
appeared to have inhibition for topo II cleavage activity (appearing as the two upper lines in 
the gel). The rest of the compounds showed negative results.
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Figure 26a: The results of topoisomerase II cleavage activity showed a light activity of 
artesunate and artemisinin.
1: artesunate 50 pM + pRYG + topoll. 2: artesunate 75 pM + pRYG + topoll. 3: 
artesunate 100 pM + pRYG + topoll. 4: artemisinin 50 pM + pRYG + topoll. 5: 
artemisinin 75 pM + pRYG + topoll. 6: artemisinin 100 pM + pRYG + topoll
7: free.
8: pRYG + topoll. 9: pRYG + 0.5 pL DMSO. 10: pRYG + topoll + 0.5 pL DMSO. 11: 
linearised pRYG. 12: pRYG + topoll + VP-16 (etoposide, inhibitor). 13: free. 14: free. 15: 
baicalein 50 pM + pRYG + to po ll. 16: baicalein 75 pM + pRYG + topoll. 17: baicalein 
100 pM + pRYG + topoll. 18: baicalin 50 pM + pRYG + topoll. 19: baicalin 75 pM + 
pRYG + topoll. 20: baicalin 100 pM + pRYG + topoll
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Figure 26b: The results of topoisomerase II cleavage second part.
1: cantharidin 50 pM + pRYG + topoll. 2: cantharidin 75 pM + pRYG + topoll. 3: 
cantharidin 100 pM + pRYG + topoll. 4: daidzein 50 pM + pRYG + topoll. 5: daidzein 
75 pM + pRYG + topoll. 6: daidzein 100 pM + pRYG + topoll
7: puerarin 50 pM + pRYG + topoll. 8: puerarin 75 pM + pRYG + topoll. 9: puerarin 100 
pM + pRYG + topoll. 10: pRYG + topoll. 11: pRYG + topoll + 0.5 pL DMSO 12: 
linearised pRYG + 0.5 pL DMSO.
13: pRYG + topoll + VP-16 (etoposide, inhibitor). 14: quercetin 50 pM + pRYG + topoll. 
15: quercetin 75 pM + pRYG + topo ll. 16: quercetin 100 pM + pRYG + topoll. 17: rutin 
50 pM + pRYG + topoll. 18: rutin 75 pM + pRYG + topoll. 19 rutin 100 pM + pRYG + 
topoll. 20: pRYG + topoll + VP-16 (etoposide, inhibitor)
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Figure 26c: The results of topoisomerase II relaxation activity showed non conclusive 
results for any compound.
1: artesunate 50 pM + pRYG + topoll. 2: artesunate 75 pM + pRYG + topoll. 3: 
artesunate 100 pM + pRYG + topoll. 4: artemisinin 50 pM + pRYG + topoll. 5: 
artemisinin 75 pM + pRYG + topoll. 6: artemisinin 100 pM + pRYG + topoll
7: free.
8: pRYG + topoll. 9: pRYG + 0.5 pL DMSO. 10: pRYG + topoll + 0.5 pL DMSO. 11: 
linearised pRYG. 12: pRYG + topoll + VP-16 (etoposide, inhibitor).
13: free. 14: free. 15: baicalein 50 pM + pRYG + topoll. 16: baicalein 75 pM + pRYG + 
topoll. 17: baicalein 100 pM + pRYG + topoll. 18: baicalin 50 pM + pRYG + topoll. 19: 
baicalin 75 pM + pRYG + topoll. 20: baicalin 100 pM + pRYG + topoll 21: cantharidin 
50 pM + pRYG + topoll. 22: cantharidin 75 pM + pRYG + topoll.
23: cantharidin 100 pM + pRYG + topoll. 24: daidzein 50 pM + pRYG + topoll. 25: 
daidzein 75 pM + pRYG + topoll. 26: daidzein 100 pM + pRYG + topoll 27: puerarin 50 
pM + pRYG + topoll.
28: puerarin 75 pM + pRYG + topoll. 29: puerarin 100 pM + pRYG + topoll. 30: pRYG 
+ topoll. 31: pRYG + topoll + 0.5 pL DMSO 32: linearised pRYG + 0.5 pL DMSO. 33: 
pRYG + topoll + VP-16 (etoposide, inhibitor). 14: quercetin 50 pM + pRYG + topoll. 35: 
quercetin 75 pM + pRYG + topoll. 36: quercetin 100 pM + pRYG + topoll. 37: rutin 50 
pM + pRYG + topoll. 38: rutin 75 pM + pRYG + topoll. 39 rutin 100 pM + pRYG + 
topoll. 40: pRYG + topoll + VP-16 (etoposide, inhibitor)
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3.2.f: Flow Cytometry
Within the cell cycle, before cells can multiply and divide, they have to make copies of 
their DNA. Normally, most cells are not actively growing and dividing and are in the GO or 
resting phase of the cell cycle and have a diploid (two series of chromosomes, 2N DNA) 
content. Cells in G1 phase are cycling, and also have diploid content. A smaller percentage 
of cells are undergoing DNA synthesis during S phase (having between 2N and 4N DNA 
content). A few cells completed their DNA synthesis and are in G2 phase (having 4N DNA 
content). After cells double their DNA, they undergo mitosis (M phase) dividing into two 
daughters (Weinberg et al., 1996).
The ability of four structurally related flavonoids (baicalein, baicalin, daidzein and 
quercetin) to affect chemotherapy-induced apoptosis and cell cycle arrest of breast cancer 
MCF7 and leukemia cancer CCRFCEM cell lines was studied. The antitumour ability of 
flavonoids has been extensively documented (Efferth et al., 1996; Gerhauser et al., 2003; 
Wong et al., 2001), but the effect on cell cycle distribution is still unclear. Flow cytometry 
(see section 2.2.f.l) has been used in order to define in which step of the cell cycle the 
flavonoids induce apoptosis. Treatment of MCF7 breast cancer cells with the drugs showed 
that baicalein, baicalin and daidzein block in phase G1 and quercetin blocks in phase G2.
The same treatment with CCRFCEM leukemia cell lines proved that baicalein and daidzein 
act as blockers for phase Gl, daidzein also affects preGl stage and quercetin acts on preGl 
and G2 stages. See Table 7 for results.
It is noticeable these flavonoids block during the steps where the proteins are being 
synthesised (Gl) implying they can bind to earlier steps of protein cascades (by binding
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proteins and receptors) or DNA (duplex and triplex forms -  during replication). Even more, 
our postulation of these flavonoids binding DNA can be explained by the fact that quercetin 
is affecting G2 phase in MCF7 and CCRFCEM cell lines. During this stage the content of 
DNA in the nucleus is double, and this means more DNA available to be targeted; if a drug 
is said to bind preferentially DNA it will possibly do so during the stage where more DNA 
is available.
Table 7: The results of flow cytometry on both cell lines showed quercetin to be a G2 
blocker in MCF7 cell line, baicalin a preGl blocker in CCRFCEM cell line and daidzein a 
Gl blocker in both cell lines.
Stages
MCF7
Baicalein Baicalin Daidzein Quercetin Blank with 
DMSO
P reG l 3.8% 5.0% 5.7% 6.4% 8.5%
G l 57.3% 57.2% 48.5% 20.9% 58.3%
S 21.0% 20.5% 21.9% 10.3% 18.1%
G2/M
Stages
CCRFCEM
18.3% 17.7% 24.2% 62.6% 15.4%
P re G l 21.4% 53.9% 1.3% 29.6% 38.3%
G l 29.3% 22.0% 49.5% 19.5% 16.6%
S 35.4% 19.8% 30.1% 33.4% 30.5%
G2/M 14.9% 4.8% 19.8% 18.2% 15.1%
3.2.g: MTS Cell Proliferation Assay
MCF7 breast cancer cell line is an epithelial cell line while CCRFCEM is a cancer cell line 
in suspension; the interest of testing our compounds in these two cell lines relies also on the 
interest of studying if the compounds prefer epithelial cancer cell lines or cells in 
suspension (leukemias and lymphomas). Cell proliferation assay (see section 2.2.f.2) 
measures the cell proliferation rate and conversely, when metabolic events lead to apoptosis
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or necrosis, the reduction in cell viability. Data obtained from the present study indicate 
that flavonoids with very similar structures may not produce an identical biological 
response. At 24 hours of incubation, the compounds have IG50 near 100 pM in both cell 
lines. When the incubation period was prolonged to an incubation of 48 hours, the IG50 
values dropped to around 65 pM for baicalein and baicalin on MCF7, and 50 pM for 
baicalin and daidzein on CCRFCEM cell line. The incubation period of 72 hours showed 
that baicalein has some activity against MCF7 (33.12 pM) but not CCRFCEM cancer cell 
lines. Baicalin has activity in both cell lines at 72 h (63 and 44 pM for MCF7 and 
CCRFCEM cell lines respectively). Daidzein promotes growth of MCF7, something that 
could be expected as this line expresses estrogenic receptors and daidzein has estrogenic 
structure; moreover the compound does not have a strong anticancer activity on 
CCRFCEM. Quercetin showed to have anticancer activity on both cell lines when the 
incubation period was 72 hours (83.6 pM for MCF7 and 38.15 pM for CCRFCEM cell 
lines). The results are shown in Table 8.
Table 8: The results of the MTS proliferation assay demonstrated that the compounds are 
not good anticancer drugs in both cell lines. Baicalein proved to have some activity in 
MCF7 cell line at 72 h of incubation and quercetin showed some antiproliferation activity 
on CCRFCEM cell line after 72 h of exposure.
Compound IG50 MCF7 (pM) IG50 CCRFCEM (pM)
Baicalein > 100 (24); 69.65 (48); >100 (24); >100 (48); >100
33.12 (72) (72)
Baicalin >100 (24); 78.83 (48); 63.3 >100 (24); 63.98 (48);
(72) 44.56 (72)
Daidzein 93.14 (24); >100 (48); >100 59.66 (24); 44.5 (48); >100
(72) (72)
Quercetin >100 (24); >100 (48); 83.6 >100 (24); >100 (48); 38.15
(72) (72)
129
Good anticancer drugs have IC50 values in the order of 1 - 5 jxM (Czyz, 2005), this group of 
compounds clearly do not show a remarkable anticancer activity, it is possible they are 
metabolised to a less active compound, or they can’t reach properly the DNA inside the 
nucleus.
3.2. h: COMET ASSAY -  Alkaline electrophoresis
The experiment (see section 2.2.f.3) has been performed in both cell lines. Daidzein 
showed no result on MCF7 cell line, but baicalein and quercetin showed to be active in this 
cell line indicating these compounds entered into the nucleus and produced some DNA 
damage. For CCRFCEM cell line, only quercetin showed to be active and entered into the 
nucleus while baicalein, baicalin and daidzein were negative. Comparing with the results 
obtained from the cell proliferation assay and flow cytometry we can stipulate that 
quercetin may effect its anticancer activity in both cell lines by entering into the nucleus 
and affecting the DNA, this hypothesis could also apply for baicalein on MCF7 cell line but 
not on CCRFCEM, which may indicate this compound binds to another target rather than 
DNA in this cell line. Baicalin was negative on both cell lines for the comet assay, but it 
produced significant anticancer activity when compared to the other compounds, this can 
be explained either because baicalin does not enter into the nucleus and / or it has another 
target in the cells rather than DNA. See Figures 27 a, b and c for examples.
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Figure 27 a: MCF7 cell line control, no modification in shape is found.
Figure 27 b: MCF7 cell line positive control, the presence of hydrogen peroxide produces 
comet tails in the cells, a clear indication of entrance into the cell and DNA damage.
Figure 27 c: MCF7 cell line in the presence of baicalein produces comet tails in the cells, a 
clear indication of entrance into the cell and DNA damage
5.2. j: Hemin sesquiterpenes interactions
The mechanism of action of artemisinin is still unclear. Most likely it involves the 
formation of free radical intermediates, originating from the direct interaction of the
endoperoxide group with the heme iron (Messori, et al. 2003). Artesunate and artemisinin 
have no UV spectra, and it is reported that they interact with hemin as a mechanism of 
action for their antimalarial activity (Meschnick et al., 1991). We have, thus, decided to use 
hemin as a revealing agent for any DNA -  drug interaction. Hemin has a main peak at 385 
nm that shifts to 414 nm in oxidizing conditions and to 529 -  565 nm when the ferric ion is 
in low spin (Grandori et a l , 2000). Therefore, we expected that any shift in the UV 
spectrum of hemin would be an indication of a binding between DNA and artesunate / 
artemisinin if the mechanism of action involved the drugs acting as peroxides.
With artesunate (or artemisinin), hemin acts as a catalyst, reducing artesunate (or 
artemisinin) in the same way it reduces hydrogen peroxide by cleaving the oxygen-oxygen 
bond (Chen et al., 1998)
Hemin-Fe3+ + e‘ ----------► Hemin-Fe 2+
*------7-------------------------------------- 1
Hemin-Fe 2+ + artesunate (oxidised)  ►Hemin-Fe3+ + artesunate (reduced)
We used hemin as a revealing agent of any activity between artesunate / artemisinin and 
DNA. Titrations were performed between: drug -  hemin, hemin -  DNA, hemin -  DNA- Fe 
2+, hemin -  drug -  Fe 2+, hemin -  drug -  DNA -  Fe 2+, hemin -  DNA -  drug. From the 
results we obtained we can conclude that artesunate / artemisinin interacts with hemin in 
the presence or abscence of Fe 2+, but the complexes formed do not show any interaction 
with DNA in the conditions used here. In Figures 28 a, b, c, d, e the results for artesunate 
binding titrations are shown.
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Hem In (18exp-6M ) t it ra te d  w ith  DNA
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Figure 28a: Hemin titrated with DNA, there is a small increase in the absorbance upon the 
first addition of DNA and no more changes after it.
Hemin (18exp-6M) titra ted  w ith  a rte su n a te
 0 artesunate
 3exp-6
7.12exp-6
 10.68exp-6
 14.24exp-6
 17.8exp-6
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Figure 28 b: Hemin titrated with artesunate, interaction is observed as a decrease in the 
absorbance of hemin.
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Hemin 18ep-6M titrated with artesunate In presence of 18exp-6M of Fe2+
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Figure 28 c: Hemin titrated with artesunate in presence of Fe, moderate interaction is 
observed but not the one expected as a shift in the hemin absorbance spectrum.
Hemin (18exp-6M) + DNA (18 exp-6M) titrated with artesunate
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Figure 28 d: Hemin titrated with DNA in presence of artesunate, only a random interaction 
is observed.
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Hemin (18exp-6M) + Fe2+(18oxp-6M) + DNA (18oxp-6M) titrated with artesunate
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Figure 28 e: Hemin in presence of Fe2+ and artesunate titrated with DNA, no defined 
interaction is observed.
3.3.j: CYP1A1 metabolites assay
Flavonoids are known for inhibiting the CYP family of enzymes (Chan et al., 2002), and as 
explained in section 2.2.g, CYP1A1 is responsible of bioactivating a vast amount of 
compounds of the daily diet.
We decided to study the effect this enzyme has on our group of four flavonoids and to 
investigate a possible mechanism of metabolization for baicalein, baicalin, daidzein and 
quercetin.
We found that at high concentration of drug (>50 pM) the enzyme CYP1A1 (see section
2.2.g for methodology) is inhibited and no metabolites are found. While baicalein, daidzein 
and quercetin gave a positive response at a concentration of 25 pM; baicalin gave a positive
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response at a concentration of 50 pM, probably because the carbohydrate hinders the 
interaction with the substrate pocket of CYP1A1.
Table 9 shows the results obtained in this experiment. Derivatisation of flavonoids with 
BSTFA produces a main peak that is the molecular weight of the compound minus 15, a 
methyl group of the derivatising agent, and a second peak that is the molecular weight 
(Owen et al., 2003).
Table 9: CYP1A1 results for baicalein, baicalin, daidzein and quercetin. All compounds 
showed some kind of interaction after being incubated with the enzyme.
Compound Retention
time
(min)
Main 
peak (M- 
15)
Second 
peak( M)
Concentration 
of drug with 
positive 
response
Main 
peak (M- 
15)
Second 
peak( M)
Baicalein 15.3 471 486 25 pM 441 456
Baicalin 34.3 471 486 50 pM 247 262
Daidzein 18.5 383 398 25 pM 345 360
Quercetin 17.5 647 661 25 pM 264 279
Hydroxylation is the main metabolic pathway to follow, but other possibilities can be 
contemplated; in our experiment baicalein seems to follow methylation or addition of an 
acetyl group, see Scheme 2. Baicalin does not seem to follow any specific pattern and the 
only peak we can assign would be the one for the carbohydrate, which contradicts the fact 
that carbohydrates can not be derivatised by BSTFA (Owen et al., 2003), see Scheme 3. 
Daidzein seems to undergo double hydroxylation, see Scheme 4. Quercetin did not show 
any proper hydroxylation or transformation pattern in the whole molecule. This could be
due to the high hydroxylation pattern it already has. Interestingly, the peak we obtained 
seems to be some sort of modification in one ring, Scheme 5 shows different possibilities 
explaining the result obtained.
Scheme 2: baicalein after CYP1 Al, methylation is a possible process.
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Scheme 3: baicalin after CYP1A1, it is possible that CYP1A1 would act on the sugar.
2.5%HO.
HO.
OH
HO
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Scheme 4: daidzein after CYP1A1 produced hydroxylation
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Scheme 5: quercetin after CYP1A1 seemed to have produced different patterns of 
modifications in either A ring or B ring.
None of these results can be definitive as we would also need NMR spectra of each 
metabolite to define the real structure of the peaks. Unfortunately the material left from the 
incubation was not enough to perform an NMR assay. We could only presume based on the 
results of the mass spectrometry and literature. The binding studies showed that the number 
of hydroxyls is extremely relevant when considering the interaction with STDNA; the more 
number of hydroxyls a flavonoid has, the higher the binding constant. In the case of 
daidzein, hydroxylation seems to follow as metabolic pathway; but for quercetin, baicalein 
and baicalin this pathway seems to not appear. These results could explain the fact that 
some of the compounds (like baicalein and quercetin) can bind reasonably tight to DNA but 
not show a strong anticancer activity, even though they may enter to the nucleus; we can 
assume these compounds are subjected to some kind of inactivation before entering into the
nucleus or binding some other target. Baicalin showed to be slightly active in the cell work 
when cells were exposed for 72 h, but the binding to STDNA was quite weak. According to 
our results from the CYP1A1 assay, baicalin is metabolised by the enzyme and loses the 
carbohydrate. It is possible that the metabolism of baicalin results in a more reactive agent 
as anticancer agent against MCF7 and CCRFCEM cell lines, through binding to a different 
target than DNA.
3.2k: Determination o f pKa
DNA is a molecule negatively charged. We would therefore that assume a positively 
charged compound would be favoured for DNA binding. In order to know if our 
compounds are protonated on not in the conditions we used for our binding studies we 
performed appropriate studies to determine the pKa of our compounds. Artemisinin and 
cantharidin have no ionisable protons, so the experiment was performed for artesunate, 
baicalein, baicalin, daidzein, puerarin, quercetin and rutin (see section 2.2.b). According to 
the results obtained, the flavonoids are neutral at physiological pH (pH=7.4). This would 
would improve its binding to a negatively charged molecule such as DNA. Therefore, all 
our experiments are being conducted at pH 7.4, except in the case of the purine triplex 
(pH6.5) that requires a light acid pH for the conformation. In Table 10 the results of the pKa 
experiments are shown.
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Table 10: The data obtained by the pKa determination assay are presented. The compounds 
showed to be protonated at physiological pH, with the exception of artesunate and baicalin.
Artesunate Baicalein Baicalin Daidzein Puerarin Quercetin Rutin
pKa 5.67 7.57 6.33 8.42 8.57 10.3 8.02
percentage of 5.0 50.0 10.0 90.0 90.0 99.0 80.0
neutral molecule
at pH 7.4 (%)_____________________________________________________________________
The possible aqueous equilibrium for the compounds when titrated with NaOH are shown 
in Schemes 6.
CHoQC H ,0
.0
0 -N a +OH
CHCH
Scheme 6 a: artesunate loses the acidic proton
HO,HO
HOHO
HO
HO
Scheme 6 b: baicalein loses the more acidic proton
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OH. OH,OH, 0-Na+-HO-
OHHO HO OHHO OH
Scheme 6 c: baicalin loses the more acidic proton
OH
HO NaO
Scheme 6 d:daidzein loses the more acidic proton
HO n
OH ONa
Scheme 6 e: puerarin loses the more acidic proton
Scheme 6 f: quercetin loses the more acidic proton. On position 4, probably we can find an 
enolic equilibrium with arrangement (in presence of an alkali like NaOH), on positions 3’, 
4’ we can find resonance structures in the same medium
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Scheme 6 g: rutin loses the more acidic proton
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3.3 Conclusions for the foundation compounds
This study has provided a quantitative molecular basis for the DNA binding behaviour and 
biological activity of the types of intercalating compounds that formed our initial set of 
compounds. Stabilisation studies by temperature denaturation demonstrated that the 
compounds interfere mainly with the stabilization of triplex polydAdTdT and G- 
quadruplex. While the majority of the compounds destabilise the structure by 
approximately 6°C for the first melting transition point in polydAdTdT, baicalein and 
quercetin stabilized this structure by 3.2 and 7.3°C respectively. In the case of G- 
quadruplex, baicalein stabilised the first melting point transition and allowed the G- 
quadruplex to melt in a single transition. Baicalin and daidzein destabilised the structure 
and while quercetin affected the denaturation pattern.
Many techniques were employed to study the drug-DNA binding interactions in addition to 
the UV-Vis and fluorescence titrations. Ethidium bromide displacement and quenching 
were used but they did not provide any result, possibly due to the low affinity these 
compounds have for DNA. Nuclear magnetic resonance was also considered as an option, 
unfortunately this kind of experiment requires high concentrations of DNA and drug; the 
drugs need to be solubilised in DMSO prior to dilution into the aqueous buffer and at the 
concentration required for NMR studies the percentage of DMSO was over 10% in final 
volume. As this would affect the DNA (personal communication Dr. Gary Parkinson), this 
series of experiments had to be abandoned. Binding constants obtained by UV 
spectrophotometry were in the order of 103 - 104M The results indicate that baicalein and 
quercetin emerge as the most potent among the set of flavonoids, with the binding constants 
in the range of 2-8x104 M'1. Interaction with DNA is thought to involve the planar ring
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structures. The double bond of the O in C4, gives planarity to the molecule, and this allows 
the molecule to intercalate the bases in the different nucleic acid structures. The number of 
hydroxyl groups in the flavonoid also plays an important role, 3 or more hydroxyl groups 
seem to allow a better binding to different forms of nucleic acids and the position of them is 
also relevant as quercetin, with two hydroxyl groups in the B ring, showed a remarkable 
binding activity to G-quadruplex.
Competition dialysis provided us with data on the affinity of the dyes for triplex, 
quadruplex and duplex structures. We confirmed with this study the observation that 
baicalein and quercetin binds preferentially to triplexes and quadruplex by UV-visible 
titrations. Baicalein shows specificity for the AT bases, triplex and quadruplex and proved 
to be active in MCF7 cell line by arresting in G1 phase. Baicalin and Rutin have activity 
towards AT bases and baicalin arrests the preGl/Gl phase in CCRFCEM cell line. 
Daidzein and Puerarin are weak binders with specificity for GC bases. Daidzein is 
considered a phytoestrogen, promotes activity where estrogen receptors are located; that 
would explain the promotion of growth effected on MCF7 cell line.
Quercetin has interaction with tetraplex and triplex, presented activity on CCRFCEM cell 
line by arresting in G2 stage. The hydroxyl groups in positions 5, 7, 3’ and 4’ seem to have 
a strong influence on the interaction with the nucleic acids.
There is no strong correlation between the DNA -  binding and antiproliferative activity 
against the two cell lines. These facts clearly indicate that binding to DNA is not the only 
determinant for anticancer action, but other factors such as cellular uptake and protein 
inhibition may also contribute. In conclusion, quercetin can be chosen as a leading
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compound from our original set of compounds and the flavone skeleton has been 
considered for the design of a new generation of higher order DNA binding agents.
The results for topo I and II assay showed the drugs are not topo I inhibitors, and only 
artesunate and artemisinin appeared to have inhibition for topo II cleavage activity. The rest 
of the compounds showed negative results.
The employment of metal cations did not appear to improve the binding association 
constant in most cases. Moreover, they decreased by 10 fold the binding association 
constant of baicalein on STDNA; probably by reacting with some centre in the molecule 
that is involved in the binding. In the case of rutin, however, when the ratio is 1:1 the 
cations Fe (II), Fe (III), Mn and Zn improved the binding from 10 to 103 fold depending on 
the metal.
pKa values obtained for the family of flavonoids showed that they are weakly acidic which 
means they are predominantly neutral at pH 7.4 (cellular environment).
CYP1A1 metabolites experiments gave a positive response for a hydroxylation pattern in 
daidzein and a possible methylation for baicalein. For quercetin and rutin, no definitive 
response could be intepreted.
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4.1: Obtaining DNA intercalating ligands
In order to get a successful DNA intercalating agent, some properties need to be taken into 
account:
> degrees of freedom: the major requirement for intercalating agents is the planar 
aromatic ring structure. This structure fits between adjacent base pair planes and can 
have some, rotational freedom within the plane of the ring. The ligand itself may 
have flexibility of structural parts outside the DNA binding site and may contain 
more than one intercalating side chain (Laughton et al., 1999)
> role of base pair sequence: base pair sequence does not play a large role on the 
specific nature of most intercalating complexes, but some affinity has been found 
for some intercalating agents, as in the case of acridines for GC bases. (Belousov et 
al., 2004)
> counter ion effect: DNA is a negatively charged polyanion attracting counter ions, 
positively charged Na+, or Ca2+ and Mg2+ ions as well as protonated basic residues 
of proteins. The presence of small counter ion affect drug binding, since the counter 
ions can screen and shield the negative backbone surface allowing non electrolytes 
as well as positively charged ligand to interact more strongly with the DNA target. 
High ionic strength, however, reduces non-covalent interaction mediated by 
hydrogen bonds and electrostatic interactions. (Olmsted et al., 1996)
> role of solvent: there are three general classes of interactions to be considered 
during binding
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• ligand solvent interaction
• DNA solvent interaction
• ligand-DNA complex with solvent interaction (Blankenship et al., 2002)
> rational drug design: when a compound intercalates into nucleic acids, there are 
changes that occur on the DNA and the compound during the complex formation 
that can be used to study the ligand DNA interaction. The binding is an equilibrium 
process because no covalent bond formation is involved and the binding constant 
can be determined by measuring the free and DNA bound forms of the ligand. In the 
present project the intercalating substrates are aromatic chromophores, therefore the 
binding constants were obtained spectroscopically.
In addition to these properties, a consensus definition of an intercalator (Ashbey, 1985) 
requires molecules having a combination of several of the following groups: benzene ring, 
heterocyclic ring (both aromatic and aliphatic), aliphatic amine (preferably tertiary), 
carboxamide group, alcoholic hydroxyl group, carboxy ester, keto group.
We decided to further investigate chromophores constituted by a flavonoid skeleton with 
substitutions in the A and B ring for studying the mode and affinity as DNA binding 
ligands; some other chemical forms, such as isoflavonoids, flavones and 3 aromatic fused 
rings were also studied on DNA binding interactions. The data obtained allowed us to 
formulate some structure-activity relationships for this second generation of compounds.
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Amongst the steric constraints that control the interactions, the presence of methoxy or 
acetoxy substituents on the molecule is relevant as far as the drug -  DNA binding is 
concerned.
For a general study, we decided to use primarily STDNA, as it contains both A-T and G-C 
sequences, and would provide preliminary information about the changes in the binding. 
The techniques used were UV-Vis absorbance and fluorescence spectrophotometric 
titrations, as they can give an indication of the binding affinity, and orientate in the mode of 
binding of the molecule, as well as information on which specific moiety plays a major role 
during the interaction. For this part of the project some compounds were purchased from 
Sigma Aldrich (United Kingdom), Acros (United Kingdom) and Lancaster Chemicals 
(United Kingdom) and some others were synthesized and characterized by NMR (nuclear 
magnetic resonance), mass spectroscopy and IR (infrared) Spectroscopy.
4.2: Organic synthesis
With the intention of deciphering the way of binding, we modified our chosen scaffold by 
placing substituents at different positions in the three rings.
From the preliminary results we concluded that a flavone skeleton would be suitable and 
this should enable us to gain an insight into the binding interactions with DNA. 
Consequently, we envisaged a model composed by the parent chromone (A and C rings) in 
which the B ring is appended in different positions and in which the level of saturation of 
the chromone is changed. These are described in Scheme 7.
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i s o f l a v o n e
O c h ro m o n e
f la v o n e x a n th o n e
f la v a n o n e
Scheme 7: Different chromone possibilities. Rings A and C are fused to provide a planar 
molecule that could intercalate between stacked nucleic acid bases. Flavone has the B ring 
located at C-2, while isoflavone has the B ring in C-3. Xanthone has a C-2 / C-3 ring 
fusion, maintaining a planar system. In the case of flavanone, a distortion appears as a 
result of the saturation of the C ring.
Flavanone, xanthone and flavone were purchased; the synthesis of isoflavone (Scheme 8) 
employed thallium (III) acetate (TTA) and 4-toluenesulfonic acid. The product was easily 
purified by HPLC.
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Scheme 8: Isoflavone synthesis. Acid catalysed enolization of flavanone followed by 
alkoxythallation leads to two unstable intermediate thallium adducts (syn and anti to the 
aryl group). The anti adduct is predominant and dethallation proceeds via migration of the 
aryl group resulting in the formation of isoflavone.
To examine the role of the carbonyl group we proposed to synthesise flavothione (Hafez 
1991; Kataoka, 2004). We used 2,4-bis(4methoxyphenyl)-l,2,3,4-dithiophosphetan-2,4- 
disulfide (Lawesson’s reagent) as a thiating agent as shown in Scheme 9. The reaction was 
straightforward and the product was easily purified by preparative TLC plates giving a red 
powder.
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L a w e s s o n 's r e a g e n t ,  t o lu e n e ,  
r e f l u x ,  O N
O
Sheme 9: Flavothione synthesis. The carbonyl in position 3 is replaced by sulfur.
We also investigated the role of nitrogen, as many DNA binding agents have nitrogen in 
their scaffold (Wang et a l , 1994). We used several protocols, as shown in Schemes 10, and 
11.
QEI
fA v / C0’H
S02C12,DMF
kJ —  v
X N . .C02Et i. c
f  acetophenone, /  V /
NaNH2, etherEtOHrfx 
 ►
Py+Cl'
EtOH, H+, 2 acetophenone in THF,LDA»n ,78CAcCl C0CH2C0C6H5
1)LDA
2)RT
3) reflux
Scheme 10: Nitrogen introduction in A ring. The upper reaction uses sulfonyl dichloride to 
produce substitution in the acid; the reaction did not pass step 3. The lower reaction 
employed ethanol and acetyl chloride to produce acid chloride and ethyl acetate as first 
step, but the reaction did not proceed as expected.
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For the C ring, salicylamide was mixed with benzoyl chloride in toluene, the generation of 
HC1 provided the acid environment needed for the O- to N- rearrangement to proceed; the 
addition of p-toluenesulfonic acid led to dehydration that resulted in the desired product 
(Scheme 11). The water of the dehydration step was collected in the Dean-Stark apparatus.
Cl .OH.OH
N,NH2
O o
p T S A
a z e o t r o p ic  d i s t i l l a t i o n
O
Scheme 11: Synthesis of 3-azaflavone.
4.2,a: Flavone and its derivatives
The literature regarding flavonoids synthesis is vast, but not all protocols prove to be 
effective, in the presence of hydroxyl and chloride substituents. We tried a range of 
methodologies as shown in Schemes 12, 13 and 14.
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.OH nTBU, K2C03, Tol
a z e o tr o p ic  d is t i l l a t io n  in  
to lu e n e
.OH
p T S A ,  T o l
Scheme 12: The Baker-Venkataram approach. This scheme is appropriate for MeO or 
unsubstituted systems, but in the case of -OH groups the main product is an over 
benzoylated derivative that interferes with the rearrangement process (Jain, 1982). Yields of 
the desired product were typically in the range of 1 -  2 %.
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N a H  in  T H F  o r  K O H  i n  p y r id in e
.OH
Scheme 13: Another possibility that would replace toluene with pyridine, acting as catalyst 
too (Ares et al., 1995). This scheme works with a high yields (total 60 %) on unsubsituted 
systems or with MeO substitutions. The second step can be performed with NaH in THF 
giving higher yields than the variant KOH in Py. Rearrangement in acidic conditions leads 
to 50% of yield in this last step.
Cushman resolved in part the problem of -OH or other substituents in the 2-hydroxy 
acetophenone as starting materials by employing 4 equivalents of lithium 
bis(trimethylsilyl)amide (Cushman et al., 1994). This forms lithium enolate from the acetyl 
group in the 2-hydroxyacetophenone. Treatment of the lithium enolate with 1 equivalent of 
aroyl chloride affords a 1,3-diketone that is subsequently cyclised in acidic conditions 
(Scheme 14). Unfortunately we found this methodology to be inconvenient due to the low 
yield when scaling up.
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.O H
LiN(SiM e3)2, THF
rO
.O H
Scheme 14: Cushman’s approach for synthesis of flavones.
Ares resolved the scale up problem by using potassium tert-butoxide (Ares et al, 1993). 
The first equivalent of KOBu forms a potassium aroxide anion and treatment with benzoyl 
chloride forms the benzoyl ester; a second equivalent of KOBu promotes rearrangement to 
the diketone by forming an intermediate enolate as shown in Scheme 15. Treatment of the 
diketone with sulfuric acid and acetic acid gives the flavone (general yield after purification 
10%).
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1) KOBu, THF
1)KOBu
2)reflux, ON
H2S 0 4) HO A c
Scheme 15: Ares’ approach for synthesis of flavones.
We used this protocol successfully for several compounds (6) and we also used an 
adaptation for introducing nitro substitutions as shown in Schemes 16 and 17. In the case of 
3’,5’-dinitroflavone, the 3,5-dinitrobenzoyl chloride would react in any conditions forming
3.5-dinitrobenzoic acid and would not react later on with the 2-hydroxyacetophenone. To 
overcome this problem we reacted the 2-hydroxyacetophenone with triethylamine (TEA) 
and then with 3,5-dinitrobenzoyl chloride forming 2-acetylphenyl-3,5-dinitrobenzoate and 
triethylamine chloride which precipitated as white pellets. For 5-hydroxy-8-nitroflavone, 
we first reacted the 2-hydroxyacetophenone with nitric acid in glacial acetic acid forming
2.5-dihydroxy-3-nitroacetophenone as a yellow powder. We tried to nitrate flavone and 7- 
hydroxyflavone in order to reduce them and to form amino flavones, but we had no success 
as the yields were extremely low (< 1%) only detectable as traces in mass spectrometry.
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O
i ■
+ TEA
NO;
O
O
N O ,
NOo H +
KOBU, ice bath
RT
reflux
NO;
O H
NO;
O O
Scheme 16: 3'5'-Dinitroflavone synthesis. In this synthesis the first step was carried in 
presence of triethylamine (TEA) to replace the first equivalent of KBuO as following the 
complete Ares approach did not work when benzoyl chloride has nitro substitutions. The 
rest of the synthesis follows Ares’ approach.
OH O O
n o 2
OH
1) K O B u, TH FH N 0 3, H O A c
2) BzCl
3) K O B u
Sheme 17: 5-Hydroxy-8-nitroflavone synthesis. In this synthesis we first nitrated the 2,5- 
dihydroxyacetophenone with HNO3 in HOAc. The purified 2,5-dihydroxy-3- 
nitroacetophenone was reacted with benzoyl chloride following Ares’ approach.
Since hydroxyl groups are likely to be extremely relevant for the binding of the compounds 
to the DNA, as they are essential for intercalating the bases and form complexes 
(Yamashita et al., 1999), we decided to study different hydroxyl positions in the A and B 
rings. Chrysin (5,7-dihydroxyflavone), 7-hydroxyflavone and 3'4'-dihydroxyflavone were 
purchased from Sigma-Aldrich UK Ltd and Lancaster Chemicals UK. 5-Hydroxyflavone 
and 6-hydroxyflavone were synthesised by Ares’ protocol using 2 ,5-dihydroxyacetophone 
and 2,4-dihydroxyacetophenone respectively; 5-hydroxyflavone was also synthesised as in 
Scheme 14 but the yield was so low (< 1%) it could not be enough for the binding studies; 
fortunately the use of KOBu helped to increase the yield. 6 -Hydroxyflavone was also 
synthesised by using the Scheme 14 but the yield was so low we had to try another 
protocol; as the same case as 5-hydroxyflavone, the employment of KOBu helped to
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increase the yield and to obtain the desired product. Unfortunately we could not obtain 
flavones with hydroxyl groups in positions 8 and 7 & 8; most likely due to the formation of 
unreactive species. Different approaches involving protecting groups were tried but no 
success was had.
Chlorine atoms can provide an electronegative environment in a flavone while enhancing 
lipophilicity. We used Ares’ approach to synthesise 3'4’-dichloroflavone. We also tried to 
synthesise 2’6,-dichloroflavone, but the chlorines in 2,6-dichlorobenzoyl chloride would not 
allow the reaction to proceed; we were always obtaining 2,6-dichlorobenzoic acid that 
would not react with the 2-hydroxyacetophenone. Different approaches were employed but 
with no success.
One or two methoxy groups, similarly, could provide a lipophilic environment and, 
moreover, may remove important interactions present in the parent hydroxy groups that are 
relevant to the binding of the flavone to DNA. Therefore, we employed a methylation 
strategy (Scheme 18) for chrysin and 7-hydroxyflavone. Position 7 proved to be easily 
methylated as it is the most acidic. The hydroxyl group in position 5 forms a hydrogen 
bond with the carbonyl in position 4, this bond decreases the acidity of the hydroxyl 
making it less likely to react to extract the proton and accept substitutions; to overcome this 
problem we employed a second step using sodium hydride in tetrahydrofuran to increase 
the acidity of position 5 and make it able to react.
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HO. MeO. OMe-
Mel, NaH 
THFTHF
R=OH=H R1=OMe or H
Scheme 18: Methylation of ring Ahydroxylated flavones.
Adding extra carbonyl groups could provide some more information about steric 
impediments as well as selectivity of DNA for certain groups. We used acetoxylation in 
chrysin in order to obtain an acetoxy derivative.
HO
Ac20 , Pyridine
OH
AcO
OAc O
Scheme 19: Acetoxylation synthetic route
Tertiary amines could provide a completely different environment, as at pH 7.4 they would 
be protonated, making them more suitable for binding to the negatively charged phosphates 
of the DNA. For tertiary amines we used dimethylaminoethanol, dimethylaminopropanol 
and morpholinoethanol as subsituent agents for chrysin. Only position 7 could be 
substituted.
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Mitsunobu reaction was used with chrysin as starting material in order to create other 
possibilities for studying DNA - drug interactions. An insight of the process is shown in 
scheme 2 0 .
PPh3
©
©
.Ri
I O 4 PPh^-^
-VC'f f r
Rf  'PPh3 
© V , Y r
I O H
^ 0^N'Ny V
$  O I
R’'o 'pr 3 ©
o
V
Rj is the 5,7-dihydroxychrsyin, and R2 is the substituent
Scheme 20: Mitsunobu reactions. The reactions were carried out under sonication where 
TPP (or PPI13) (triphenylphosphine) combines with DIAD (diisopropyl azodicarboxylate) to 
generate a phosphonium intermediate that binds to the alcohol oxygen, activating it as a 
leaving group. Substitution by a nucleophile completes the process.
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With this reaction we employed chrysin as a flavone starting material to produce 3 
compounds, as shown in scheme 21.
N
TPP, 2-morpholinoethanol 
DIAD, sonication
TPP, N.N-dimethylethanolamine 
DIAD, sonication OH O TPP, N,N-dimethyIpropanolamine DIAD, sonication
OH O OH O
Scheme 22: Tertiary amine derivatives
4.3: Obtaining binding association constants
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In order to chose an appropriate scaffold to make modifications and study suitable 
substituents, we employed UV-Vis and fluorescence titrations (see section 2.2.C .2 to
2.2.C .4) to get binding constants and to be able to determine which strucuture preferentially 
binds to STDNA. We also used these same methodologies to assess if the addition of 
cations assists on the binding to nucleic acids of flavonoids with hydroxyl groups in close 
positions to the carbonyl. As well as studying binding constants, we also studied the 
thermal stability of this new batch of compounds with STDNA using thermal denaturating 
studies (see section 2.2.C .1). To assess an improvement in the biological activity we studied 
some of the compounds for cell proliferation activity (see section 2.2.h.2)
4.3. a: Localization o f the B ring and the relevance o f the double carbon
bond in the C ring
The B ring can be either in C-2 forming the flavonoid family or in C-3 forming the 
isoflavonoid family, and these structures can affect the mode of binding. The double bond 
C-2 to C-3 makes a small distortion in the molecule, and also changes the saturation of the 
C ring. See compounds 10, 11, 12.
flavone O isoflavone 0flavanone Q
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Compounds 10,11, 12: The different possibilities of localization of the B ring are shown, 
in flavone (10) the B ring is in C2, as is in flavanone (11) but with a saturated C ring; in 
isoflavone (12) the ring is in C3.
I
The binding constants obtained are shown in Table 11. From these results we can conclude 
that the binding constants are quite similar and at such low values that we can not rely on 
this method to choose a scaffold. However, if we consider the results in chapter 3 and we 
based our choices in the results of the binding constants, of the initial compounds the 
flavone scaffold appears to be the preferred choice for further structure activity relationship 
studies.
Table 11: The results of the binding association constants for flavone, flavanone and 
isoflavone proved to be quite similar in the magnitude of 103 M'1. Flavone and isoflavonoid 
presented fluorescence properties, but showed no measurable change in the emission signal 
upon titration with DNA.
Compound STDNA (UV) 
KCMT1) N
STDNA (Fluorescence) 
K(M') N
Flavone 1221.7 2.6 No interaction observed
Flavanone 1237.8 2.5 1238.92 (exc 300, emis 375) 2.04
Isoflavonoid 1767 10 No interaction observed
4.3.b: Three fused rings
Intercalating agents share the common feature of the planar polyaromatic systems which 
bind by insertion between the DNA base-pairs, with preference for 5f-pyrimidine-purine-3' 
steps. The chromophores are linked to basic chains that might also play a role in the affinity 
and selectivity shown by this class of agents. The planar structure of acridines (Hutchins, 
2003) confers to the molecules the ability to bind DNA by intercalation. A large number of
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synthetic acridine derivatives have been tested as anticancer agents and only a few 
molecules have entered clinical trials and have been approved for chemotherapy. Based on 
this premise, we tested a compound with three fused rings, see compound 13, maintaining 
the central structure of the C ring (see Compound 13). This molecule is known as xanthone 
and has been found to act as antimalarial agent (Dua, 2004), antidepressant working as a 
MAO (monoamime oxidase) inhibitor (Nunez et al,  2004), anticancer agent on HL60 
leukemia cell line (Matsumoto et a l , 2004) and chemopreventative agent (Jiang et a l,  
2003).
O xanthone
Compound 13: Xanthone with its three fused rings.
The binding constant of xanthone with DNA, was measured by UV-Vis spectroscopy and 
fluorescence quenching, and the results are shown in Table 12.
Table 12 : The binding association constants for xanthone proved to be similar to the one 
for flavone.
Compound STDNA (UV)
k  pvr1)
STDNA (Fluorescence)
N K n
Xanthone 2323.31 2 2283.7 (exc 340 emis390) 2.1
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From the analysis of the plain molecules, we can conclude the strength of binding for 
STDNA is the same for the system with three fused rings (xanthone) as for the system with 
the third aromatic ring (B ring) in C-2 (flavone) or in C-3 (isoflavone). Therefore, we will 
retain the flavone structure as the scaffold for our further modifications.
4.3.c: Sulfur and nitrogen in the 3-ring system
Nitrogen, sulfur and electronegative atoms, added into a naked scaffold would produce a 
small distortion into the planar structure and a charged molecule when it is tested at pH 7.4; 
see compounds 14 and 15. In the case of aza-3-flavone (azaflavone), no interaction was 
observed by UV-Vis spectroscopy, but a binding association constant was obtained by 
fluorescence spectroscopy, giving a very low value, see Table 13. For flavothione (or 
thioflavone) we observed in the UV-Vis spectrum an isosbestic point at 304 nm, see Figure 
29, further on the curves end on a single line without showing any clear isosbestic point. 
This could indicate a two binding mode for this compound and STDNA. The fitting of the 
UV-Vis results gave a sigmoid curve (Figure 30) that could not be fitted into our one mode 
of binding equation, possibly other binding models would be able to fit this results. On the 
other hand, fluorescence titrations gave a general binding association constant for 
flavothione on STDNA which showed that flavothione had the highest binding association 
constant for an unsusbsituted compound, with an association constant of 15550 M '1.
O azaflavones
thioflavone
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Compounds 14,15: Thioflavone (14) has a sulfur anion in C4 while azaflavone (15) has a 
nitrogen replacing C3.
thioflavone - STDNA
Figure 29: The results of the titration of thioflavone on STDNA shows an isosbestic point 
at 304 nm.
a b s o rb a n c e  o f fla vo th io n e  a t 470 nm
0.45 n 
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c  0.35 re€
8 0.3
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Figure 30: The titration of flavothione on STDNA produced a sigmoid curve when the 
absorbance at a specific wavelength was plotted against the concentration of STDNA.
169
Table 13: The results of the binding association constants for flavothione and aza-3- 
flavone are shown, indicating a very high binding constant for flavothione.
Compound STDNA (UV) STDNA (Fluorescence)
K (M'1) K ( M l) N
Flavothione Not defined 15538.7 (exc 420 , emis 464 ) 9.3
Azaflavanone No interaction observed 876.9 (exc 340, emis 422) 2.1
4.3. d: The difference between flavones andflavonols
Flavonoids are polyphenolic secondary metabolites widely dispersed throughout the plant 
kingdom. In plant tissues, flavonols and flavones are found conjugated to sugars, primarily 
glucose, rhamnose and rutinose, and most conjugation occurs at the 3 position of the B 
ring. The main difference between these two families is the presence of one hydroxyl group 
in C-3, see compound 16. We tested the relevance of this hydroxyl for the binding to 
STDNA, and we found that 3-hydroxyflavone is not soluble in phosphate buffer, even in 
presence of 10% of DMSO (dimethylsulfoxide).
O
3-hydroxyflavone
Compound 16: 3-hydroxyflavone is not soluble in buffer A at a 10% DMSO concentration
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4.3.e: Modifications on the A ring
The basic flavonoid structure originates from two sources: The A ' ring is formed from 
three acetate units (via the malonic acid pathway) and the 'B' ring with the 3-carbon bridge 
is constructed of a phenylpropane unit via the shikimic acid pathway. As antioxidants, these 
phytochemicals can donate an electron, accompanied by a hydrogen nucleus, from the -OH 
groups attached to their phenolic rings, to a free radical. This electron stabilizes and 
inactivates the damaging radical, in the process, the polyphenolic reducing agent becomes 
an aroxyl radical which is considerably more stable than the free radical that it has reduced; 
the result is the cessation of damaging oxidative chain reactions (Skaper et al., 1997). From 
our previous results, we found hydroxyl groups in flavonoids were crucial for promoting 
DNA binding. Some compounds such as luteolin, see compound 17, already have reported 
DNA binding activities, have been found to have antioxidant properties by neutralizing 
peroxides, as well as work as anti-inflammatory, anticancer, antiallergic agents and have 
immune-modulating properties (Hyuncheol et al., 2004).
OH
.OH
HO.
OH O luteolin
Compound 17: luteolin has two hydroxy groups in each of the A and B rings.
We studied the importance of key positions of hydroxyl groups like in positions 5, 6 and 7, 
see compounds 18,19, 20,21.
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q  7-hydroxyflavone OH O
chrysin
o
6-hydroxyflavone
5-hydroxyflavone
Compounds 18, 19, 20 and 21: 7-hydroxyflavone (18), 6-hydroxyflavone (19) and 5- 
hydroxyflavone (20) have one hydroxyl in the A ring. Chrysin (21) has two hydroxyls in 
positions 5 and 7.
As a further step, we studied substitution in the A-ring, and we postulated some specific 
positions with hydroxyl groups.
We also investigated the relevance of hydroxyl groups as electron donors by methylating 
and acetylating the hydroxyls, see compounds 22, 23, 24, 25; this study would give an 
indication o f :
> the presence of a group increases the binding and helps to the intercalation
> the chemical characteristic of the substituted promotes stability and binding to the 
complex.
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OMe O 5,7-dim ethoxy chrysin OAc O5,7-diacetoxychrysin
MeO MeO
JL lj 11 5-hydroxy-7-methoxy chrysin UH Uo
7-m ethoxy fl avone
Compounds 22, 23, 24 and 25: We approached studied substitutions, subsituting in the 
case of 5,7-dimethoxychrysin (22) the two hydroxyls with methoxy groups, as well as in 
the case of 5,7-diacetoxychrysin with the acetoxy groups (23). In 7-methoxyflavone (24) 
and 5-hydroxy-7-methoxyflavone (25) we have substituted only the position 7.
As the DNA is negatively charged a protonated drug would bind stronger or the complex 
would be more stable, a tertiary amine would be protonated in an environment of pH 7.4, 
offering the drug a positive charge. Therefore we studied the substitution of 7 hydroxyl 
with N,N-dimethylethanolamine, N,N-dimethylpropanolamine and 2-morpholinoethanol 
(by Mitsunobu reactions); as well as the position 8 with a nitro substitution, see compounds
26, 27, 28, 29.
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OH O
5-hydroxy-8nitro flavone
7-(3-(dimethylamino)-ethoxy)- 
t-phenyl-4H-chrom
il
q j _ j  q  7-(3-(dimethylamino)-propoxy-
5-hydroxy-3-phenyl-4H-chromen-4-one
OH O
7-(2-(morpholinoethoxy)-
3-phenyl-4H-chromen-4-one
Compounds 26, 27, 28 and 29: We studied the relevance of a nitro group in the A ring 
with 5-hydroxy-8-nitroflavone (26). In the group of tertiary amines we studies an ethyl 
chain in 7-dimethylaminoethoxy-5-hydroxyflavone (27), a propyl chain in 7- 
dimethylaminopropoxy-5hydroxyflavone (28) and morpholine substitution in 7- 
morpholinoethoxy-5-hydroxyflavone (29).
In Table 14 we can see the results obtained for this group of compounds with modifications 
in the A ring. The highest association binding constants for 7-dimethylaminoethoxy-5- 
hydroxyflavone and 7-morpholinoethoxy-5-hydroxyflavone clearly show a tertiary amine 
with a two carbon chain is really appropriate for the binding increasing the binding of the 
unsubstituted molecule (chrysin) by 100 fold. It also showed that two methyl groups joined 
to the tertiary amine assist to the binding in a more favourable way than a morpholine 
substitution. In contrast, 7-dimethylaminopropoxy-5-hydroxyflavone in which the tertiary
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amine was on a three carbon chain, show a binding in the order of 103 M'1, this could 
indicate that the flavone intercalates the base pairs of the DNA by positions 7 and 8. A two 
carbon chain could probably seal this intercalation, but a three carbon chain would inhibit 
the binding probably by steric hindrance. Chrysin, considering it only has two hydroxyls (in 
positions 5 and 7) also showed a strong binding activity (104 M'1) when compared to other 
flavones with the same number of hydroxyls but in different positions. Considering that 7- 
hydroxyflavone presents only one third of the binding of chrysin and 5-hydroxyflavone did 
not show any binding activity, we can conclude the most relevant position in the A ring is 
position 7. 5-Hydroxyflavone did not show any interaction with STDNA, but when we 
added a nitro group in position 8, the binding increased giving a binding constant of 
7781.4 M_1. Hydroxyl groups in position 6 did not help the binding to STDNA. Methoxy 
and acetoxy substitutions inhibit the binding to the DNA as it was shown by the drecrease 
of the binding constant of the unsubstituted parent compound (chrysin) when methoxy and 
acetoxy groups were added. Some compounds did not provide identical results in the UV- 
Vis calculated binding association constants and fluorescence association constants, but this 
is possibly due to the fact that the equation is not appropriate for very low binding 
constants, obtained by compounds such as the one in the order of 103 M'1, like 5-hydroxy- 
7-methoxychrysin, 5,7-diacetoxychrsyin, chrysin and luteolin.
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Table 14: The results of the biding association constants show 7-dimethylamino-ethoxy-5- 
hydroxyflavone and 7-morpholino-ethoxy-5-hydroxyflavone as the strongest binders 
followed by chrysin and luteolin. These results clearly show the relevance of a subsituent in 
the 7 position.
*Nio: no interaction observed.
Compound Uv -Vis 
K(M-1) N
Fluorescence
K(M-1) N
5-hydroxyflavone N i o* N i o*
6-hydroxyflavone 1155.4 2.6 1266.8 (exc 
420, emis 481)
2
7-hydroxyflavone 8134.9 3.4 N i o*
7-methoxyflavone 1567.4 2 1575.9 (exc 
340, emis 534)
2.6
5-hydroxy-
7-methoxychrysin
714.2 1.7 5865.4 (exc 
340, emis 442)
2
5,7-methoxychrysin 1474.6 2.3 1947.4 (exc 
340, emis 442)
2
5,7-acetoxychrysin 3200 2.7 1695.4 (exc 
340, emis 528)
2
chrysin 28460.5 4 7499.4 (exc 
340, emis 442)
3
5-hydroxy-8-
nitroflavone
N i o* 7781.4 (exc 
340, emis 383)
4
luteolin 11193.8 12.9 2214.6 (exc 
340, emis 383)
4
7-dimethylamino-
ethoxy-5-
hydroxyflavone
189714.6 2.3 N i o*
7-dimethylamino-
propoxy-5-
hydroxyflavone
2189.5 1.5 1728.2 (exc 
420, emis 490)
3.3
7-morpholino-ethoxy-5-
hydroxyflavone
110679.3 0.85 N i o*
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4.3.f: Modifications on the B ring
In quercetin, the B ring seems to play an important role when bound to the DNA 
(Yamashita, 1999) so we studied different substitutions on this ring. Electron-withdrawing 
groups are present in many anticancer drugs (Chu, 1980) so we studied other substituents 
like Cl- and NO2’. See compounds 30, 31 and 32.
OHNO;
OH
N O ;
3'5' nitroflavone 3'4' dihydroxyflavone
Compounds 30,31, 32: We studied nitro substitutions in 3,5,-dinitroflavone (30), hydroxyl 
groups in 3'4’-dihydroxyflavone (31) and chloride groups in 3’4-dichloroflavone (32).
In Table 15 we can appreciate the results of the binding association constants. We would 
expect hydroxyl groups in the B ring to be responsible of a reasonable part of the DNA- 
drug interaction. However, after analyzing results from luteolin and chrysin we can 
conclude that hydroxyl groups in 3’ and 4’ positions decrease the binding. Moreover, if we 
extend the assumption to the original set of compounds we can speculate that the hydroxyl 
in position 3 in quercetin helps to improve the binding or does not affect the binding in any 
way. Chlorine and nitro substitutions did not improve the binding as it would be expected.
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Table 15: The results of the binding association constants show clearly that substitutions in 
the B ring do not assist in a remarkable way the interaction with STDNA.
Compound STDNA (UV) 
K fM '1) N
STDNA (Fluorescence)
Kflvr1) n
3',5'-dinitroflavone 1138.9 2.2 1181.1 (exc 340, emis 384) 2
3',4'-dihydroxyflavone 1978.9 7.2 1217.9 (exc 320, emis 467) 3
3’,4’-dichIoroflavone 763.6 1.9 1345 (exc 420, emis 464) 5.4
4.3.g: DNA -  drug -  metal interactions
Drugs can bind to metals directly or indirectly by using the hydration water; and metal 
cations have preferences for the bases in the DNA, helping the selectivity of the drug for 
the nucleic acid structure and modifying its conformation from B to Z or A -  DNA 
(Anastassopoulou, 2003).
From the structural related studies we have two main groups with hydroxyl groups that 
show relatively high binding association constants:
> tertiary amines, with the substituted chrysin
> chrysin, luteolin and 7-hydroxyflavone with free hydroxyl groups.
From these two groups, the second one provided compounds with hydroxyl groups in ortho 
position to the carbonyl in position 4 and hydroxyl groups in position 7 which showed to be 
relevant to binding with DNA; these 3 drugs were studied for metal -  drug -  DNA 
interactions (see section 3.3.b.4). Chrysin and luteolin have hydroxyl groups next to the 
carbonyl, but 7-hydroxyflavone has not, so that would be possible to have a negative
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control in this study if it corroborates what Yamashita {et al, 1999) observed about copper 
interacting first with quercetin and then with DNA. As the drugs have only one hydroxyl 
next to the carbonyl we used a ratio 1:1 of drug:metal. In Table 16 the results for this study 
are shown, and they indicate that Fe3+, Mg2+and Mn2+ increase by 1000 times the binding 
constants of 7-hydroxyflavone for DNA. This clearly shows the metals bind to the drug and 
allow it to better interact the DNA. For chrysin Cu2+, Fe2+, Fe3+, Mn2+and Mg2+ helped to 
increase 100 times the binding constant, but Zn2+ increased only by 75%. In the case of 
luteolin, no metal helped with the bindings. These results indicate the flavones bind 
preferentially using the 7-hydroxy position and metal cations improved remarkably this 
process. The fact that chrysin has stronger binding than 7-hydroxyflavone can be due to the 
hydroxyl in position 5, which could interact forming bonds with a metal joined to the 
carbonyl. Only crystallization of this complex would elucidate the actual structure.
Table 16: The results of the titrations of the metal -  drug -  DNA complexes. The binding 
association constants are expressed in M'1, the n value appears between brackets.
Cation 7-hydroxyflavone 
1:1, K (M 1)
Chrysin 
1:1, KCM*1)
Luteolin 
1:1, K f M 1)
Cu2+ 10541 (2.29) 136723(1.9) 1390.4(2.3)
Fe2+ 10932.3(2.1) 589632 (4) 1428.4 (2.4)
Fe3+ 200550 448189.5 (2.5) 1366.2
(2.09) (2.6)
Mg2+ 1032439(1.4) 1179875(1.5) 1518.4
(2.8)
Mn2+ 107741 (2) 251482 (2.7) 1372.7
(2.2)
Zn2+ 9935.5(2.18) 74901 (5) 1447.6 (3)
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4.4: Selectivity for different structures
4.4.a: Competition dialysis
Selectivity for different isoforms of DNA is always relevant when drug -  nucleic acid 
interactions are under study. We studied this second set of compounds on 8 different 
isoforms of nucleic acids (STDNA, polydAdT, poly[dAdT]2, polydGdC, poly[dGdC]2,
i
polydAdT-dT, purine triplex, G-tetraplex) using competition dialysis (see Chapters 2 and 3) 
Figures 31 a -  s show the results of these experiments. Thioflavone showed remarkable 
preference for G-quadruplex and polydGdC-dGdC. It is possible that thioflavone prefers 
quadruplex DNA as these strucutures present more available space for intercalation and the 
sulfur in thioflavone could possibly play an important role in the stabilization of the 
complex. For duplex DNA structures, thioflavone clearly prefers GC sequences. Flavone 
also showed preference primarily for G-quadruplex, with high affinities for poly[dGdC]2 
and purine triplex (GCG). This is a clear indication of preference for GC. Presence of a 
nitrogen as part of the ring, as in the case of azaflavone, changed the preference for G- 
quadruplex to GCG triplex and polydAdT-dAdT. It appears that the flavone scaffold 
interacts preferentially with high order DNA structures. However, when the skeleton 
changes, the marked preference for GC bases also changes to AT bases. As well as 
thioflavone and and flavone, 3,,4'-dichloroflavone, luteolin, 3',5'-dinitroflavone, chrysin, 7- 
morpholinoethoxy-5-hydroxyflavone, 7-dimethylaminoethoxy-5-hydroxyflavone and 7- 
dimethylaminopropoxy-5-hydroxyflavone showed a remarkable preference for G- 
quadruplexes in first place, followed by preference for GCG triplex and polydGdC-dGdC 
for second place. 5-Hydroxy-8-nitroflavone showed preference for polydGdC-dGdC and 
secondly for G-quadruplex, in this case the preference was inverted when compared with
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the previously described compounds. 3',4'-Dihydroxyflavone showed preference for G- 
quadruplex followed by equal preferences for GCG triplex, polydGdC-dGdC, polydGdC 
and polydAdT-dAdT. Adding two methoxy groups in chrysin started to change the 
preference for G-quadruplex to STDNA, but adding only one methoxy group kept the 
initial preference for G-quadruplex and added a remarkable preference for polydAdT. 
Introduction of two acetoxy groups in chrysin inverted the preference of G-quadruplex and 
polydGdC-dGdC to polydGdC-dGdC primarily and G-quadruplex secondly. 7- 
hydroxyflavone and 5-hydroxyflavone showed a clear preference for STDNA, but when we 
added a methoxy group to 7-hydroxyflavone the preference changed dramatically to 
polydAdTdT. 6-Hydroxyflavone showed preference for poly[dGdC]2 and polydAdT. It 
appears that any preferential binding to GC rich duplex DNA is for the alternating purine- 
pyrimide GC step and not for the polydGpolydC homopurine-homopyrrimidine strands, in 
agreement with previous data of intercalators showing a preference for GC steps (Ren and 
Chaires, 1999).
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Figure 31 a: Flavone shows preference for G-quadruplex and poly[dGdC]2
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Figure 31 b: Thioflavone shows preference for G-quadruplex, poly[dGdC]2  and purine 
triplex.
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Figure 31 c: Aza-3-flavone shows preference for purine triplex and poly[dAdT]2
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Figure 31 d: 3',4'-Dichloroflavone shows preference for G-quadruplex, poly[dGdC] 2  and 
purine triplex.
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Figure 31 e: 3',5' -Dinitroflavone shows preference for G-quadruplex, poly[dGdC] 2  and 
purine triplex.
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Figure 31 f: 5-Hydroxy-8-nitroflavone shows preference for poly[dGdC]2  and G- 
quadruplex.
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Figure 31 g: Luteolin shows preference for G-quadruplex, poly[dGdC]2  and purine triplex.
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Figure 31 h: 3',4'-Dihydroxyflavone shows preference for G-quadruplex and purine
triplex.
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Figure 31 i: Chrysin shows preference for G-quadruplex, purine triplex and poly[dGdC]2 .
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Figure 31 j: 5-Hydroxy-7-methoxyflavone shows preference for G-quadruplex,
polydAdT, poly[dGdC] 2  and purine triples.
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Figure 31 k: 5,7-Dimethoxychrysin shows preference for STDNA, G-quadruplex and 
purine triplex.
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Figure 311: 5,7-Diacetoxychrsyin shows preference for poly[dGdC]2 .
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Figure 31 m: 7-Dimethylaminoethoxy-5-hydroxyflavone shows preference for G- 
quadruplex, poly[dGdC] 2  and purine triplex
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Figure 31 n: 7-Dimethylaminopropoxy-5-hydroxyflavone shows preference for G-
quadruplex, poly[dGdC] 2  and purine triplex
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Figure 31 o: 7-Morpholinoethoxy-5-hydroxyflavone shows preference for G-quadruplex,
poly[dGdC]2  and purine triplex.
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Figure 31 p: 7-Hydroxyflavone shows preference for STDNA.
7 - m e t h o x y f l a v o n e
p o ly (dG dC )2
Po lydG dC
P oly (dA dT )2
Po lydA dT
T e tra p le x
GCG
l
l
1
1
I
:  1
ATT 1
STDNA 1
in itia l 1
c1 1 0  20 30 40 50 b o u n d  ( u l \ § P
Figure 31 q: 7-Methoxyflavone shows preference for polydAdTdT.
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Figure 31 r: 5-Hydroxyflavone shows preference for STDNA.
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Figure 31 s: 6-Hydroxyflavone shows preference for poly[dGdC]2  and polydAdT.
4.5: Stabilisation o f  the double helix
4.5.a: Melting points
Alongside binding association constants binding preference and metal contributions to the 
binding, we studied the effect of the modified set of compounds on the stabilization of 
STDNA. 6-Hydroxyflavone, luteolin and azaflavone showed extremely low binding 
constants, but these 3 compounds stabilised the DNA by an average of 2 -  3 °C, 
demonstrating that association binding does not correlate with DNA stabilisation. 5- 
Hydroxy-7-methoxyflavone, 5,7-dimethoxyflavone, 5-hydroxy-8-nitroflavone, 7- 
dimethylaminopropoxy-5-hydroxyflavone, 3 '4'-dichloroflavone and flavothione destabilise 
the duplex helix of STDNA. 7-Dimethylaminoethoxy-5-hydroxyflavone, 7- 
morpholinoethoxy and 3'5'-dinitroflavone produced some effect in the STDNA that 
affected its melting profile, resulting in an inabiltiy to accurately calculate melting points, 
see Figure 32.
3 ',5 '-dinitroflavone
0.096
0.094
0.092 -
0 .09 -
0 .088 -
0.086
0.084
0.082 -
te m p e ra tu re
Figure 32: The result of the melting point of 3',5'-dinitroflavone on STDNA showed the 
drug to destabilise the double helix in a way not possible to measure or produce colloids in 
the test solution.
191
The results from the temperature denaturation studies are shown in Table 17 and indicate 
that the compounds do not have a clear effect on the double helix.
Table 17: The results of the melting points for these compounds show luteolin and aza-3- 
flavone have a small stabilisation effect on the double helix while the rest of the 
compounds do not affect it. 7-Dimethylaminoethoxy-5-hydroxyflavone, 7- 
morpholinoethoxy-5-hydroxyflavone and 3 5'-dinitroflavone produced some effect in the 
STDNA that made the assay impossible to perform.
Compound AT (°C)
5-hydroxyflavone 0
6-hydroxyflavone 2.5
7-hydroxyflavone 0
7-methoxyflavone 0
5-hydroxy-7-methoxychrysin -3
5,7-dimethoxychrysin -1
5,7-diacetoxychrysin -1.9
5-hydroxy-8nitroflavone -1.5
luteolin 3.4
7-dimethylaminoethoxy-5-hydroxyflavone No defined interaction
7-dimethylaminopropoxy-5-hydroxyflavone -1.5
7-morpholinoethoxy-5-hydroxyflavone No defined interaction
3',5'-dinitroflavone No defined interaction
3',4-dihydroxyflavone 0.4
3',4-dichloroflavone -1.5
flavothione -0.6
azaflavanone 3.4
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4.6: Biological evaluation
4.6. a: Cell viability results
To evaluate the anticancer activity of these compounds we tested the most relevant ones 
against the two cell lines studied in chapter 3, MCF7 breast cancer cell line and CCRFCEM 
leukemia cell line. We compared the results obtained here with flavone in order to see if we 
could get some improvement based in our rational drug design studies. We studied the 
inhibition of growth by 50 % of the population of cells at 24, 48 and 72 hours of incubation 
of the cells with the test drugs at 0, 1, 5, 10, 50, 100, 500 and 1000 pM. Unfortunately none 
of the compounds proved to be an effective anticancer drug with the majority of them 
having a IG50 > 100 pM. Only 7-dimethylaminoethoxy-5-hydroxyflavone and 7- 
dimethylaminopropoxy-5-hydroxyflavone presented IG50 in the order of 65 -  85 pM. It is 
worth noting that nitro substitutions promote growth in these two cell lines, possibly by 
forming some metabolites that assist cell growth. This effect does not appear to be related 
to estrogenic activity, previously seen by daidzein (see Chapter 3), as the molecules have a 
similar effect on both cell lines tested. In Table 18 the results are shown.
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Table 18: The results of the MTS proliferation assay showed the compounds are not 
cytotoxic in both cancer cell lines. 7-Dimethylaminoethoxy-5-hydroxyflavone proved to 
have some activity in CCRFECM cell line at 72 h of incubation and 7- 
dimethylaminopropoxy-5-hydroxyflavone showed some antiproliferation activity on both 
cell lines after 72 h of exposure. 5-Hydroxy-8-nitroflavone, 3',5,-dinitroflavone and flavone 
promote growth.
IGso MCF7 (pM) at 72 
hours
IGso CCRFCEM (pM) at 
72 hours
5-hydroxy-8-nitroflavone Promotes growth > 100
luteolin > 100 > 100
7-dimethylaminoethoxy-5- > 1 0 0 69.9
hydroxyflavone
7-dimethyIaminopropoxy- 88.6 65.9
5-hydroxyflavone
7-morphoIinoethoxy-5- > 1 0 0 > 100
hydroxyflavone
3',5'dinitroflavone Promotes growth Promotes growth
3',4’-dihydroxyflavone > 1 0 0 > 1 0 0
3',4'-dichloroflavone > 1 0 0 > 1 0 0
flavothione > 1 0 0 > 100
azaflavanone > 1 0 0 > 1 0 0
flavone Promotes growth > 1 0 0
194
4.7: Conclusions to Chapter 4
Several protocols can be employed with the purpose of synthesizing flavonoids, 
unfortunately majority of them work given rise to very small yields or do not work at all, 
and this is even worse when some hydroxyl groups are present in the flavone scaffold. The 
employment of potassium terbutoxide as catalyst did help for getting better yields in the 
synthesis of the study compounds. Other synthetic routes like Mitsunobu reactions, 
methoxylation and acetoxylation were employed with successful results. Drug design can 
be employed to understand analogues of drugs which best utilise a particular feature of the 
DNA structure to maximise the interactions. The rational design has indicated the overall 
order of DNA affinity, suggesting that the intercalation model has relevance for the mode 
of action and tertiary amines are the most appropriate groups, by giving binding constants 
in the order of 106 M '1. The length of the carbon chain in the substituted chrysin for 
obtaining the amine derivatives plays a major role when binding to DNA, demonstrating 
that this particular position (7) binds directly to the DNA bases and with a particular length; 
it resulted to be more important having a length of 2 carbons instead of 3 carbons, rather a 
morpholino group replacing a dimethylamine group. The relevance in the introduction of 
hydroxyl groups into the flavone sekeleton could not be analysed by denaturation melting 
studies, as almost all flavonoids did not show any stabilisation of the double helix. 
Introduction of chloride and nitro groups did not improve the binding or stability in the 
duplex helix of STDNA. The competition dialysis experiments showed a remarkable 
preference for high order structures of DNA (like G-quadruplexes and triplexes) in majority 
of the cases as it was already found for the group of compounds in chapter 3. Metal cations
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did assist on improving the binding of the drugs to DNA when the compounds have 
hydroxyls in position 7. The results for the cell viability assay showed the anticancer 
activity could not be improved even though the binding has been improved by 100 folds. 
Other factors such as metabolism, cellular uptake, drug persistency, cytotoxicity, and other 
possible reactions with cellular components could be responsible of the apparent lack of 
anticancer activity on the cell lines tested.
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Chapter 5: Conclusions and further work
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Cancer chemotherapeutic drugs may be classified according to their mechanism of action 
into several classes: hormones, immunological agents, radiosensitisers, antimetabolites, 
mitotic agents and those that interact with nucleic acid. The choice of a feasible target has 
been made considering a big diversity of treatments for antitumour cells and nucleic acids 
showed to be a workable target for antitumour activity. DNA interactive agents can bind to 
the nucleic acids in different ways. We have studied the mode of action of a group of 
compounds on nucleic acids and their biological anticancer activity and we have used 
different approaches to improve both their binding to the nucleic acids and their antitumour 
activity.
For that purpose we have chosen two families of herbal extracts (sesquiterpenes and 
flavonoids) and studied their binding to different isofoims of DNA in order to assess any 
sequence or structural preference and strength of binding.
Our group of sesquiterpenes was composed of artesunate, artemisinin and cantharidin; 
unfortunately these compounds did not have any UV-Vis spectrum or fluorescence; 
therefore we were limited to a small set of techniques we could employ to test any DNA- 
drug activity. Amongst these methodologies we used denaturating points, footprinting, 
DNA damage, topoisomerase I & II, and hemin as an indicator of any activity between 
artesunate and artemisinin on STDNA. Unfortunately none of these compounds appeared to 
interact with STDNA in any way. Artesunate and artemisinin, however, showed to have 
some inhibition of topoisomerase II activity, maybe by acting on the enzyme toposiomerase 
rather than the nucleic acid.
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From our preliminary set of compounds, the flavonoids baicalein, baicalin, daidzein, 
puerarin, quercetin and rutin demonstrated preference for higher order DNA structures like 
G-quadruplex, and purine and pyrimidine triplexes; with baicalein and quercetin giving 
binding association constant values in the order of 2-8x104M '\ In the cell work, the 
compounds baicalein, baicalin, daidzein and quercetin proved not to be active anticancer 
agents by giving very high values of GI50 for the two cell lines employed (MCF7 breast 
cancer and CCRFCEM leukaemia cell lines). Baicalin showed very low binding constants 
for the nucleic acids, but had the slowest GI50 values on both cell lines, possibly by acting 
as an anticancer agent in these two cell lines through binding to some other target or by 
being metabolised to a more active intermediate. In the metabolite CYP1A1 assay only 
baicalein and daidzein gave results that would allow speculation of hydroxylation and 
methylation patterns. Baicalin and quercetin proved to be unstable during the assay or to 
produce results that we could not interpret in our assay.
From this screening of activities we could conclude that the flavonoids are DNA 
intercalator agents and the flavone skeleton is a useful scaffold to explore binding sites on 
the DNA.
The synthesis of flavones is not an easy task as it is shown in the literature or in the design 
of a mechanism of reaction. Different approaches were considered and the use of a strong 
base as potassium tert-butoxide helped to drive the reaction to completion. In the case of 
the substitutions with tertiary amines, the employment of Mitsunobu reactions helped to 
produce some novel compounds as 7-dimethylaminopropoxy-5-hydroflavone and 7- 
morpholinoethoxy-5-hydroflavone and the known 7-dimethylaminoethoxy-5-hydroflavone.
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In this second generation of compounds, the majority of the compounds kept the preference 
for higher order of DNA structures like G-quadruplexes, purine triplex and the duplex 
poly[dGdC]2. Unfortunately the anticancer activity in the cell lines used (MCF7 and 
CCRFCEM cell lines) did not appear to improve. We can speculate that this class of 
compounds is metabolised inside the cell and are thus not able to bind to DNA inside the 
nucleus and effect their anticancer activity. Furthermore, molecules they also possibly bind 
to protein or receptor targets inside the cell.
The binding association constants provided invaluable information about the mode of 
binding of the flavonoids to the STDNA, which can be summarised as follow:
> the binding is improved when the B ring is located in the C3 position
> insertion of nitrogen into the skeleton did not improve the binding, but insertion of 
sulphur improved the binding 6 -fold
> substitutions of nitro and chloride moieties did not improve the binding, but 
substitutions of nitro plus hydroxyl groups in the same molecule improved the 
binding
> methoxylation and acetoxylation reduced the original binding association constants
> tertiary amines helped to improve the binding association constants, when 
associated in a two carbon chain like is the case of 7-morpholinoethoxy-5- 
hydroflavone and 7-dimethylaminoehtoxy-5-hydroflavone where the binding was 
improved 100-fold, but in the case of 7-dimethylaminopropoxy-5-hydroxyflavone 
where the carbon chain is 3 carbon atoms, the binding was reduced 10-fold
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> position 7 in the A ring is the most important for interacting with STDNA; and
when position 5 is added the binding is improved 4 folds, even though the binding
of position 5 alone is non-existent
> substitution in B ring did not prove to be too effective
> metal cations did improve the binding when added to 5 ,7 -dihydroxyflavone 
(chrysin) and to 7-hydroxyflavone; which agrees with the speculation of position 7 
as extremely relevant in the binding.
More studies are needed in order to get a better understanding of the interaction between 
flavones and DNA and to improve this binding, some possibilities to explore are:
> substitutions with amino groups
> substitutions with piperazine groups
> substitutions with fluoride
> running the same panel of compounds but with a flavothione scaffold
> running similar panel of compounds but with a xanthone scaffold
> exploring substitutions in the B ring employing Mitsunobu reactions
> formation of dimers in different positions (like in 7, 3 and 3’)
> test of the drugs in other cell lines
All the information provided by this project and all the information that would be 
provided by the suggested items, could assist in the design of novel agents with 
improved bioavailability and anticancer activity.
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Figure 33: Acridine -  STDNA (UV-Vis)
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Figure 34: Acridine -  STDNA (fluorescence)
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Figure 35: Baicalein - STDNA (UV-Vis absorbance)
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Figure 36: Baicalein - STDNA (fluorescence)
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Figure 38: Baicalin - STDNA (fluorescence)
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Figure 39: Daidzein - STDNA (UV-Vis)
80000 -
c
a>
N~o
‘ro
CD
oc0o
C/5
CD
O
u_
70000 - o
------- —
ooo
■
o
\°\o\°
Data: daidzein  - STDNA
0 ^ 9 - Model: m issailid is with n
60000 - ChiA2 = 4 1 0 7 9 7 0 .8 0 3 8 4
R A2 = 0 .9 4 4 4 4
- P1 7 8 1 7 3 .6 1 5 8 8 ± 7 8 2 8 6 .5 1 4 0 8
P2 6 1 8 2 0 .7 3 5 6 3 ± 1 8 2 4 .4 7 6 8 6
P3 9 5 2 .2 4 9 8 6 ± 1 4 7 5 9 .0 1 5 6 6
50000 - P4 0 .0 0 0 0 3 ±0
P5 3 .0  ±0
i
0.0000
I ' I 1 I '
0.0002 0.0004 0.0006
I
0.0008
' I '
0.0010
I
0.0012
STDNA(M)
Figure 40: Daidzein - STDNA (fluorescence)
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Figure 41: Puerarin - STDNA (fluorescence)
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Figure 42: Puerarin - STDNA (fluorescence)
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Figure 43: Quercetin - STDNA (UV-Vis)
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Figure 44: Quercetin - STDNA (fluorescence)
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Figure 45: Rutin - STDNA (UV-Vis)
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Figure 46: Rutin - STDNA (fluorescence)
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Figure 47: Baicalin - polydAdT
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Figure 49: Quercetin - polydAdT
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Figure 50: Baicalein polydAdT-dAdT
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Figure 51: Baicalin -  polydAdT-dAdT
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Figure 52: Puerarin -  polydAdT-dAdT
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Figure 53: Ruitn - -PolydAdT-dAdT
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Figure 54: Daidzein - PolydGdC
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Figure 55:Baicalin - PolydGdC
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Figure 56: Rutin -  PolydGdC
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Figure 57: Quercetin -  PolydGdC
0 . 5 2 -
0 . 5 0 -
c'
J32 0 . 4 8 -
10
w  0 . 4 6 - j
I
A  0 . 4 4  - |
O (/)
<  0 . 4 2 -
0 .4 0  -
 1---
0.0000
I
0.0001
D a ta : B a ic a le in  -  p o ly d G d C - d G d C
M o d e l:  m is s a i l id is
C h iA2 =  0 .0 0 0 0 4
R A2 =  0 .9 7 4 8
P1 0 .3 8 0 5 5 ± 0 .0 0 8 9 9
P 2 0 .5 1 4 4 5 ± 0 .0 0 3 2 8
P 3 1 2 1 4 3 .0 0 3 0 8 ± 3 2 0 7 .3 6 3 5 8
P 4 0 .0 0 0 0 4 ± 0
P 5 2  ± 0
0 .0 0 0 2  0 .0 0 0 3
PolydGdC-dGdC (M)
i
0 . 0 0 0 4
I
0 . 0 0 0 5
Figure 58: Baicalein -  PolydGdC-dGdC
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Figure 59: Baicalin -  PolydGdC-dGdC
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Figure 60: Daidzein -  PolydGdC-dGdC
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Figure 61: Puerarin -  PolydGdC-dGdC
0.46 -  
0.44 -  
0.42 -  
£  0.40 -
3§  0 .3 8 -
S  0.36 -  
8c  0 .3 4 -j 
■8
|  °'32^ 
<  0.30 -j
0.28 -
0.26 -
 1---
0.0000
 1—
0.0001
D a ta :  Q u e r c e t in  -  p o ly d G d C - d G d C
M o d e l:  m is s a i l id is
C h iA2 =  0 .0 0 0 1 7
R A2 =  0 .9 5 9 0 9
P1 0 .2 2 8 5 2 ± 0 .0 1 5 8 1
P 2 0 .4 6 4 9 8 ± 0 .0 1 1 0 4
P 3 1 4 9 2 4 .5 0 4 1 6 ± 4 7 5 6 .1 8 1 7 7
P 4 0 .0 0 0 0 3 ± 0
P 5 2  ± 0
0.0002 0.0003
PolydG dC -dG dC  (M)
i
0 . 0 0 0 4
I
0 . 0 0 0 5
Figure 62: Quercetin -  PolydGdC-dGdC
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Figure 63: Rutin -  PolydGdC-dGdC
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Figure 64: Baicalein -  PolydAdT-dT
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Figure 65: Quercetin -  PolydAdT-dT
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Figure 66: Baicalein -  Purine triplex
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Data: Quercetin - purine triplex
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Figure 67: Quercetin -  Purine triplex
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Figure 68: Baicalein -  G-quadruplex
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Figure 69: Quercetin -  G-quadruplex
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Figure 70: 7-Hydroxyflavone -  STDNA -Zn
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Figure 71: 7-Hydroxyflavone -  STDNA -  Mn
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Figure 72: 7-Hydroxyflavone -  STDNA -  Mg
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Figure 73: 7-Hydroxyflavone -  STDNA -  Fe(II)
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Figure 74: 7-Hydroxyflavone -  STDNA -  Fe(III)
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Figure 75: 7-Hydroxyflavone -  STDNA -  Cu
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Figure 76: Baicalein -  STDNA- Mn
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Figure 77: Baicalein -  STDNA -  Zn
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Figure 78: Baicalein -  STDNA -  Mg
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Figure 79: Baicalein -  STDNA -  Fe(III)
0.56 -
0 .5 5 -
(D
g  0 .5 4 -j 
ro
$  0 .5 3 -  
c
EL .
w 0 .5 2 -
0.51 -
0.50
D a ta : :1 B a ic a le in  - F e  ( I I ) -  D N A
M o d e l:  m is s a i l id is
C h iA2 =  0 .0 0 0 0 5
R A2 =  0 .8 6 6 1 3
P1 0 .4 2 1 4 8 ± 1 .7 6 8 4 2
P 2 0 .5 6 0 4 2 ± 0 .0 0 6 8 9
P 3 1 1 1 7 .5 3 2 7 3 ± 3 7 8 0 7 .1 8 4 3 9
P 4 0 .0 0 0 0 5 ± 0
P 5 2 .6 8 5  ± 3 6 7 .9 5 5 2 9
0.0000 0.0001 0.0002 0.0003
STDNA(M)
0.0004 0.0005
Figure 80: Baicalein -  STDNA -  Fe(II)
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Figure 81: Baicalein -  STDNA -  Cu
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Figure 82: Baicalein -  STDNA - Zn
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Figure 83: Baicalein - STDNA -  Mn
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Figure 84: Baicalein -  STDNA -  Mg
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Figure 85: Baicalein - STDNA -  Fe(II)
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Figure 86: Baicalein -  STDNA -  Cu
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Figure 87: Baicalin -  STDNA -  Fe(II)
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Figure 88: Baicalin -  STDNA -  Fe(III)
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Figure 89: Baicalin -  STDNA -  Cu
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Figure 90: Baicalin -  STDNA -  Zn
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Figure 91: Baicalin -  STDNA -  Mn
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Figure 92: Baicalin -  STDNA -Mg
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Figure 93: Chrysin -  STDNA- Zn
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Figure 94: Chrysin -  STDNA -  Mn
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Figure 95: Chrysin -  STDNA -  Mg
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Figure 96: Chrysin -  STDNA- Fe(III)
—i—
0.0000
— I—
0.0001
— I—
0.0002
— I—
0.0003
— I---
0.0004
 1---
0.0005
D a ta : C h ry s in  -  M g D N A
M o d e : m is s a il id is
C h iA2 =  3 .9 2 8 9 E -6
R A2 =  0 .9 9 9 3
P1 0 .1 1 4 7 3 ± 0 .0 0 1 8 4
P 2 0 .2 3 4 8 9 ± 0 .0 0 1 9 8
P 3 1 1 7 9 8 7 5 .1 6 4 8 9  ± 1 5 2 3 6 8 1 .8 8 2 2
P 4 0 .0 0 0 0 5 ± 0
P 5 1 .4 7 2 7 7 ± 0 .0 7 0 1 3
248
0 .4 5  - . D a ta : C h ry s in  -  F e ( l l)  -  D N A  
M o d e l: m is s a il id is
C h iA2  =  0 .0 0 0 2 2  
R A2  =  0 .9 8 6 9 70 .4 0
± 0 .0 1 0 6 1P1
P 2
P 3
P 4
P 5
0 .1 1 5 4 6  
0 .5 1 0 2  ± 0 .0 2 6 9 3  
5 8 9 6 3 2 .1 6 8 5 8  ± 9 4 3 5 0 1 .4 2 7 8 9  ±0
3 .9 0 4 9 2  ± 0 .3 4 0 1 1
0 .3 5  -
0 .0 0 0 0 5
0 .3 0
€
0 .2 5
0.20 -
0 .1 5
0.10 -
0 .0 0 0 2 0 .0 0 0 3 0 .0 0 0 4 0 .0 0 0 50.0000 0.0001
S T D N A (M )
Figure 97: Chrysin -  STDNA -  Fe(II)
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Figure 98: Chrysin -  STDNA -  Cu
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Figure 99: Luteolin -  STDNA -  Zn
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Figure 100: Luteolin -  STDNA- Mn
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Figure 101: Luteolin -  STDNA -  Mg
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Figure 102: Luteolin -  STDNA -  Fe(lII)
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Figure 103: Luteolin -  STDNA -  Fe(II)
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Figure 104: Luteolin -  STDNA -  Cu
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Figure 105: Quercetin -  STDNA -  Cu
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Figure 106: Quercetin -  STDNA- Mn
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Data: 1:2 quercetin - Zn - DNA
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Figure 107: Quercetin -  STDNA -  Zn
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Figure 108: Quercetin -STDNA -  Mg
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Data: 1:2 Quercetin - Fe (II) - DNA 
Model: missailidis1.04-,
ChiA2 = 0.00006 
RA2 = 0.97469
1.02- 0.8741 ±0.19151 
1.05045 
14447.81225 ±81657.07769
0.00005 
8.38107
±0.01442P2
P3
P4
P51.00- ±3.06888C
(U 0.98 -3s
§  0 .9 6 -
S •
^  0 .9 4 -
0 .9 2 -
0.90
0.00050.0000 0.0001 0.0002 0.0003 0.0004
STDNA(M)
Figure 109: Quercetin -  STDNA -  Fe(II)
Data: 1:2 Quercetin - Fe (III) - DNA 
Model: missailidis
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Figure 110: Quercetin -  STDNA -  Fe(III)
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Data: 1:1 Quercetin - Z n - DNA
Model: missailidis
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Figure 111: Quercetin - STDNA -  Zn
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Figure 112: Quercetin -  STDNA -  Mn
Data: 1:1 Quercetin - Mn - DNA 
Model: missailidis
ChiA2 = 0.00012
RA2 = 0.98482
P1 0.89181
P2 1.19461
P3 7885.16649
P4 0.00005
P5 3.29357
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±12767.70094±0
±3.88358
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Figure 113: Quercetin -  STDNA -  Mg
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Figure 114: Quercetin - STDNA -  Fe(III)
Data: 1:1 Quercetin - Mg - DNA
Model: missailidis
ChiA2 = 0.00016
RA2 = 0.98728
P1 0.88497
P2 1.21424
P3 10959.8877
P4 0.00005
P5 2.31898
±0.06014
±0.01231
±11838.47479±0
±2.33299
Data: 1:1 Quercetin - Fe (III) - DNA 
Model: missailidis
ChiA2 = 0.00009
RA2 = 0.99318
P1 0.78416 ±0.05867
P2 1.14384 ±0.00913
P3 9504.0908 ±8442.88923
P4 0.00005 ±0
P5 2.76066 ±2.00791
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Figure 115: Quercetin - STDNA -  Fe(II)
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Figure 116: Quercetin -  STDNA -  Cu
Data: 1:1 Quercetin - Fe(ll) - STDNA
Model: missailidis
ChiA2 = 0.00042
RA2 = 0.9619
P1 0.9313 ±0.08563 
P2 1.24799 ±0.02019
P3 12899.60462 ±22186.20719
P4 0.00005 ±0
P5 2.49065 ±3.30436
Data: 1:1 Quercetin - C u - DNA
Model: missailidis
ChiA2 = 0.00025
RA2 = 0.9906
P1 0.81912 ±0.06274
P2 1.30986 ±0.01568
P3 12132.4825 ±9768.88807
P4 0.00005 ±0
P5 1.94341 ±1.68602
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Figure 117: Rutin -  STDNA -  Mn
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Figure 118: Rutin -  STDNA- Zn
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Model: missailidis
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Figure 119: Rutin -  STDNA -  Fe(II)
Data: 1:1 Rutin - Fe(ll) - DNA 
Model: missailidis
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Figure 120: Rutin -  STDNA -  Fe(III)
260
0.905 -I
0.900 -
•§ 0.895-1
8 c
■i 0.890-1 
8
0.885 -
0.880
STDNA(M)
Figure 121: Rutin -  STDNA -  Cu
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Figure 122: Rutin -  Zn -  STDNA
Data: 1:1 Rutin - Cu - DNA 
Model: missailidis with n
ChiA2 = 2.7179E-6 
RA2 = 0.94452
P1 0.93493
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Data: 1:2 Rutin - Mn (II) - STDNA 
Model: missailidis
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RA2 = 0.97542
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Figure 123: Rutin -  STDNA -  Mn
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Data: 1:2 Rutin - Mg (II) - STDNA 
Model: missailidis
ChiA2
 1 1 1---0.0000 0.0001
RA2 = 0.98124
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Figure 124: Rutin -  STDNA -  Mg
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Figure 125: Rutin -  STDNA -  Fe(III)
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Data: 1:2 Rutin - Fe(ll) - DNA 
Model: missailidis
ChiA2 = 6.0953E-6
RA2 = 0.97289
P1 1.10173 ±1.00965
P2 0.99041 ±0.00737
P3 1049.26802 ±25919.40926
P4 0.00005 ±0
P5 2.06782 ±306.254
Figure 126: Rutin -  STDNA -  Fe(II)
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Figure 127: Rutin -  STDNA -  Cu
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Data: Luteolin 
Model: missailidis
ChiA2 = 5227285.80353
RA2 = 0.98615
P1 150109.73797 ±42346.76015
P2 89915.98337 ±1884.22835
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P4 0.00005 ±0
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Figure 128: Luteolin -  STDNA
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Data: 3'5'-Dinitroflavone 
Model: missailidis
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Figure 129: 3’5’- dinitroflavone - STDNA
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Data: 3'4'-Dihydroxyflavone 
Model: missailidis
ChiA2 = 683025948.67245
RA2 = 0.92561
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Figure 130: 3’4’-dihydroxyflavone -  STDNA
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Figure 131: 3’4’-dichloroflavone -  STDNA
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Data: 7-Moprholinoethoxy 5-hydroxyflavone 
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Figure 132: 7-morpholino, 5-hydroxyflavone -  STDNA
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Data: 3'4'-Dichloroflavone 
Model: missailidis
ChiA2 = 14374030.1732
RA2 = 0.76516
P1 67361.196
P2 22992.8881
P3 1345.06597
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P5 5.40264
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±324.53578
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Data: 6-Hydroxyflavone 
Model: missailidis
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RA2 = 0 .9519
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Figure 133: 5-hydroxyflavone -  STDNA
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Data: 5-Hydroxy 8 -nitroflavone 
Model: missailidis
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Figure 134: 5-hydroxy,8-nitroflavone - STDNA
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Model: missailidis£  108000
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Figure 135: Aza-3-flavone - STDNA
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Data: Flavothione 
Model: missailidis
ChiA2 = 130653291.34833
RA2 = 0.8987
P1 617239.40444 ±117187.46173
P2 722902.90758 ±9899.32569
P3 15538.77308 ±103772.25136
P4 0.00005 ±0
P5 9.32864 ±4.75291
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Figure 136: Flavothione - STDNA
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Figure 137: 7-dimethylaminoethoxy,5-hydroxyflavone -  STDNA
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Data: Flavanone
Model: missailidis
ChiA2 = 1047097.15436
RA2 = 0.67861
P1 48606.69171 ±128264.79993
P2 59114.39923 ±965.49007
P3 1238.92116 ±42683.28401
P4 0.00005 ±0
P5 2.04556 ±367.43622
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Figure 138: Flavanone - STDNA
Data: 7-Dimethylaminoethoxy 5-hydroxyflavone 
Model: missailidis
ChiA2 = 1702787674.91511  
RA2 = 0.97182
P1 1344213.9033 ±296695.37981
P2 667869 .8 9 4 5  ±32997.8122
P3 4 4 468 .13092  ±172134.66494
P4 0 .00005  ±0
P5 10.46487 ±2.18129
 1 ' 1 ' 1 1 1 1 1 1 1 1 1 1 1
0 .0 0 0 0  0 .0 0 0 1  0 .0 0 0 2  0 .0 0 0 3  0 .0 0 0 4  0 .0 0 0 5  0 .0 0 0 6  0 .0 0 0 7
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88000 Data: Xanthone 
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Figure 139: Xanthone -  STDNA
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Data: 7-Methoxyflavone
Model: missailidis
ChiA2 = 8834782.07442
RA2 = 0.97953
P1 61646.22153 ±807278.794
P2 225184.92461 ±22906.06748
P3 1575.95472 ±23984.43527
P4 0.00005 ±0
P5 2.57723 ±143.35961
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Figure 140: 7-methoxyflavone - STDNA
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Data: 5,7-Dimethoxychrysin 
Model: missailidis
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Figure 141: 5,7-dimethoxyflavone - STDNA
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Data: Chrysin
Model: missailidis
ChiA2 = 6950393.85877
RA2 = 0.95884
P1 71011.99854 ±28428.27702
P2 22408.83699 ±2344.17321
P3 7499.38669 ±11911.91932
P4 0.00005 ±0
P5 3 ±0
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Figure 142: Chrysin -  STDNA
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Figure 143: 5-hydroxy,7-methoxyflavone -  STDNA
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Figure 144: 5-hydroxyflavone -  STDNA
Data: 5-Hydroxy 7-methoxyflavone
Model: missailidis
ChiA2 = 18250368.3808 
RA2 = 0.80419
P1 71725.0786 ±66947.78429
P2 111399.49228 ±17915.64839
P3 5865.38239 ±46970.39286
P4 0.00005 ±0
P5 2.07407 ±33.80329
Data: 7-Hydfroxyflavone - STDNA 
Model: missailidis
ChiA2 = 0.00002
RA2 = 0.97973
P1 0.45376
P2 0.56583
P3 8134.98205
P4 0.00005
P5 3.4071 ±1.0711
0.0000 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007
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Data: 5-Hydroxy 7methoxyflavone
Model: missailidis
ChiA2 = 0.00005
RA2 = 0.88096
P1 0.4484 ±2.56147
P2 0.27086 ±0.0066
P3 714.23785 ±26274.47189
P4 0.00005 ±0
P5 1.68912 ±632.22555
0.0000 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007
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Figure 145: 5-hydroxy,7-methoxyflavone -  STDNA
Data: 3'5-Dinitroflavone 
Model: m issailidis
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Figure 146: 3’,5’-dinitroflavone -  STDNA
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Data: Flavanone
Model: missailidis
ChiA2 = 0.00005
RA2 = 0.12847
P1 0.13731 ±1.26441
P2 0.22 ±0
P3 1237.77084 ±50029.76173
P4 0.00005 ±0
P5 2.5048 ±389.76407
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Figure 147: Flavanone -  STDNA
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Figure 148: Chrysin - STDNA
Data: Chrysin 
Model: missailidis
ChiA2 = 0.00021
RA2 = 0.98418
P1 0.11101 ±0.01436
P2 0.47267 ±0.01011
P3 28460.53959 ±10472.58004
P4 0.00007 ±0
P5 4 ±0
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0.0006
 1---
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Data: 5,7-Dimethoxychrysin
Model: missailidis
ChiA2 = 0.00001
RA2 = 0 .99626
P1 0.33144 ±0.26312
P2 0 .67233 ±0.00331
P3 1474.60747 ±3411.81053
P4 0 .00005 ±0
P5 2 .34754 ±21.7237
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Figure 149: 5,7-dimethoxychrysin -  STDNA
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Data: 5,7-Diacetoxychrysin
Model: missailidis
ChiA2 = 8.9562E-6
RA2 = 0.95945
P1 0.10944 ±0.06556
P2 0.17184 ±0.00288
P3 3200.01563 ±12506.25016
P4 0.00005 ±0 |
P5 2.67134 ±19.82323
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Figure 150: 5,7-diacetoxychrysin -  STDNA
275
0 .52  -
0.50 -
8  0 .4 8 -
9 0.46-1
0.44 -
0.42 -
0.40
Data: 3'4'-Dihydroxyflavone
Model: missailidis
ChiA2 = 0.00001
RA2 = 0.99294
P1 0.2309 ±0.53731
P2 0.54615 ±0.011
P3 1287.21573 ±6683.55199
P4 0.00005 ±0
P5 2.72973 ±58.52926
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Figure 151: 3’,4’-dihydroxyflavone -  STDNA
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Data: 3’4-Dichloroflavone 
Model: missailidis
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Figure 152: 3’,4’-dichloroflavone -  STDNA
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Data: 7-Morpholinoethoxy 5-hydroxyflavone
Model: missailidis
ChiA2 = 0.00002
RA2 = 0.98818
P1 0.15717 ±0.00227
P2 0.26684 ±0.00397
P3 110679.35214 ±49339.97455
P4 0.00005 ±0
P5 0.8508 ±0.20662
o O
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Figure 153: 7-morpholinoethoxy,5-hydroxyflavone - STDNA
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Data: Xanthone
Model: missailidis
ChiA2 = 5.1003E-6
RA2 = 0.97491
P1 0.18072 ±0.05257
P2 0.24616 ±0.00216
P3 2547.59938 ±7364.57794
P4 0.00005 ±0
P5 2.01528 ±18.7446
I 1 I
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Figure 154: Xanthone -  STDNA
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Figure 155: 7-dimethlyaminopropoxy,5-hydroxyflavone -  STDNA
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Data: 7-Dimethyaminoethoxy 5-hydroxyflavone 
Model: missailidis
ChiA2 = 0.00005
RA2 = 0.97741
P1 0.387 ±0
P2 0.52184 ±0.00682
P3 189714.64155 ±123115.9629
P4 0.00005 ±0
P5 2.35273 ±0.37319
0.0000 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007
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Figure 156: 7-dimethlyaminoethoxy,5-hydroxyflavone -  STDNA
Data: 7-dimethylaminopropoxy 5-hydroxyflavone 
Model: missailidis
ChiA2 = 0 .00004  
RA2 = 0 .95673
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Data: Flavone 
Model: missailidis0.51
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0.2912 ±0.38738 
0.51514 
1221.47856 
0.00005 
2.69233
0.49 ±0.00627
±6275.48035
±0
±59.23652
P2
P3
P4
P5
0.48a>co>TO 0.47
g  0.46
_  0 .45 -  O 0)
<  0 .44 -
0.43
0 .42 -
0.0000 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007
STDNA(M)
Figure 157: Flavone -  STDNA
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Data: Luteolin
Model: missailidis
ChiA2 = 0.00001
RA2 = 0.9932
P1 0.13073 ±0.24709
P2 0.40366 ±0.00884
P3 1773.79305 ±5349.73454
P4 0.00005 ±0
P5 3.5961 ±26.16059
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Figure 158: Luteolin -  STDNA
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Data: Isoflavone
Mode missailidis
ChiA2 = 1.6135E-6
RA2 = 0.88418
P1 0.424 ±0
P2 0.45109 ±0.00102
P3 1767.45684 ±2037.07545
P4 0.00005 ±0
P5 9.92231 ±21.02208
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Figure 159: Isoflavone -  STDNA
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Figure 160: Melting denaturation curve of polydAdT alone
280
polydAdTdT
0.033 -r- 
0.031 - 
0.029 - 
0.027 - 
0.025 - 
0.023 - 
0.021 -  
0.019 - 
0.017 - 
0.015 - -
25 35 45 55 65 75 85 95
Figure 161: Melting denaturation curve of polydAdTdT
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Figure 162: Melting denaturation curve of polydAdT-dAdT
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G-quadruplex and 1st derivative
t  0 . 0 2
1.85 - 0.015
a>oc(0
JQ
0.01
1.75 - 0.005o \.( -CO
■S 1.65-f
-0.005
1.55 - 0.01
31 41 61 71 81 9151
temperature
Figure 163: melting denaturation curve of G-quadruplex with the 1st derivative
Melting denaturation of G-tetraplex with quercetin
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Figure 164: melting denaturation curve of G-quadruplex in the presence of quercetin
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